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Abstract 
Previous meta-analyses of psychological treatments for emotional distress in breast 
cancer (BCa) conclude that efficacious psychological treatments exist. Consequently, 
their implementation in routine care is widely promoted by healthcare policy. 
However, decisions to implement and recommend these treatments should be based 
on high quality empirical data. It is widely recognised that high-quality randomised 
controlled trials (RCTs) provide the most reliable evidence of treatment efficacy. 
Therefore, this thesis began with a scoping review of the relevant published literature 
to identify potential systematic reviews on the quality of psychotherapy RCTs for 
emotional distress in BCa. Nine reviews were identified; all of which inadequately 
assessed the methodological quality of the included RCTs. A systematic review of the 
quality of psychotherapy RCTs of emotional distress in BCa was therefore conducted. 
91 RCTs were eligible. Overall, methodological quality was low. Numerous 
methodological limitations were identified; three limitations were of considerable 
concern. Only 51% of RCTs used a treatment manual; only 15% specified inclusion 
criterion that participants were distressed; and only 11% reported the clinical 
significance of findings. If relevant health policies are to be adequately empirically 
informed, meta-analyses must account for these methodological limitations.  
As previous meta-analyses have failed to account for important methodological 
limitations; none focused specifically on clinically distressed patients, excluded non-
manualised treatments, or examined whether treatment effects were clinically 
significant, their practical relevance is questionable. Therefore, an individual patient 
data meta-analysis of RCTs of manualised psychological treatments for emotional 
distress in BCa patients was conducted. Treatment efficacy was evaluated using both 
effect size and clinical significance analyses; and analyses were conducted on the total 
sample (including distressed and non-distressed patients), and the clinically distressed 
sub-sample. Individual patient data was collected for 17 (n=2,996) of 26 (n=5,049) 
eligible trials. In the total sample, controlled effect sizes comparing treated and control 
patients were non-significant. In the clinical significance analysis, statistically 
significant benefits at post-treatment belied small differences and no differences 
remained at follow-up. In the distressed sub-sample, controlled effect sizes favouring 
treated patients were significant at post-treatment, but not at follow-up. In the clinical 
significance analysis, overall recovery was low: at post-treatment only 28-32% of 
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treated patients recovered compared to 17-27% of controls. At follow-up, only 24-
33% of treated patients recovered compared to 24-34% of controls. Psychological 
treatments do not appear to alleviate emotional distress for most BCa patients. This 
contradicts previous meta-analyses and highlights the pressing need to develop more 
efficacious psychological treatments for distressed BCa patients. 
To develop more efficacious psychological treatments for distressed BCa patients, a 
better understanding of the psychological processes associated with the development 
and maintenance of emotional distress in BCa is needed. Two psychological constructs 
that could explain distress in BCa survivors are beliefs about thinking, known as 
metacognitive beliefs; and the tendency to find uncertain situations distressing, known 
as intolerance of uncertainty. Therefore, an experience sampling methodology study 
examined the role of metacognitive beliefs and intolerance of uncertainty in predicting 
emotional distress and repetitive negative thinking (i.e. worry & rumination) in BCa 
survivors. Neither metacognitive beliefs nor intolerance of uncertainty predicted 
emotional distress. However, negative metacognitive beliefs about the 
uncontrollability and danger of repetitive negative thinking predicted repetitive 
negative thinking after controlling for intolerance of uncertainty and were a better 
predictor than baseline repetitive negative thinking, age at diagnosis, tumour stage at 
diagnosis, employment status, living alone or not, and time since finishing adjuvant 
therapy. 
Psychological treatments of greater efficacy are urgently needed for BCa patients with 
emotional distress. Improvements in understanding the psychological processes 
underpinning emotional distress in BCa may lead to more efficacious treatment 
development. 
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Thesis Overview 
The thesis reports four studies conducted to meet two broad aims: i) advance 
knowledge and understanding regarding the efficacy of psychological treatments for 
emotional distress in breast cancer (BCa); and ii) identify the psychological processes 
associated with the development and maintenance of emotional distress in BCa 
survivors.  
Chapter 1 provides a general overview of the impact of emotional distress among BCa 
patients. Screening methods for emotional distress in BCa; psychological treatments 
currently available to BCa patients to alleviate emotional distress; and conclusions of 
previous meta-analyses regarding the efficacy of psychological treatments for 
emotional distress in BCa are discussed. The chapter ends by highlighting the impact 
that methodological quality of RCTs included in meta-analyses has on their findings 
and subsequent conclusions. 
Chapters 2 to 5 address the first aim of this thesis by challenging the widespread 
assumption that efficacious psychological treatments for emotional distress in BCa 
exist. Chapter 2 presents a scoping review of systematic reviews evaluating the quality 
of psychotherapy RCTs for emotional distress in BCa.  Chapter 3 presents a systematic 
review of the quality of RCTs of psychological treatments for emotional distress in 
BCa. Following a review and critique of the Jacobson clinical significance method in 
chapter 4, chapter 5 presents an individual patient data meta-analysis (IPD-MA) of the 
efficacy of manualised psychological treatments for emotional distress in BCa 
patients. 
Chapters 6 to 8 address the second aim of this thesis by attempting to identify the 
psychological processes associated with the development and maintenance of 
emotional distress in BCa survivors. Chapter 6 provides an overview of two 
psychological models that could account for the development and maintenance of 
emotional distress in BCa: the intolerance of uncertainty model (Dugas, Gagnon, 
Ladouceur, & Freeston, 1998) and the Self-Regulatory Executive Function (S-REF) 
model (Wells & Matthews, 1994, 1996; Wells, 2009). Following a brief overview of 
Experience sampling methodology (ESM) in chapter 7, chapter 8 presents an ESM 
study examining the key constructs of the S-REF model (metacognitive beliefs) and 
the intolerance of uncertainty model (intolerance of uncertainty) in predicting 
xx 
repetitive negative thinking (i.e. worry and rumination) and emotional distress in BCa 
survivors. 
Finally, chapter 9 summarises the overall findings of the thesis. The limited efficacy 
of available psychological treatments and the implications this has on future research 
and practice are discussed.  
 1 
Chapter 1. An Overview of Breast Cancer and Emotional Distress 
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1.1 What is breast cancer? 
Cancer is a term used for a collection of diseases in which abnormal cells grow in an 
uncontrollable manner and invade healthy cells in the body. Breast cancer (BCa) is an 
uncontrolled growth of cells within the breast. BCa usually begins in the cells of the 
ducts, the passages that drain milk from the lobules to the nipple (Ductal Carcinoma); 
but can also begin in the cells of the lobules, the glands that produce breast milk 
(Lobular Carcinoma). If left untreated, primary BCa cells (non-metastatic BCa) can 
spread, or metastasise, through the lymphatic or blood system to other body parts 
(metastatic BCa).  
1.2 Breast cancer prevalence and survival 
Although both genders can develop BCa, over 99% of cases are in women (Siegel, 
Miller, & Jemal, 2017). Globally, BCa is the most common cancer amongst women, 
accounting for almost 1 in 4 female cancer cases (Bray et al., 2018). An estimated 2.1 
million women are diagnosed with BCa worldwide each year (Bray et al., 2018) whilst 
one in eight women in the United States and UK are diagnosed with BCa in their 
lifetime (Siegel, Miller, & Jemal, 2018; Cancer Research UK, 2015). In the early 
20th century, the life-expectancy after BCa diagnosis was approximately three years 
(Charache, 1932). However, improvements in detection methods and advances in 
medical treatment over the past century have significantly increased survival rates in 
BCa (Page & Adler, 2008). It is estimated that there are around 3.5 million BCa 
survivors in the United States (Miller et al., 2016) and 570,000 in the UK (Maddams 
et al., 2009); and the 5, 10 and 15-year survival rates for BCa are now 90%, 83% and 
78%, respectively (Howlader, Noone, & Krapcho, 2015). This improvement in 
survival has led to an increased focus on understanding the psychosocial consequences 
of BCa. 
1.3 Emotional distress in breast cancer 
The term ‘distress’ has many different meanings. The National Comprehensive 
Cancer Network (NCCN) Distress Management Panel defines distress as; 
“…a multi-determined unpleasant emotional experience of a psychological 
(cognitive, behavioral, emotional), social, and/or spiritual nature that may 
interfere with the ability to cope effectively with cancer, its physical symptoms 
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and its treatment. Distress extends along a continuum, ranging from common 
normal feelings of vulnerability, sadness and fears to problems that can 
become disabling, such as depression, anxiety, panic, social isolation, and 
spiritual crisis” (National Comprehensive Cancer Network, 2003).  
However, prevalence of emotional distress in BCa is usually defined in terms of 
general distress, anxiety disorders, and/ or depressive disorders opposed to an all-
encompassing definition as above. 
Emotional distress is common throughout the BCa disease trajectory. Approximately 
50% of BCa patients report clinical levels of emotional distress shortly after diagnosis, 
and 25% of patients do so in each of the second, third and fourth years after diagnosis 
(Bouchard et al., 2016; Burgess et al., 2005). In addition, life-time prevalence of BCa 
related post-traumatic stress disorder (PTSD) is 10-12% - almost twice that of the 
general female population (Andrykowski & Kangas, 2010; Frans, Rimmö, Åberg, & 
Fredrikson, 2005). Consequently, emotional distress is recognised globally as the sixth 
vital sign of BCa care used alongside pulse, temperature, respiration, blood pressure 
and pain (Bultz & Carlson, 2006) to assess patient's health and well-being. 
1.4 Trajectory of emotional distress after breast cancer diagnosis 
For most BCa patients, emotional distress shortly after diagnosis represents a normal 
and potentially adaptive stress response to a traumatic and threatening event, and 
would be expected to resolve spontaneously without specialist help (Brennan & 
Moynihan, 2004). In a study investigating trajectories of emotional distress in BCa 
across a five-year period, the most spontaneous reduction in distress prevalence 
occurred in the first 3 months following diagnosis (Helgeson, Snyder, & Seltman, 
2004). However, distress does not always resolve naturally. Some patients remain 
distressed or become distressed at a later stage. Henselmans et al. (2010) assessed 
distress at five key points in the BCa disease trajectory (i.e. soon after diagnosis, post-
surgery, immediately after adjuvant therapy, and two- and six-months after adjuvant 
therapy). Although most BCa patients experienced no distress (36%) or returned to 
normal within 6 months following completion of adjuvant therapy (33%), a small 
minority experienced persistent distress throughout the trajectory (15%) or only 
became distressed soon after adjuvant therapy ended (15%). Evidence of these distress 
trajectories has been supported by other studies in BCa (Boyes et al., 2013; Deshields, 
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Tibbs, Fan, & Taylor, 2006; Millar, Purushotham, McLatchie, George, & Murray, 
2005). Thus, it cannot be assumed that, following a diagnosis of BCa, all patients 
follow one and the same trajectory of emotional distress. 
1.5 Impact of emotional distress in breast cancer 
One of the highest unmet needs raised by BCa patients relates to the psychological 
domain (Armes et al., 2009; Okediji, Salako, & Fatiregun, 2017; Sanson‐Fisher et al., 
2000).  Almost half (45%) of BCa patients report that the emotional sequelae of cancer 
has the greatest negative impact on their quality of life (QoL; Macmillan Cancer 
Support, 2016).  
Moreover, BCa patients experiencing emotional distress are less compliant with 
adjuvant therapy (Colleoni et al., 2000) and more likely to use community health or 
accident and emergency services (Carlson & Bultz, 2004), placing greater demands 
on health-care provision and costs. Emotional distress also increases the risk of suicide 
(Reddy, 2010), the incidence being 1.4 times higher in BCa patients who are at least 
one year following diagnosis than the general population (Misono, Weiss, Fann, 
Redman, & Yueh, 2008). Subsequently, healthcare policies worldwide specify that 
BCa patients should be screened for emotional distress at key points in the disease 
trajectory (i.e. immediately after diagnosis, transition into adjuvant therapy, and 
shortly after completion of adjuvant therapy) and have access to psychological 
treatment if required (Holland, Watson, & Dunn, 2011; Page & Adler, 2008; Tit et al., 
2017).  
1.6 Screening for emotional distress in breast cancer 
Screening for emotional distress in BCa is heavily orientated around the diagnostic 
model of identifying need, according to which detecting emotional distress indicates 
the need for explicit psychological treatment (Salmon, Clark, McGrath, & Fisher, 
2015). Many healthcare policies follow a tiered-model approach. In the UK, the 
National Institute for Health and Care Excellence (NICE) recommend a four-tier 
model (National Institute for Clinical Excellence, 2004). At level 1, compassionate 
communication and general psychological support is available to patients regardless 
of distress by front line staff (e.g. doctors, nurses and allied healthcare professionals). 
At level 2, health & social care professionals with additional expertise screen patients 
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for distress using a self-report measure, such as the distress thermometer (a single-
item self-rated visual analogue scale), to rapidly identify patients reporting distress 
indicative of needing psychological treatment. If necessary, basic psychological 
techniques, such as problem-solving and psycho-education are provided. At level 3 
and 4, patients with severe distress scores are referred to trained and accredited 
psychological professionals (i.e. counsellors, psychiatrists or health and clinical 
psychologists) for a psychological assessment and, if appropriate, offered specialist 
psychological treatment (e.g. cognitive behavioural therapy; CBT).  
However, focusing solely on intensity of distress when screening is not the most 
comprehensive approach, and other factors such as desire for help (felt need), demand 
and enthusiasm for psychological services (expressed need), and identification of 
adaptive and maladaptive emotional responses also need to be considered (Dekker et 
al., 2017; Girgis, Smith, & Durcinoska, 2018; Salander, 2017; Salmon et al., 2015; 
Schaeffeler et al., 2015; Tondorf et al., 2018). 
At what point in the disease trajectory patients are screened is also important. 
Screening and addressing emotional distress shortly after diagnosis is not always 
appropriate. Recently diagnosed BCa patients often view distress as a temporary and 
understandable reaction to cancer and do not want early psychological intervention 
(Baker et al., 2016). Interrupting this normative experience may disrupt the 
equilibrium of adaptive processing (Brennan & Moynihan, 2004; Dekker et al., 2017). 
Moreover, PTSD literature suggests that early intervention can do more harm than 
good (Litz, Gray, Bryant, & Adler, 2002; Rose, Bisson, & Wessely, 2003). Thus, while 
there is a consensus about the importance of identifying patients in need of 
psychological support, the most appropriate method of determining need has not been 
established. 
1.7 Psychological treatments for emotional distress in breast cancer 
In recognition of the persistent emotional sequelae of BCa, numerous psychological 
treatments for emotional distress in BCa patients have been evaluated. The most 
commonly evaluated approaches are cognitive behavioural therapy (CBT), 
psychoeducation, and supportive therapy (Fors et al., 2011). In recent years, several 
studies have also evaluated mindfulness-based therapy (MBT). The overwhelming 
consensus in psycho-oncology research is that these treatments are efficacious and 
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alleviate emotional distress in BCa. Two Cochrane reviews (Jassim, Whitford, Hickey, 
& Carter, 2015; Mustafa, Carson-Stevens, Gillespie, & Edwards, 2013) and eight 
additional meta-analyses (Cobeanu & David, 2018; Duijts, Faber, Oldenburg, van 
Beurden, & Aaronson, 2011; Naaman, Radwan, Fergusson, & Johnson, 2009; Tatrow 
& Montgomery, 2006; Xiao et al., 2017; Ye et al., 2018; Zimmermann, Heinrichs, & 
Baucom, 2007) of randomised controlled trials (RCTs) evaluating the efficacy of 
psychological treatments compared to control conditions (assessment only, wait-list 
controls, treatment as usual, or active controls) have been conducted, with all ten 
concluding that efficacious psychological treatments exist. Consequently, healthcare 
policies and clinical practice guidelines internationally specify that psychological 
treatment should be available to BCa patients as part of their routine care throughout 
the disease trajectory (Dauchy et al., 2012; Holland et al., 2011; Howell et al., 2009; 
Li et al., 2016; National Breast Cancer Centre, 2003; National Comprehensive Cancer 
Network, 2003; National Institute for Clinical Excellence, 2004; Page & Adler, 2008; 
Reese, Weis, Schmucker, & Mittag, 2017; Tit et al., 2017). However, decisions to 
implement and recommend these treatments should be based on high quality empirical 
data. 
1.8 Importance of methodological quality of randomised controlled trials in 
breast cancer 
Confidence in conclusions of previous meta-analyses relies on the quality of their 
evidence-base. It is widely recognised that high-quality RCTs provide the most 
reliable evidence of treatment efficacy; and that low-quality RCTs tend to 
overestimate treatment effects (Barth et al., 2016; Bohlmeijer, Prenger, Taal, & 
Cuijpers, 2010; Bolier et al., 2013; Cuijpers, van Straten, Bohlmeijer, Hollon, & 
Andersson, 2010; Huhn et al., 2014; Klein, Jacobs, & Reinecke, 2007).  A recent meta-
analysis of 115 RCTs evaluating the efficacy of psychological treatments for 
depression found that effect sizes were significantly smaller in high-quality RCTs 
(d=0.22) than low-quality RCTs (d=0.74; Cuijpers et al., 2010). Treatment effects can 
also be overestimated even when RCTs neglect individual aspects of quality. For 
example, larger effects sizes have been found in RCTs not using blinded outcome 
assessors (Jauhar et al., 2014), not using intention to treat (ITT) analyses (Frühauf, 
Gerger, Schmidt, Munder, & Barth, 2013; Klein et al., 2007), and not adequately 
randomising participants to conditions (Gellatly et al., 2007). 
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The overestimation of treatment effects is not the only concern of poor quality RCTs. 
Poor quality also undermines the confidence in the conclusions that can be drawn from 
RCTs (Gerber et al., 2011; Öst, Havnen, Hansen, & Kvale, 2015; Thoma et al., 2012). 
For example, if concomitant treatments (i.e. pharmacotherapy or additional 
psychotherapy) are not controlled for, it is difficult to determine the impact of the 
specific treatment being assessed; if the control condition receives assessment only, it 
remains unclear whether observed effects are due to specific treatment ingredients or 
features that are common across different therapies; and if the sample is not 
representative of those seeking treatment in practice, researchers cannot be confident 
that the findings are generalisable to the clinical setting.  
It is therefore crucial that the quality of RCTs of psychological treatments is known if 
policymakers and clinicians are to make informed decisions about the implementation 
of, and referral to, psychological treatments in clinical services. Assessing the 
methodological quality of RCTs has been fundamental to advancing the scientific 
credibility and reporting standards of psychotherapy outcome trials in mental health 
settings (Cuijpers et al., 2010; Gerber et al., 2011; Öst et al., 2015; Thoma et al., 2012). 
For example, it appears that as the quality of psychotherapy RCTs for depression have 
improved, the magnitude of treatment effects have diminished.  
It is clear that the methodological quality of RCTs included in meta-analyses can have 
a substantial impact on their subsequent conclusions. Therefore, the general 
conclusion that efficacious psychological treatment for emotional distress in BCa exist 
can only be ascertained if the RCTs that these conclusions are based on are of good 
quality. 
1.9 Summary 
Emotional distress in BCa is a significant problem worldwide. Therefore, access to 
efficacious psychological treatments for emotional distress in BCa is essential. Meta-
analyses of RCTs conclude that efficacious psychological treatments for emotional 
distress in BCa exist. However, confidence in these conclusions is determined by the 
quality of their evidence-base. Thus, the quality of the evidence-base with which 
previous conclusions are based needs to be known in order to determine the level of 
confidence one can have in the general conclusion that efficacious psychological 
treatments for emotional distress in BCa exist. 
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Chapter 2. Study 1: A Scoping Review of Reviews Assessing the Quality of 
Randomised Controlled Trials of Psychological Treatments for Emotional 
Distress in Breast Cancer 
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2.1 Introduction 
To determine the quality of the evidence-base with which previous meta-analytic 
conclusions in BCa are based, a scoping review of the relevant published literature 
was conducted to identify potential systematic reviews on the quality of psychotherapy 
RCTs for emotional distress in BCa. This chapter presents the findings of this scoping 
review. First, however, an overview of the different methods used to assess RCT 
quality, and the importance of assessing specific design elements when evaluating 
RCT quality is presented. 
The term ‘methodological quality’ is a multidimensional construct which 
encompasses design, implementation, analysis, reporting, replicability, and 
generalisability (Sundell & Åhsberg, 2016). Within the healthcare literature there are 
inconsistencies in how methodological quality is defined, and the terms ‘quality’ and 
‘bias’ are often used interchangeably (Hartling et al., 2009). However, these terms 
should be distinguished from each other. Bias refers only to the internal validity of a 
trial (i.e. reliability or accuracy of trial results; Higgins et al., 2011); while quality 
refers to the extent to which a trial was conducted to the highest possible standards 
(Verhagen, de Vet, de Bie, Boers, & van den Brandt, 2001). Thus, the concept of 
methodological quality includes more than just internal validity. It also includes 
external validity (i.e. generalisability of trial results to the target population), construct 
validity (i.e. extent to which a trial measures the intended construct), and statistical 
conclusion validity (i.e. extent to which trial data can be regarded as revealing a link 
between independent and dependant variables; Berlin & Rennie, 1999; Farrington, 
2003).  
To assess trial quality, three types of assessment tools exist: quality scales, quality 
checklists, and domain-based evaluations (Jüni, Witschi, Bloch, & Egger, 1999; Zeng 
et al., 2015). Although often used interchangeably, these terms are distinct (Olivo et 
al., 2008). With quality scales, individual items are numerically rated and combined 
to give an overall quality score. With quality checklists, individual items are given a 
categorical rather than a numerical rating (i.e. yes or no/ reported or not reported). 
With domain-based evaluations, each domain (e.g. detection bias) is given a 
categorical rating opposed to each individual item within that domain. As neither 
quality checklists nor domain-based evaluations rate items numerically, generating an 
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overall quality score is not possible. However, some quality checklists and domain-
based evaluations include a summary judgement enabling an overall assessment of 
trial quality. For example, the quality checklist developed by Beatty et al. (2018) 
categorises trials as high quality if at least 8 of the 11 quality criteria are met.  
Conclusions about trial quality vary according to the design elements being assessed. 
For example, Armijo-Olivo et al. (2015) used two quality assessment tools to assess 
the quality of 97 physical therapy RCTs. The two assessment tools differed with 
regards to the design elements being assessed. Only 11 of the 97 RCTs that were of 
adequate quality according to one assessment tool were of adequate quality according 
to the other. Yet, there is extensive variation in the design elements assessed by 
different assessment tools. A recent analysis in health research found that 130 different 
design elements were assessed across 19 quality assessment tools (Armijo-Olivo, 
Fuentes, Ospina, Saltaji, & Hartling, 2013). 
Consensus on the design elements of RCTs which determine methodological quality 
does not exist. However, it is broadly accepted that several design elements are 
essential; proper randomisation,  clear description of the sample,  use of power 
analysis, sample representative of the target population, use of valid and reliable and 
specific outcome measures, use of an adequate comparator condition, control of 
concomitant treatments, adequate length of follow-up, complete outcome data (i.e. 
handling of attrition), adequate statistical methods, and assessment of clinical 
significance (Gerber et al., 2011; Kocsis et al., 2010; Liebherz, Schmidt, & Rabung, 
2016; Öst, 2008; Sundell & Åhsberg, 2016). 
Assessment of the methodological quality of psychotherapy RCTs has to contend with 
several interacting components which can be difficult to operationalise (Munder & 
Barth, 2018), Thus, when conducting a psychotherapy RCT, items such as 
manualisation, therapist adherence and competence, number of therapists, and equality 
of therapy hours also need to be considered (Kocsis et al., 2010; Luborsky & 
DeRubeis, 1984; Öst, 2008; Perepletchikova, Treat, & Kazdin, 2007). 
The following section provides an overview of the importance of design elements 
essential to the methodological quality of RCTs in general as well as those specific to 
psychotherapy RCTs. 
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2.1.1 Generic design elements 
Proper randomisation  
The aim of randomisation is to ensure that confounding variables are equally 
distributed between participants within each group, increasing the likelihood that any 
observed differences between groups are due to treatment (Suresh, 2011). Proper 
randomisation depends on two separate but interlinked features: generation of an 
unpredictable random sequence (i.e. random sequence generation); and concealment 
of the random sequence (i.e. allocation concealment). Generation of an unpredictable 
sequence ensures that any future assignments cannot be anticipated. Randomisation 
based on a single sequence of random assignments, known as simple randomisation, 
is the most reliable method (Higgins et al., 2011). However, when simple 
randomisation is used on small samples, sample sizes between groups may be 
imbalanced. Thus, methods such as blocked or stratified randomisation are required 
(Kang, Ragan, & Park, 2008). Concealment of the unpredictable sequence prohibits 
selective enrolment of participants. For example, it prevents participants assigned to 
the treatment group who may be viewed as ‘inappropriate’ from being excluded 
(Higgins et al., 2011). Central randomisation by an independent third party is the most 
reliable method of allocation concealment (Higgins et al., 2011). 
Sample representative of the target population  
To enhance the external validity of an RCT and ensure results are clinically 
meaningful, findings must be generalisable to patients who would be offered treatment 
in routine practice (Rothwell, 2005). One of the most frequently reported reasons for 
the underuse of guideline-recommended treatments is the lack of empirical evidence 
for their efficacy amongst the type of patients seen in practice (Garfield & Garfield, 
2000). To increase generalisability of findings, recruitment for RCTs should occur 
across several sites and eligibility criteria should avoid exclusion of representative 
patients. 
Clear description of sample  
A comprehensive description of patients included in an RCT is needed to ensure 
accurate interpretation of results (Amundsen et al., 2018). If the sample is poorly 
described, it is difficult to determine the representativeness of the sample or compare 
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outcomes across RCTs. A complete description of the eligibility criteria and the 
characteristics of the recruited sample are essential.   
Use of power analysis 
Power of an RCT refers to the probability of detecting a significant difference when a 
significant difference exists. The stronger the power, the less likely the probability of 
type II error (i.e. a false negative result). The power of an RCT is directly proportional 
to the sample size; and should be determined a priori to be at least 80% (i.e. the sample 
is large enough to detect a significant difference that exists 80% of the time) by 
conducting data-informed power analysis (Biau, Kernéis, & Porcher, 2008). Post-hoc 
power analysis should be avoided as they are often incorrect and misleading 
(Goodman & Berlin, 1994; Levine & Ensom, 2001).  
Valid, reliable and specific outcome measures 
Outcome measures need to have good psychometric properties to avoid unreliable or 
invalid data (Souza, Alexandre, & Guirardello, 2017). Essential psychometric 
properties are reliability and validity (Lohr, 2002). Reliability refers to the extent to 
which repeated measurements produce consistent results. Two types of reliability are 
important for outcome measures: test-retest reliability (i.e.  reproducibility of results 
over time) and interrater reliability (i.e. reproducibility of results across different 
raters). Validity refers to the extent to which an outcome measure measures what was 
intended. Three types of validity are important for outcome measures: construct 
validity (i.e. extent to which an outcome measure measures the intended construct), 
content validity (i.e. extent to which an outcome measure measures all elements of the 
intended construct) and criterion validity (i.e. extent to which scores on one outcome 
measure predicts those on another). Outcome measures also need to be specific (i.e. 
relevant to the population in question).  
Use of an adequate comparator condition 
One of the primary purposes of a comparator condition in an RCT is to control for 
threats to internal validity (Mohr et al., 2009). As estimates of treatment efficacy 
depend on the contrast being made between conditions, the choice of comparator is 
central to any conclusions drawn. The least stringent comparators are wait-list control 
(WLC) or assessment only conditions. Although these conditions may control for non-
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specific factors such as instillation of hope and trust (Modi, Wagner, Smith, 
Kellermann, & Michaelis, 2017), they do not control for other non-specific factors 
such as therapeutic alliance. A more reliable comparator is standard care or ‘treatment 
as usual’ (TAU). TAUs are more common in psychotherapy RCTs opposed to 
pharmacological RCTs (Freedland, Mohr, Davidson, & Schwartz, 2011). Using a 
TAU addresses the question of whether a new treatment is more beneficial than the 
current one being implemented. However, TAU varies considerably across services, 
hospitals and countries (Dawson et al., 2009; Freedland et al., 2011; Mohr et al., 2009), 
and is often poorly defined (Smelt, van der Weele, Blom, Gussekloo, & Assendelft, 
2010) making it difficult to interpret results. The most stringent comparator in 
pharmacological RCTs is a placebo control as they control for non-specific factors 
(Simmonds, 2010). However, as it is difficult to adequately blind patients to 
psychological treatment, it is difficult to translate placebo controls into psychotherapy 
RCTs. Therefore, the most stringent comparator in psychotherapy RCTs is either an 
active control (e.g. supportive therapy or nondirective therapy) or another bona-fide 
psychological treatment; both of which help ensure observed differences are due to 
specific opposed to non-specific treatment factors.  
Control of concomitant treatment 
If receipt of concomitant treatment (i.e. additional pharmacological or psychological 
treatment) is not controlled for, it is difficult to determine whether observed effects 
are due to the treatment being evaluated or additional treatments (Öst et al., 2015). 
One way to increase internal validity of an RCT is to exclude patients receiving 
concomitant treatments. Another way is to ensure that, if patients are receiving 
concomitant pharmacological treatment, the dosage is kept stable before and during 
the RCT. If concomitant treatments are permitted, it is imperative that these treatments 
are reported for each group to ensure accurate interpretation of results.  
Adequate length of follow-up  
To check whether any observed effects are sustained, outcomes need to be measured 
beyond immediately post-treatment. The longer the follow-up period, the better the 
indication of the sustainability of effects. Any treatments patients receive during the 
follow-up period (i.e. pharmacological or psychological) need to be reported to 
improve interpretation of results and increase internal validity. 
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Complete outcome data (i.e. handling of attrition) 
Incomplete outcome data due to attrition increases the likelihood that observed effects 
are biased (Higgins et al., 2011). Patients often drop out of a specific group due to lack 
of treatment success (Klein, Stone, Hicks, & Pritchard, 2003; Liebherz et al., 2016; 
Swift, Callahan, & Levine, 2009). If these patients are excluded from analyses, 
conclusions may be inaccurate. Patients who drop-out may also differ from completers 
on specific sample characteristics. Therefore, analyses should be conducted on intent 
to treat (ITT) basis and sample characteristics of those who completed treatment 
should be compared to those who dropped out.  
Adequate statistical methods 
Statistical analyses that appropriately test the hypotheses of an RCT are needed to 
guarantee reliable results (Norström, 2015).  
Assessment of clinical significance 
While statistical significance and effect sizes provide valuable group information, they 
provide no information about individual variability in treatment response (Loerinc et 
al., 2015). This makes it difficult to interpret the practical value of findings. Therefore, 
an evaluation of clinical significance is needed to indicate the proportion of patients 
who benefit from treatment (see chapter 4 for more details).   
2.1.2 Psychotherapy-specific design elements 
Manualisation 
Psychotherapy outcome research is uninformative if there is a lack of clarity over the 
nature of the treatment evaluated (Chambless & Hollon, 1998). Therefore, treatment 
manuals are crucial to standardising psychological treatment and allowing 
discrimination between alternatives. Treatment manuals improve dissemination and 
the quality of treatment delivery (Addis, Cardemil, Duncan, & Miller, 2006) and help 
bridge the gap between research and practice. In the United States, psychological 
treatments must be manualised to be considered “evidence-based” and in turn 
recommended for use in clinical practice (Chambless & Hollon, 1998).  
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Therapist training 
A manual alone cannot ensure that a treatment is delivered as intended.  Therefore, 
treatment must be delivered by therapists trained to provide psychological treatments 
(e.g. licensed clinical or health psychologists). Therapists should also be trained in the 
specific treatment being evaluated. For example, a clinical psychologist delivering 
MBT must also be specifically trained to deliver MBT.  
Therapist adherence & competence 
Well-trained therapists may still fail to deliver a treatment correctly. Thus, adherence 
to the treatment manual and therapy competence also need to be assessed. Adherence 
refers to the extent to which therapists remain faithful to the prescribed treatment 
procedures, whereas competence refers to the degree of skill and judgment that 
therapists display when delivering the treatment (Barber, Sharpless, Klostermann, & 
McCarthy, 2007).  
Number of therapists 
Accumulating evidence indicates that therapists have a significant effect on outcome, 
accounting for around 5–10 % of unexplained variance (Crits-Christoph et al., 1991; 
Kim, Wampold, & Bolt, 2006). Therefore, to avoid confounding between therapist 
and therapy method, treatments must be delivered by multiple therapists and therapists 
must be included as a random design factor in analysis. 
Equality of therapy hours 
Internal validity of an RCT can be compromised if the duration and intensity of 
treatment conditions are not matched. Merely spending time with a therapist can lead 
to significant improvements in treatment outcome (Freedland et al., 2011). Therefore, 
if a comparator condition receives markedly less therapy hours, it is difficult to judge 
whether observed effects are due to the specific treatment being investigated or 
additional time spent with a therapist. However, equality of therapy hours is not always 
feasible; for example, RCTs evaluating different doses of the same treatment.  
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2.1.3 Aims  
To be confident in conclusions of psychotherapy RCTs, and reviews based on those 
RCTs, the above design elements need to be correctly implemented.  Therefore, the 
aims of this scoping review were to identify any reviews assessing the methodological 
quality of psychotherapy RCTs for emotional distress in BCa, and evaluate the nature 
and quality of the assessment tools used to determine RCT quality in those reviews. 
As bias represents one aspect of quality, reviews assessing the risk of bias (RoB) were 
also included. 
2.2 Method 
2.2.1 Search strategy 
Relevant studies were identified by systematic searches of the following electronic 
databases: PubMed, PsycINFO, Web of Science, Scopus, and the Cochrane Database 
of Systematic Reviews. Databases were searched from their inception until June 2018 
using Medical Subject Headings (MeSH) terms where possible. The search used a 
combination of terms associated with reviews (including: “review* OR meta*),  BCa 
(including: “breast neoplasms” OR “breast cancer”), emotional distress (including: 
“Depression”[Mesh] OR “depressive disorder”[Mesh] OR “depressive disorder” 
OR “anxiety”[Mesh] Or “anxiety disorders”[Mesh] OR “anxiety disorders” OR 
“anxiety” OR “depression” OR “emotional distress” OR “psychological distress”), 
and psychological treatments (including: “Psychotherapy”[Mesh] OR 
“psychotherapy” OR “psychological therapy” OR “counselling” OR “counselling” 
OR “psychological intervention” OR “cognitive behavioural therapy”  OR “group 
therapy” OR “psychosocial therapy”). No date restriction was applied but only 
English language articles were included. The final search strategy used for each 
database is available in Appendix 1. 
2.2.2 Eligibility criteria 
Review type: Reviews of RCTs published in English in a peer-reviewed journal. 
Reviews not focusing specifically on RCTs were excluded. 
Participants: Reviews exclusively comprising adults aged 18 years or older with a 
histologically confirmed diagnosis of BCa.  
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Treatment: RCTs included in reviews evaluated a psychological treatment in at least 
one condition.   
Control: RCTs included in reviews had a no treatment (usual care) control, an active 
(attention placebo) control, or an alternative treatment in at least one condition. 
Outcomes: The primary and/or secondary outcome of the RCTs included in reviews 
was emotional distress, defined as anxiety, depression, general mood, or global 
emotional distress. 
Quality assessment: The methodological quality of RCTs included in reviews was 
assessed using a quality or RoB scale, checklist, or domain-based evaluation.  
2.2.3 Review selection 
After removing duplicates, a single reviewer (JT) screened titles and abstracts to 
remove irrelevant studies.  Next, full-text of all potentially relevant papers was 
retrieved and assessed for inclusion by the same reviewer (JT). Uncertainties were 
discussed with a second reviewer (PF). 
2.2.4 Data extraction 
Data were extracted independently by one reviewer (JT) for all included reviews using 
a specially devised data extraction protocol. Data extracted was year of publication; 
number of RCTs included in the review; primary aim of review; outcomes measured 
in the review; type of quality assessment tool used; and items included in the quality 
assessment tool. 
2.3 Results 
Figure 2.1 presents an overview of the study selection procedure. The systematic 
search retrieved 864 citations of which 47 were potentially eligible following the title 
and abstract screening stage. After reading the full text, nine reviews published from 
2009 to March 2018 were eligible and included. Six of the nine reviews included RCTs 
evaluating emotional distress whilst other RCTs within the same review measured 
different constructs such as QoL or survival. In this case, only the RCTs evaluating 
emotional distress were included in this review.  
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Characteristics of each review are presented in Table 2.1. Six reviews exclusively 
included; metastatic BCa patients (n=2), non-metastatic BCa patients (n=1), BCa 
patients who had completed surgery (n=2), or BCa patients who had completed 
adjuvant therapy (n=1). The remaining three reviews included BCa patients 
irrespective of disease stage or trajectory phase. Seven of the nine reviews assessed 
RoB only; and two assessed the broader domain of quality. To assess RoB, three 
assessment tools were used - one was a domain-based evaluation (Cochrane RoB tool; 
Higgins & Green, 2011) and two were scales (Jadad RoB scale; Fors' RoB scale; Fors 
et al., 2011; Jadad et al., 1996). To assess quality, two assessment tools were used – 
one was a checklist (Beatty's quality checklist; Beatty et al., 2018) and one was a scale 
(Naaman's quality scale; Naaman et al., 2009).  
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Figure 2.1: Flow chart showing review identification and selection
Records identified through database searching  
(n=864) 
Web of Science (n=309) 
Scopus (n=424) 
PubMed (n=39) 
PsycINFO (n=82) 
Cochrane Library (n=10) 
Records after duplicates removed  
(n=709) 
Records screened based 
on titles and abstracts 
(n=709) 
Records excluded  
(n=662) 
Full-text articles excluded, with reasons  
(n = 38) 
No quality assessment (n=13) 
Participants not exclusively BCa (n=9) 
Not a review (n=6) 
Review has been updated (n=1) 
No relevant outcomes (n=1) 
No psychological intervention (n=1) 
Not exclusively RCTs (n=7) 
Additional records identified through other 
sources  
(n=0) 
Full-text articles assessed 
for eligibility  
(n=47) 
Studies included in quantitative 
synthesis (n=9) 
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Table 2.1: Characteristics of included reviews  
Review Type of 
review 
Objectives Sample  Type of 
treatments 
Outcomes measured RCTs 
included  
RCTs 
measuring 
distress in 
BCa 
Year 
range 
for 
RCTs 
included 
Beatty et 
al. 2018 
Systematic 
review 
To summarise the evidence‐base of 
psychological treatments for women 
with metastatic BCa, by mode of 
delivery (group, individual, or low‐
intensity interventions) 
Women with metastatic 
BCa 
Any 
psychological 
treatment 
Primary outcomes: 
Emotional distress, coping, QoL, survival 
15 13 1981-
2012 
Fors et al. 
2017 
Systematic 
review  
Determine the effectiveness of 
psychoeducation, CBT and social 
support interventions used in the 
rehabilitation of BCa patients 
Female BCa patients who 
had completed surgery and 
adjuvant therapy 
Psychoeducation, 
CBT and social 
support 
Primary outcomes: 
QoL 
Mood 
    Depression, anxiety, stress 
Clinical symptoms 
    Nausea, dizziness, health coping, work 
    disability, leisure 
Social functioning 
18 17 1999-
2008 
Haller et al. 
2017 
Systematic 
review & 
meta-analysis 
Systematically update the evidence 
for MBT in women with BCa 
Women with BCa (Stage 
0-IV) regardless of current 
treatment status 
MBT Primary outcomes: 
HRQoL, cancer-specific QoL, 
Secondary outcomes: 
Fatigue, sleep, stress, anxiety, depression 
10 9 2009-
2016 
Jassim et 
al. 2015 
Cochrane 
review 
To assess the effects of 
psychological treatments on 
psychological morbidities, QoL and 
survival among women with non-
metastatic BCa 
Women with non-
metastatic BCa 
Any 
psychological 
treatment 
Primary outcomes: 
Anxiety, depression, stress, mood disturbance 
Secondary outcomes: 
QoL, coping, adjustment, survival 
28 28 1996-
2013 
Mustafa et 
al. 2015 
Cochrane 
review 
To assess the effects of 
psychological treatments on 
psychosocial and survival outcomes 
for women with metastatic BCa 
Women with metastatic 
BCa 
Any 
psychological 
treatment 
Primary outcomes:  
Psychological outcomes 
10 8 1989-
2010 
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Review Type of 
review 
Objectives Sample  Type of 
treatments 
Outcomes measured RCTs 
included  
RCTs 
measuring 
distress in 
BCa 
Year 
range 
for 
RCTs 
included 
Anxiety, depression, emotional distress, 
QoL, pain, condition-specific outcomes, 
relationship and social support 
Survival outcomes 
Naaman et 
al. 2009 
Meta-analysis Determine the overall efficacy of 
psychological treatments in BCa 
patients, specifically looking at three 
outcome variables: anxiety, 
depression, and QoL 
Female BCa patients who 
had completed surgery 
Psychological/beh
avioural 
treatments 
Primary outcomes: 
Anxiety, depression, QoL 
18 16 1981-
2003 
Xiao et al. 
2017 
Meta-analysis Assess the efficacy of individually 
delivered CBT on improving the 
depressive symptoms of women 
with BCa 
BCa patients who had 
completed surgery (time-
frame not given) 
CBT Primary outcomes: 
Depression 
10 10 1996-
2015 
Ye et al. 
2018 
Meta-analysis Examine the effect of CBT on QoL 
and psychological health of BCa 
patients 
Female BCa patients and 
survivors (survivors not 
defined) 
CBT Primary outcomes: 
QOL, depression, anxiety, stress 
10 10 2003-
2015 
Zhang et 
al. 2016 
Systematic 
review & 
meta-analysis 
Quantify the effects of MBT on 
physical health, psychological 
health and Qol in patients with BCa 
Women with BCa (Stage 
0-IV) regardless of current 
treatment status 
MBT 
 
 
 
 
Primary outcomes:  
Psychological health 
Anxiety, depression, spirituality, 
emotional well-being, stress, fear of 
recurrence 
QoL 
Physiological health 
7 5 2009-
2014 
Note. CBT = cognitive behavioural therapy; QoL = quality of life; HRQoL = health related quality of life; MBT = mindfulness-based therapy; BCa = breast cancer; RCT = randomised controlled trial 
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2.3.1 Quality assessment tools and reviews 
The quality findings from each review are presented in Table 2.2. A summary of each 
assessment tool followed by a summary of the findings from each review using that 
assessment tool is provided below. 
2.3.1.1 Cochrane Risk of Bias tool 
The Cochrane RoB tool (Higgins & Green, 2011) assesses seven domains: random 
sequence generation, allocation concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome data, selective outcome 
reporting (i.e. reporting only a sub-set of outcomes, depending on the nature and 
direction of the results), and a supplementary domain ‘other bias’. For each RCT, users 
assign a judgement of ‘high’, ‘low’ or ‘unclear’ RoB to each domain. The guidelines 
recommend that an RCT has a ‘low RoB’ if a low RoB is found for all key domains, 
an ‘unclear RoB’ if an unclear RoB is found for one or more key domains, and a ‘high 
RoB’ if a high RoB is found for one or more key domains (Higgins & Green, 2011). 
2.3.1.2 Reviews using the Cochrane Risk of bias tool 
Mustafa et al., 2013 
Mustafa et al. (2013) conducted a Cochrane review evaluating ten RCTs of 
psychological treatments for emotional distress and survival in metastatic BCa 
patients. Eight of the ten RCTs included emotional distress as an outcome variable. 
The RoB was unclear in all eight RCTs. Five of the seven domains (random sequence 
generation, allocation concealment, blinding of participants and personnel, incomplete 
outcome data, and selective reporting) were rated as having a low RoB in most RCTs; 
one domain (blinding of outcome assessment) was rated as having an unclear RoB in 
most RCTs; and one domain (‘other biases’) received a mixture of low and unclear 
RoB ratings across RCTs.  
Jassim et al, 2015 
In another Cochrane review, Jassim et al. (2015) evaluated 28 RCTs of psychological 
treatments for emotional distress in non-metastatic BCa patients. Nineteen RCTs had 
an unclear RoB and nine had a high RoB. Five of the seven domains (random sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of 
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outcome assessment, and incomplete outcome data) were rated as having an unclear 
RoB in most RCTs, and two (selective reporting and ‘other biases’) were rated as 
having a low RoB in most RCTs. 
Haller et al., 2017 
Haller et al. (2017) carried out a meta-analysis of 10 RCTs of MBT for health-related 
QoL in BCa. Secondary outcomes included fatigue, sleep, stress, safety, and emotional 
distress. Nine of the ten RCTs included emotional distress as an outcome variable. All 
nine RCTs had a high RoB. Despite this, three of the seven domains (random sequence 
generation, incomplete outcome data, and ‘other biases’) were rated as having a low 
RoB in most RCTs; three (allocation concealment, blinding of participants and 
personnel, and blinding of outcome assessment) were rated as having an unclear RoB 
in most RCTs; and one (selective outcome reporting) was rated as having a high RoB 
in most RCTs. 
Ye et al., 2018 
Ye et al. (2018) conducted a meta-analysis of 10 RCTs of CBT for emotional distress 
in BCa. Eight RCTs had a high RoB, one had a low RoB, and one was rated as having 
an unclear RoB. Although most RCTs had a high RoB, five of the seven domains 
(random sequence generation, blinding of participants and personnel, incomplete 
outcome data, selective outcome reporting, and ‘other biases’) were rated as having a 
low RoB in most RCTs, while two (allocation concealment, blinding of outcome 
assessment) received mixed ratings across RCTs. 
2.3.1.3 The Jadad scale 
The Jadad scale (sometimes referred to as the Oxford quality scoring system; Jadad et 
al., 1996) is the most frequently used RoB scale in healthcare research (Olivo et al., 
2008). It consists of five questions relating to three bias domains; random sequence 
generation, blinding of participants and personnel, and incomplete outcome data. Each 
question is answered ‘yes’ or ‘no’. Each ‘yes’ scores one point and each ‘no’ scores 
zero points, producing a total score ranging from 0-5. A cut-off score of ≥ 3 out of 5 
is recommended for an RCT to be classed as adequate quality (Jadad et al., 1996). The 
reliability of the Jadad scale has been disputed with interrater reliability ranging from 
low to high (Kappa:0.37-0.89) (Clark et al., 1999; Latronico et al., 2002). 
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2.3.1.4 Reviews using the Jadad scale 
Zhang et al., 2017 
Zhang, Xu, Wang, and Wang (2016) conducted a meta-analysis of seven RCTs of 
MBT for physical health, psychological health and QOL in BCa. Five of the seven 
RCTs included emotional distress as an outcome variable. Zhang et al. (2016) defined 
high-quality RCTs as those with a score of ≥4. According to this cut-off, two RCTs 
were high-quality; and according to the pre-defined cut-off score of ≥ 3, three RCTs 
(including the 2 high-quality RCTs) were of adequate quality. Four of the five RCTs 
failed to perform ITT analysis; three failed to ensure the outcome assessor was 
blinded, specify the method of randomisation, or ensure allocation concealment; and 
one failed to report the number of withdrawals or dropouts.   
Xiao et al., 2017 
Xiao et al. (2017) conducted a meta-analysis of 13 RCTs of CBT for depression in 
BCa patients after surgery. According to the pre-defined cut-off score of ≥3, all 13 
RCTs were of adequate quality. No further information on trial quality was provided. 
2.3.1.5 Fors’ risk of bias scale  
Fors et al. (2011) devised their own assessment scale to assess bias. It was developed 
based on the Cochrane RoB tool (Higgins & Green, 2011) and consists of 11 questions 
relating to seven bias domains (random sequence generation; allocation concealment; 
blinding of participants and personnel; blinding of outcome assessment; incomplete 
outcome data; statistical methods; and reliable outcome measures). Each question is 
answered ‘yes’, ‘no’, or ‘unclear’. Each ‘yes’ receives one point and each ‘no’ or 
‘unclear’ receives zero points, producing a total score ranging from 0-11. An RCT 
with a score of ≥8 is considered high-quality, 5-7 is considered moderate-quality, and 
≤4 is considered low-quality.  
2.3.1.6 Reviews using Fors’ risk of bias scale 
Fors et al., 2011 
In their systematic review, Fors et al. (2011) evaluated 18 RCTs of psychological 
treatments across numerous outcomes in BCa. Seventeen of the 18 RCTs included 
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emotional distress as an outcome. Fourteen of those were categorised as moderate-
quality and three were categorised as high-quality. In most RCTs, adequate methods 
of randomisation were employed, reliable outcome measures were used, and statistical 
methods appropriately tested the hypotheses. However, most RCTs failed to blind 
participants, personnel or outcome assessors.  
2.3.1.7 Naaman's quality scale  
Naaman et al. (2009) developed their own quality scale based on a framework 
provided by Cook & Campbell (1979) and the Jadad scale (Jadad et al., 1996). It 
consists of seven items, each scored 0 (no) or 1 (yes), producing a total score ranging 
from 0-7. Three of the items assess two bias domains (random sequence generation 
and incomplete outcome data) and four assess other aspects of quality (power analysis, 
control for patient demoralisation, manualisation, and therapist’s adherence to 
treatment). An RCT with a score of ≥5 is considered high-quality and <5 is considered 
low-quality. 
2.3.1.8 Reviews using Naaman’s quality scale 
Naaman et al., 2009 
Naaman and colleagues (2009) meta-analysis evaluated 18 RCTs of psychological 
treatments for emotional distress and QoL in BCa. Sixteen of the 18 RCTs included 
emotional distress as an outcome. Seven of those RCTs were rated as high-quality and 
nine as low-quality. Naaman et al. (2009) only reported whether an RCT was of ‘high’ 
or ‘low’ quality. The authors did not report the overall quality score of each RCT or 
provide scores for individual items, making it impossible to know which 
methodological aspects were well-conducted or most in need of improvement. 
2.3.1.9 Beatty’s quality checklist  
Beatty et al. (2018) created their own quality checklist which combined the five 
criteria for empirically supported psychotherapies (type of comparator condition, 
sample size, power analysis, reliable outcome measures, and clear specification of 
inclusion criteria; Chambless & Hollon, 1998) and six domains from the Cochrane 
RoB tool (random sequence generation, allocation concealment, blinding of 
participants and personnel, incomplete outcome data, selective outcome reporting, and 
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‘other biases’; Higgins & Green, 2011). Beatty et al. (2018) defined ‘higher-quality 
trials’ as those meeting at least 8 of the 11 criteria. 
2.3.1.10 Review using Beatty’s quality checklist 
Beatty et al., 2018 
In their systematic review, Beatty et al. (2018) evaluated 15 RCTs of psychological 
treatments for emotional distress, survival, QoL, and somatic symptoms in metastatic 
BCa patients. Thirteen of the 15 RCTs included emotional distress as an outcome. 
Eight of those were categorised as ‘higher-quality’ and five as ‘lower-quality’. Most 
RCTs had an adequate sample size, clearly specified inclusion criteria, reliable 
outcome measures, adequate methods of sequence generation and allocation 
concealment, were free of selective reporting, and used ‘acceptable’ comparator 
conditions (though ‘acceptable’ was not defined). Most RCTs failed to conduct power 
analysis, blind participants and personnel, or remain free from ‘other biases’; and just 
under half reported strategies to deal with incomplete outcome data. 
2.3.2 Summary of results 
Seven of the nine reviews assessed RoB and two assessed the broader domain of 
quality. However, the seven reviews assessing RoB claimed to assess the broader 
domain of quality. The design elements assessed across the different assessment tools 
varied greatly. For example, only 27% of the design elements included in Beatty’s 
quality checklist (Beatty et al., 2018) were included in Naaman’s quality scale 
(Naaman et al., 2009). The methodological quality of RCTs varied drastically across 
reviews. This was in part due to the different RCTs included in reviews but mainly 
due to the different design elements being assessed. For example, Mustafa et al. (2013) 
and Beatty et al (2013) assessed the same eight RCTs using two different assessment 
tools. Mustafa et al. (2013) categorised all eight as having an unclear RoB, while 
Beatty et al. (2018) categorised five as ‘higher quality’, and three as ‘lower quality’. 
Four reviews used assessment tools with well-defined criteria (Haller et al., 2017; 
Jassim et al., 2015; Mustafa et al., 2013; Ye et al., 2018) but five (including both 
reviews assessing the broader construct of quality) used assessment tools with poorly 
operationally defined criteria (Beatty et al., 2018; Fors et al., 2011; Naaman et al., 
2009; Xiao et al., 2017; Zhang et al., 2016). For example, to assess blinding of 
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participants and personnel, Fors RoB scale asks: ‘are blinding methods adequate?’ 
without providing an explanation of what constitutes ‘adequate’. Seven reviews 
reported ratings for each individual design element (Beatty et al., 2018; Fors et al., 
2011; Haller et al., 2017; Jassim et al., 2015; Mustafa et al., 2013; Ye et al., 2018; 
Zhang et al., 2016) but two stated only the overall quality of RCTs (Naaman et al., 
2009; Xiao et al., 2017).
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Table 2.2: Trial quality findings from each review 
Review Risk of bias or quality assessment Type of assessment tool Assessment tool RCTs Quality of RCTs 
Beatty et al. 2018 Quality Checklist Beatty’s Quality 
checklist 
n=13 Higher quality n=8 (62%) 
Lower quality n=5 (38%) 
Fors et al. 2017 Risk of bias Scale Fors’ RoB scale n=17 High quality n=3 (18%) 
Moderate quality n=14 (82%) 
Haller et al. 2017 Risk of bias Domain based evaluation Cochrane RoB tool n=9 High RoB n=9 (100%) 
Jassim et al. 2015 Risk of bias Domain based evaluation Cochrane RoB tool n=28 High RoB n=9 (32%) 
Unclear RoB n=19 (68%) 
Mustafa et al. 2015 Risk of bias Domain based evaluation Cochrane RoB tool n=8 Unclear RoB n=8 (100%) 
Naaman et al. 2009 Quality Scale Naaman’s Quality 
scale 
n=16 High quality n=7 (44%) 
Low quality n=9 (56%) 
Xiao et al. 2017 Risk of bias Scale Jadad scale n=13 Adequate quality n=13 (100%) 
Ye et al. 2018 Risk of bias Domain based evaluation Cochrane RoB tool n=10 High RoB n=8 (80%) 
Unclear RoB n=1 (10%) 
Low RoB n=1 (10%) 
Zhang et al. 2016 Risk of bias Scale Jadad scale n=5 High quality n=2 (40%) 
Adequate quality n=1 (20%) 
Low quality n=2 (40%) 
Note. RoB = risk of bias; RCTs = randomised controlled trials 
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2.4 Discussion 
A scoping review of reviews assessing the methodological quality of RCTs for 
emotional distress in BCa was conducted. Nine reviews were identified, in which five 
different assessment tools were used. The methodological quality of RCTs included 
in these reviews varied drastically depending on the design elements being assessed. 
Seven of the nine reviews took a narrow approach to assessing methodological quality 
by only focusing on internal validity (i.e. RoB). However, all seven claimed to assess 
the broader domain of methodological quality. The remaining two reviews 
(corresponding to two assessment tools) went beyond assessing RoB and assessed 
other important design elements essential to high-quality RCTs (i.e. use of power 
analysis, type of comparator conditions, and use of reliable outcome measures). Yet, 
they still failed to assess many other design elements equally essential to high-quality 
RCTs (i.e. clarity of sample description, representativeness of the sample, validity and 
specificity of outcome measures, control of concomitant treatments, length of follow-
up, and assessment of clinical significance).  
Only one of the previous reviews (corresponding to one assessment tool) assessed any 
design elements specific to psychotherapy RCTs (Naaman et al. 2009). Naaman et al. 
(2009) assessed manualisation and therapist’s adherence. However, none of the 
reviews (or the assessment tools used) assessed the number of therapists, therapist’s 
level of training, therapist’s competence to treatment, or equality of therapy hours 
between conditions. Moreover, Naaman et al. (2009) only reported whether a trial was 
of ‘high’ or ‘low’ quality. Thus, the extent to which manuals were followed or 
therapists adhered to treatment remains unknown.  
Finally, the two reviews that assessed the broader construct of quality used assessment 
tools that were poorly operationally defined. This increases the likelihood of 
heterogenous ratings across different raters, limiting the reliability and validity of any 
conclusions drawn.  
2.4.1 Conclusion 
The methodological quality of RCTs of psychological treatments for emotional 
distress in BCa has been inadequately assessed. Unless the quality of these RCTs is 
adequately assessed, confidence in conclusions regarding treatment efficacy will be 
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undermined. An assessment of the methodological quality of RCTs of psychological 
treatments for emotional distress in BCa using an operationally defined assessment 
tool which assesses important generic design elements and psychotherapy-specific 
design elements is needed.  
Therefore, in the next chapter, a systematic review of the methodological quality of 
RCTs of psychological treatments for emotional distress in BCa is presented. 
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Chapter 3. Study 2: A Systematic Review of the Quality of Randomised 
Controlled Trials of Psychological Treatments for Emotional Distress in Breast 
Cancer 
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3.1 Introduction 
The aim of this study was to evaluate the methodological quality of RCTs of 
psychological treatments for emotional distress in BCa using a scale developed in the 
context of broader psychotherapy research. The most appropriate such scale is the 
Psychotherapy Outcome Study Methodology Rating Form (POMRF; Öst, 2008), 
which was explicitly designed to assess the quality of psychotherapy RCTs. It assesses 
both generic design elements and those specific to psychotherapy RCTs. The POMRF 
has been used to assess the quality of psychotherapy RCTs in several mental health 
populations (Arnberg & Öst, 2014; Öst, 2008, 2014; Öst et al., 2015; Öst & Ollendick, 
2017; Öst, Riise, Wergeland, Hansen, & Kvale, 2016; Sloan et al., 2017; Swain, 
Hancock, Dixon, & Bowman, 2015; Swain, Hancock, Hainsworth, & Bowman, 2013), 
and those assessments provide a benchmark against which to gauge the quality of 
RCTs in BCa. Therefore, using the POMRF, this study had five aims:  
Aim 1: Evaluate the overall quality of RCTs of psychological treatments for emotional 
distress in BCa, considering both generic design elements and those specific to 
psychotherapy RCTs. 
Aim 2: Evaluate specific design elements that have previously been inadequately 
evaluated in meta-analyses or are poorly implemented in RCTs. 
Aim 3: Assess the quality of RCTs in this population against the benchmark of RCTs 
in mental health populations. 
Aim 4: Assess whether the quality of RCTs differ depending on the type of treatment 
being tested. 
Aim 5: Considering the general improvement of methodological standards in 
psychotherapy RCTs over time, determine whether methodological quality in BCa 
studies has improved over time. 
3.2 Method 
3.2.1 Search strategy 
PubMed, PsycINFO, Web of Science, Scopus, PsycARTICLE, and AMED were 
searched from their inception until October 2016 using MeSH terms and keywords to 
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identify psychotherapy RCTs for emotional distress in BCa. The search used a 
combination of terms associated with BCa (including: “breast neoplasms” OR “breast 
cancer”), emotional distress (including: “Depression”[Mesh] OR “depressive 
disorder”[Mesh] OR “depressive disorder” OR “anxiety”[Mesh] Or “anxiety 
disorders”[Mesh] OR “anxiety disorders” OR “anxiety” OR “depression” OR 
“emotional distress” OR “psychological distress”), and psychological treatments 
(including: “Psychotherapy”[Mesh] OR “psychotherapy” OR “psychological 
therapy” OR “counselling” OR “counselling” OR “psychological intervention” OR 
“cognitive behavioural therapy”  OR “group therapy” OR “psychosocial therapy”). 
No date restriction was applied but only English language articles were included. The 
final search strategy used for each database is available in Appendix 2. In addition, 
relevant meta-analyses and reference lists of eligible articles were hand-searched to 
identify any additional studies that may have been missed. 
3.2.2 Eligibility criteria 
Eligibility criteria are detailed according to the PICOS framework (Liberati et al., 
2009). 
Participants: Trials in which the included participants were exclusively adults aged 
18 years or older with a histologically confirmed diagnosis of BCa. 
Interventions: Trials evaluating a psychological treatment. As “psychological 
treatment” is poorly defined in the literature (Jassim et al., 2015) a generic definition 
was used: treatments primarily using psychological techniques. Trials evaluating 
complementary alternative medicines (i.e. yoga, hypnosis, reiki, logotherapy, art 
therapy, dance therapy) or treatments involving no interaction between therapist and 
patient (i.e. based explicitly on written or visual material) were excluded. 
Controls: Trials using either a no treatment (usual care) control, an active (attention 
placebo) control or an alternative psychological treatment.  
Outcomes: Trials in which the primary and/or secondary outcome was emotional 
distress, defined as anxiety, depression, general mood, or global emotional distress.  
Studies: Only RCTs published in English in a peer-reviewed journal.  
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3.2.3 Study selection 
After removing duplicates, titles and abstracts were searched to identify relevant RCTs 
by one reviewer (JT). If this information could not be ascertained from the title or 
abstract, the full text of the article was obtained for detailed scrutiny. Any uncertainties 
regarding trial inclusion were discussed with a second reviewer (PF). When a single 
trial was published more than once, the report that most thoroughly presented the 
methods and findings was evaluated. Therefore, each paper represented a unique trial. 
3.2.4 Data extraction 
Using a standardised data extraction protocol (see Appendix 3), data were extracted 
for all included trials by two independent reviewers (JT & CH). Data extracted was 
year of publication; country of origin; number of participants randomly assigned to 
condition; mean age; distribution of trajectory stage; distribution of tumour stage; 
outcome measures; treatment type; treatment format; duration of treatment; number of 
treatment sessions; and type of control condition.  
3.2.5 Aim 1: Overall quality of trials 
Methodological quality was rated using the POMRF (see Appendix 4; Öst, 2008). It 
consists of 22 items, each scored 0 (poor), 1 (fair), or 2 (good), producing a total score 
ranging from 0 to 44, with higher scores indicating greater quality. Three items relating 
to psychiatric diagnoses (items 2, 4, & 8), irrelevant to this review, were disregarded; 
therefore, in this study, the maximum possible score was 38.  A minimum cut-off score 
to determine adequate methodological quality on the POMRF has not been 
established. However, a review (Gerber et al., 2011) which used the Randomized 
Controlled Trial Psychotherapy Quality Rating Scale (RCT-PQRS; Kocsis et al., 
2010) to evaluate the quality of psychodynamic trials provided a suitable benchmark. 
In that review, a cut off score of at least 50% of the maximum possible score on the 
RCT-PQRS was used. Thus, in this review a total score of 19 out of 38 (i.e. 50% of 
the maximum possible score) was chosen as the criterion for minimum adequate 
quality.  
To compare quality on generic and psychotherapy-specific items, POMRF items were 
allocated to two subscales: “generic design elements” (Table 3.1: maximum possible 
score of 26) and “psychotherapy-specific design elements” (Table 3.1: maximum 
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possible score of 12). To allow comparison between the two subscales, total subscale 
scores were transformed into percentages of the maximum possible on the relevant 
subscale. 
Two reviewers (JT & CH) independently rated the quality of each trial. To determine 
consistency of quality scores between the reviewers, interrater reliability was assessed 
using the intra-class correlation coefficient (ICC) for total quality scores, and the 
weighted kappa statistic for individual item scores. The ICC for total quality scores 
was 0.95 (95% CI, 0.92–0.97) and kappa for individual items ranged from 0.73 to 
0.93, with mean 0.8, indicating good inter-rater reliability. Following the assessment 
of inter-rater reliability, discrepancies in ratings were resolved through discussion and 
consensus between both reviewers.  
3.2.6 Aim 2: Quality of specific design elements  
All design elements specific to psychotherapy RCTs (Table 3.1) and generic ones that 
were particularly poorly implemented (i.e. a score of zero in at least 75% of trials) 
were descriptively evaluated. 
3.2.7 Aim 3: Quality comparison with mental health populations  
To locate meta-analyses and systematic reviews evaluating the quality of RCTs using 
the POMRF in mental health populations, all papers citing the study in which the 
POMRF was devised were identified by searching Google Scholar. Potentially 
relevant papers were retrieved and assessed for eligibility. To compare the quality of 
RCTs in BCa with RCTs in mental health populations, for which the full 22-item scale 
was reported, scores were transformed into percentages of the maximum possible 
score on the scale, as well as on the two subscales.  
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Table 3.1: Items in the Psychotherapy outcome study methodology rating form 
 
 
3.2.8 Aim 4: Quality comparison by treatment type 
Psychological treatments were coded into five categories: ‘cognitive-behavioural-
based treatments’ (CBT; treatments targeting specific thoughts or behaviours using 
cognitive behavioural techniques); ‘mindfulness-based therapies’ (MBT; treatments 
focusing on meditation, visualisation, and present-moment awareness); ‘Psycho-
education’ (treatments primarily providing psychological education) ‘support’ 
(treatments emphasising a supportive environment by providing emotional or social 
support); and ‘peer-led treatments’ (any treatment that was delivered by non-
professional peers). If a treatment did not fit into one of the five categories (i.e. it 
combined components from multiple categories without emphasising any one) it was 
Subscale 1:  Generic design elements 
(maximum possible score of 26) 
Subscale 2: Psychotherapy-specific 
design elements (maximum possible 
score of 12) 
1. Clarity of sample description 13. Manualised treatment  
3. Representativeness of sample 14. Number of therapists 
5. Specificity of outcome measures 15. Therapist training/experience 
6. Reliability and validity of outcome measures 16. Checks for therapist adherence 
7. Use of blind evaluators 17. Checks for therapist competence 
9. Assignment to treatment 22. Equality of therapy hours  
10. Design (i.e. type of comparator condition) 
 
11. Power analysis 
 
12. Assessment points 
 
18. Control of concomitant treatments  
 
19. Handling of attrition 
 
20. Statistical analyses and presentation of results 
 
21. Clinical significance 
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categorised into a sixth category - ‘other’. The categorisation of treatments was 
discussed by three reviewers (JT, CH & PF) until consensus was reached. 
One-way ANOVAs compared differences in trial quality between treatment 
categories. Total POMRF scores and the two subscales scores distinguishing generic 
and psychotherapy-specific design elements were evaluated. Post hoc Tukey HSD 
tests followed significant main effects to identify which treatment types differed. 
3.2.9 Aim 5: Quality trends over time  
Spearman correlation was calculated for year of study publication with total POMRF 
scores and the two subscale scores distinguishing generic and psychotherapy-specific 
design elements. 
3.3 Results 
The electronic database search yielded 2,210 citations; an additional 18 were identified 
through hand searching. After removal of duplicates, 1,412 remained for screening 
based on title and abstract. Of these, 1,169 clearly did not meet the inclusion criteria. 
The full text articles of the remaining 252 citations were retrieved and assessed. 
Ninety-one articles published from 1980 through October 2016 were eligible and 
included. Figure 3.1 shows the study selection process. A complete list of references 
of the included RCTs can be found in Appendix 5.  
A summary of the trial characteristics is presented in Table 3.2, while a complete 
description of each trial is presented in Table 3.3. The trials comprised 13,553 patients 
with sample sizes ranging from 14-558 (mean 149; median 117). Most trials were 
conducted in the United States and exclusively included non-metastatic BCa patients. 
The treatment approach used most frequently was CBT and most treatments were 
delivered in group format. On average, treatment involved a mean of 8 sessions 
(median 8; range 1-25), with each session lasting 1.5 hours (median 1.5; range 0.25-
3; excluding supplementary material and subsequent monitoring). Depression was the 
most common outcome variable (n=60), followed by anxiety (n=47) and mood/global 
distress (n=44). The Profile of Mood States (POMS; n=20), Centre for 
Epidemiological Studies Depression Scale (CES-D; n=19) and the Hospital Anxiety 
and Depression scale (HADS; n=17) were the most commonly used outcome 
measures. 
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Figure 3.1: Flow chart showing trial identification and selection
Records identified through database 
searching  
(n=2,081) 
Web of Science (n=783) 
Scopus (n=782) 
PubMed (n=258) 
PsycINFO (n=235) 
PsycARTICLES (n=13) 
AMED (n=10) 
 
Records after duplicates removed  
(n=1,421) 
Records excluded  
(n=1,169) 
Full-text articles excluded, with reasons  
(n = 161) 
No Psychological intervention (n=50) 
Participants not exclusively BCa (n=30) 
Language not English (n=2) 
Not an RCT (n=47) 
No relevant outcomes (n=4) 
Follow-up paper of an included trial 
(n=13) 
Unpublished paper (n=15) 
 
Additional records identified through other 
sources  
(n=18) 
Full-text articles assessed 
for eligibility  
(n=252) 
Studies included in quantitative 
synthesis (n=91) 
Records screened based 
on titles and abstracts 
(n=1,421) 
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Table 3.2: Descriptive summary of included trials by treatment type and format  
    
Treatment format  Treatment type 
 
Total sample  Individual Group Couples 
 CBT Mindfulness PsyEd Support Peer-led Other 
 
(n=91)  (n=37) (n=48) (n=6)  (n=40) (n=5) (n=6) (n=21) (n=6) (n=13) 
 
N % 
 
N % N % N %  N % N % N % N % N % N % 
Population 
         
 
            
Patients 
         
 
            
Total No. of 
patients 
13,553 
  
5,553 
 
7,334 
 
666 
 
 4,809 
 
922 
 
1,102 
 
3,913 
 
1,234 
 
1,573 
 
Mean sample 
size per study 
149 
  
150 
 
153 
 
111 
 
 120 
 
184 
 
184 
 
186 
 
205 
 
121 
 
Median 
sample size 
per study 
117 
  
120 
 
119 
 
46 
 
 100 
 
172 
 
162 
 
152 
 
198 
 
87 
 
Minimum 
sample size 
14 
  
25 
 
32 
 
14 
 
 14 
 
71 
 
66 
 
46 
 
104 
 
40 
 
Maximum 
sample size 
558 
  
558 
 
382 
 
302 
 
 355 
 
366 
 
367 
 
558 
 
305 
 
382 
 
     Mean age,   
years 
52 
  
53 
 
52 
 
50 
 
 52 
 
52 
 
49 
 
54 
 
52 
 
52 
 
Median age, 
years 
52 
  
54 
 
51 
 
52 
 
 53 
 
50 
 
50 
 
53 
 
51 
 
53 
 
Stage of disease 
         
 
            
   Non- 
   metastatic 
59 65% 
 
23 62% 31 65% 5 83%  28 70% 5 100% 5 83% 11 52% 3 50% 7 54% 
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Treatment format  Treatment type 
 
Total sample  Individual Group Couples 
 CBT Mindfulness PsyEd Support Peer-led Other 
 
(n=91)  (n=37) (n=48) (n=6)  (n=40) (n=5) (n=6) (n=21) (n=6) (n=13) 
 
N % 
 
N % N % N %  N % N % N % N % N % N % 
Metastatic 7 8% 
 
1 3% 6 13% 
  
 3 8% 
    
4 19% 
  
3 23% 
Both 15 16% 
 
9 24% 5 10% 1 17%  6 15% 
    
4 19% 2 33% 
  
NR 10 11% 
 
4 11% 6 13% 
  
 3 8% 
  
1 17% 2 10% 1 17% 3 23% 
Country 
         
 
            
USA 45 49% 
 
20 54% 20 42% 5 83%  21 53% 3 60% 3 50% 10 48% 5 83% 3 23% 
Canada 10 11% 
 
4 11% 6 13% 
  
 6 15% 
  
1 17% 2 10% 
  
1 8% 
Australia 7 8% 
 
2 5% 5 10% 
  
 3 8% 
  
1 17% 2 10% 
  
1 8% 
UK 4 4% 
 
3 8% 1 2% 
  
 
  
1 20% 
  
3 14% 
    
Sweden 4 4% 
 
2 5% 2 4% 
  
 2 5% 
    
1 5% 
  
1 8% 
Other 21 23% 
 
5 14% 13 27% 1 17%  8 20% 1 20% 1 17% 3 14% 1 17% 7 54% 
 
China (2), Croatia (1), 
Denmark (2), France 
(2), Germany (1), 
Greece (2), Holland 
(1), Iran (2), Ireland 
(1), Israel (1), Italy (1), 
Japan (2), Korea (1), 
Norway (1), Romania 
(1) 
 
Croatia (1), 
Germany (1), 
Italy (1), Korea 
(1), Romania 
(1), Greece (1) 
China (2), 
Denmark (2), 
France (2), 
Holland (1), Iran 
(1), Ireland (2), 
Israel (1), Japan 
(2), Norway (1) 
Greece (1)  China (1), 
Croatia (1), 
Denmark (1), 
France (1), Iran 
(1), Ireland (1), 
Israel (1), Italy 
(1) 
Denmark (1) Norway (1) China (1), 
Japan (1), 
Romania (1) 
Korea (1) France (1), 
Germany (1), 
Greece (2), 
Holland (1), 
Iran (1), Japan 
(1),  
Exclusively 
distressed patients 
         
 
            
Yes 12 13% 
 
7 19% 5 10% 
  
    8 20% 
    
1 5% 1 17% 2 15% 
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Treatment format  Treatment type 
 
Total sample  Individual Group Couples 
 CBT Mindfulness PsyEd Support Peer-led Other 
 
(n=91)  (n=37) (n=48) (n=6)  (n=40) (n=5) (n=6) (n=21) (n=6) (n=13) 
 
N % 
 
N % N % N %  N % N % N % N % N % N % 
No 79 87% 
 
29 81% 43 90% 6 100%  32 80% 5 100% 6 100% 20 95% 5 83% 11 85% 
Outcomes * 
         
 
            
Outcome variable                       
Anxiety  47 52% 
 
22 60% 22 46% 3 50%  24 60% 3 60% 3 50% 9 43% 2 33% 6 46% 
Depression 60 66% 
 
29 78% 27 56% 4 67%  26 65% 4 80% 4 67% 12 57% 5 83% 9 69% 
Mood/ global 
distress 
44 48% 
 
10 27% 30 63% 4 67%  21 53% 2 40% 3 50% 10 48% 2 33% 6 46% 
Outcome measure                       
CES-D 20 22%                     
POMS 19 21%                     
HADS 17 18%                     
Treatment   
(active 
treatment) 
         
 
            
No. of sessions 
         
 
            
Mean 8 
  
7 
 
9 
 
6 
 
 9 
 
8 
 
5 
 
7 
 
7 
 
9 
 
Median 8 
  
6 
 
9 
 
6 
 
 
            
Minimum 1 
  
1 
 
1 
 
4 
 
 1 
 
6 
 
3 
 
1 
 
3 
 
2 
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Treatment format  Treatment type 
 
Total sample  Individual Group Couples 
 CBT Mindfulness PsyEd Support Peer-led Other 
 
(n=91)  (n=37) (n=48) (n=6)  (n=40) (n=5) (n=6) (n=21) (n=6) (n=13) 
 
N % 
 
N % N % N %  N % N % N % N % N % N % 
Maximum 25 
  
25 
 
23 
 
8 
 
 23 
 
11 
 
6 
 
16 
 
9 
 
25 
 
Variable No. 
of sessions 
(trials) 
9 
  
4 
 
5 
   
 2 
     
5 
 
2 
   
Not reported 
(trials) 
3 
  
3 
     
 2 
     
1 
     
Length of 
sessions (hours) 
         
 
            
Mean 1.5 
  
0.75 
 
1.75 
 
0.75 
 
 1.5 
 
2 
 
1.5 
 
1.25 
 
1.25 
 
1.5 
 
Median 1.5 
  
0.75 
 
2 
 
1.5 
 
 
  
2 
         
Minimum 0.25 
  
0.25 
 
1 
 
0.5 
 
 0.5 
 
2 
 
0.25 
 
0.5 
 
1 
 
0.5 
 
Maximum 3 
  
1.5 
 
3 
 
1.5 
 
 3 
 
2 
 
2.5 
 
2 
 
1.5 
 
2.5 
 
Variable no 
of sessions 
(trials) 
12 
  
6 
 
6 
   
 4 
 
3 
   
3 
 
2 
   
Not reported 
(trials) 
14 
  
8 
 
4 
 
2 
 
 
      
3 
 
1 
 
4 
 
Treatment type 
         
 
            
CBT 40 44% 
 
14 38% 22 46% 4 67%  
            
       Mindfulness 5 5% 
   
5 10% 
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Treatment format  Treatment type 
 
Total sample  Individual Group Couples 
 CBT Mindfulness PsyEd Support Peer-led Other 
 
(n=91)  (n=37) (n=48) (n=6)  (n=40) (n=5) (n=6) (n=21) (n=6) (n=13) 
 
N % 
 
N % N % N %  N % N % N % N % N % N % 
PsyEd 6 7% 
 
2 5% 4 8% 
  
 
            
Support 21 23% 
 
11 30% 9 19% 1 17%  
            
Peer-led 6 7% 
 
5 14% 1 2% 
  
 
            
Other 13 14% 
 
5 14% 7 15% 1 17%  
            
Treatment 
Format 
 
         
 
            
Individual 37 41% 
       
 14 35% 
  
2 33% 11 52% 5 83% 5 39% 
Group 48 53% 
       
 22 55% 5 100% 4 67% 9 43% 1 17% 7 54% 
Couples 6 7% 
       
 4 10% 
    
1 5% 
  
1 8% 
Note. No. = number; NR = not reported; CBT = cognitive behavioural therapy; PsyEd = psychoeducation; * Because several trials used multiple outcome measures, the number of trials presented for the type of outcome measure exceeds the 
total number of trials 
 
Table 3.3: Descriptive summary of each included trial  
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Abad 2016 Iran 36 NR  NR Cognitive behavioural CBT Ind 8 2 hrs No Anx, dep DASS 
Allard 2007 Canada 117 54 I-IIa Attention focused, 
symptom management, 
coping mechanisms 
Other Ind 2 NR No Mood/ 
distress  
POMS-SF 
Allen 2002 USA 164 42 I-IIIa Problem solving training CBT Ind 6 NR No Mood/ 
distress 
MHI-5, 
IES 
Andersen 
2004 
USA 227 51 II-III Coping skills, stress 
management, relaxation, 
health behaviour, 
communication 
Other Grp 18 1.5 hrs No Mood/ 
distress 
POMS 
Anton 2015 Croatia 120 57 NR Cognitive behavioural CBT Ind Varied Varied Yes Anx, dep HAM-D, 
HAM-A 
Antoni 2001 USA 136 50 0-II CBSM CBT Grp 10 2 hrs No Dep, 
mood/ 
distress 
CES-D, 
POMS 
composite 
Antoni 2006 USA 199 50 0-III CBSM CBT Grp 10 2 hrs No Anx, 
mood/ 
distress 
ABS 
composite
, HAM-A 
Antoni 2009 USA 128 50 0-III CBSM CBT Grp 10 NR No Anx, dep, 
mood/ 
distress 
ABS 
composite
, HAM-A 
Arving 2007 Sweden 179 55 0-IV Relaxation, distraction, 
techniques, problem 
solving 
CBT Ind 0-23 35 mins - 
1hr 
No Anx, dep HADS, 
STAI 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Ashing 
2014 
USA 211 53 0-III Education; problem 
solving training; stress 
management;  
CBT Ind 8 40-50 mins Yes Dep CES-D 
Badger 
2007 
USA 96 54 I-III Interpersonal 
counselling 
Support Ind 6 35 mins   No Anx, dep CES-D, 
self-
constructe
d anxiety 
measure 
Badger 
2013 
USA 52 52 I-IV Interpersonal 
counselling 
Support Cpl 8 30 mins No Anx, dep CES-D, 
STAI, 
PANAS-
Negative 
affect 
subscale 
Badger 
2013 
USA 90 47 I-III Interpersonal 
counselling 
Support Ind 8 29 mins No Dep CES-D 
Baucom 
2009 
USA 14 NR  I-II Relationship 
enhancement, problem 
solving skills, emotional 
expression 
CBT Cpl 6 1.25 hrs No Mood/ 
distress 
BSI-18 
Beutel 2014 Germany 157 52 0-IV Psychodynamic Other Ind 25 NR  Yes Dep HADS-D, 
SCID 
Bjornklett 
2012 
Sweden 382 58 NR Education, support, 
relaxation, Qi-gong, 
liberating dance 
Other Grp 7 + 4 follow-
up 
NR No Anx, dep HADS 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Boesen 
2011 
Denmark 205 NR  I-IIIa Existential–cognitive 
therapy 
CBT Grp 10 32 hrs No Mood/ 
distress 
POMS-SF 
Bower 2015 USA 71 47 0-III Mindfulness meditation Mindfulness Grp 6 2 hrs No Dep CES-D 
Bredal 2014 Norway 367 55 0-III Education, stress 
management, support 
PsyEd Grp 5 2 hrs No Anx, dep HADS 
Budin 2008 USA 249 54 0-III Support, counselling, 
education,  
Support Ind 8 NR No Mood/ 
distress 
PAL-C 
psycholog
ical sub-
scale 
Burton 1995 UK 215 62 I-IV Counselling   Support Ind 1 NR No Anx, dep HADS 
Carlson 
2013 
Canada 271 55 I-IV SET Support Grp 8 (+ 1 
workshop) 
1.5 hrs (+ 6 
hrs) 
Yes Mood/ 
distress 
POMS 
Chan 2006 China 87 49 I-III SET Support Grp 8 2 hrs No Mood/ 
distress 
GHQ-12 
Christensen 
1983 
USA 20 40 0-III Problem solving, 
communication, 
emotional expression  
Other Cpl 4 NR No Anx, dep BDI, 
STAI-
state 
Classen 
2001 
USA 125 53 IV SET Support Grp Varied 1.5 hrs No Mood/distr
ess 
POMS 
Classen 
2008 
USA 353 50 I-IIIa SET Support Grp 12 1.5 hrs No Anx, dep, 
mood/ 
distress 
POMS, 
HADS 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Cohen 2007 Israel 114 54 I-II Cognitive behavioural CBT Grp 9 1.5 hrs No Mood/ 
distress 
BSI 
Cousson-
Gelie 2011 
France 92 53 0-III Managing irrational 
thoughts, perceived 
control, coping, 
relaxation 
Other Grp 8 2 hrs No Anx, dep HADS 
Creuss 2000 USA 34 46 I-II CBSM CBT Grp 10 2 hrs No Mood/distr
ess 
POMS 
Davis 1986 Canada 25 51 I Cognitive   CBT Ind 13 45 mins No Anx STAI-
state 
Dirksen 
2007 
USA 81 58 I-III Cognitive behavioural CBT Grp 6 Varied No Anx, dep CES-D, 
STAI 
Dolbeault 
2009 
France 203 53 NR Problem solving, 
cognitive restructuring, 
education 
CBT Grp 8 2 hrs No Anx, 
mood/ 
distress 
POMS, 
STAI 
Dowlatabad
i 2016 
Iran 42 37 NR Positive psychotherapy Other Grp 10 1.5 hrs Yes Dep BDI 
Edelman 
1999a 
Australia 60 48 I-II Cognitive behavioural CBT Grp 12 2 hrs No Anx, dep POMS 
Edelman 
1999b 
Australia 124 50 IV Cognitive behavioural CBT Grp 11 NR No Mood/ 
distress 
POMS 
Edmonds 
1999 
Canada 66 51 IV CBT, coping skills 
training 
CBT Grp 35 (+15 
additional if 
requested) 
2 hrs No Mood/ 
distress 
POMS, 
POMS-SF 
 48 
Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Ferguson 
2012 
USA 40 50 I-IIIa Cognitive behavioural CBT Ind 4 30-50 mins No Anx, dep CES-D, 
STAI 
Ferguson 
2016 
USA 47 55 I-III Cognitive behavioural CBT Ind 8 30-45 mins Yes Anx, dep DASS-21 
Fillion 2008 Canada 94 52 0-III Education, stress 
management, exercise 
PsyEd Grp 4 (+1 
booster) 
2.5 hrs (+ 
15 mins) 
No Mood/ 
distress 
POMS 
Fukui 2000 Japan 50 53 I-III Coping skills training, 
CBT, education  
Other Grp 6 1.5 hrs No Anx, 
mood/ 
distress 
HADS, 
POMS 
Gaston 2000 USA 110 NR  II-IV Cognitive restructuring, 
relaxation/guided 
imagery  
CBT Ind 1 NR No Anx, dep BDI, 
STAI 
Giese-Davis 
2016 
USA 104 NR  0-IV Peer counselling, 
support 
Support Ind Varied Varied No Dep CES-D 
Goodwin 
2001 
Canada 235 51 IV SET Support Grp >52 1.5 hrs No Mood/ 
distress 
POMS 
Gotay 2007 USA 305 54 I-IIIa Peer counselling, 
support, stress 
management 
Support Ind 04-Aug NR No Dep CES-D 
Graves 2003 USA 32 56 0-III Coping skills training, 
relaxation, CBT 
CBT Grp 8 1.5 hrs No Mood/ 
distress 
POMS 
Groarke 
2012 
Ireland 355 54 0-IV CBSM CBT Grp 5 3 hrs No Anx, dep HADS 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Gudenkauf 
2015 
USA 183 54 0-III CBSM CBT Grp 5 1.5 hrs No Dep ABS 
depression 
subscale, 
IES-R 
Heiney 
2003 
USA 66 50 NR Education, coping 
strategies, support 
PsyEd Grp 6 1.5 hrs No Mood/ 
distress 
POMS-SF 
Henderson 
2012 
USA 172 50 I-II MBSR Mindfulness Grp 7 + (1 retreat 
session + 3 
booster) 
3.5 hrs 
(+7.5 +2 
hrs) 
No Anx, 
mood/ 
distress 
BDI, BAI, 
SCL-90-R 
Hoffman 
2012 
UK 229 50 0-III MBSR Mindfulness Grp 8 (+ 1 extra) 2 hrs (+ 6 
hrs)  
No Mood/ 
distress 
POMS 
Hopko 2011 USA 80 55 0-IV BATD CBT Ind 8 1 hr Yes Anx, dep BDI, 
HAM-D, 
BAI 
Kalaitzi 
2007 
Greece 40 53 0 Couple and sex therapy Other Cpl 6 NR No Mood/ 
distress 
CES-D, 
STAI 
Kissane 
2003 
Australia 303 46 I-II Cognitive existential  CBT Grp 20 (+3 
relaxation) 
1.5 hrs (+50 
mins) 
No Anx, 
mood/ 
distress 
ABS, 
HADS 
Kissane 
2007 
Australia 227 52 IV SET Support Grp Varied 1.5 hrs No Mood/ 
distress 
IES 
Lane 2005 Australia 42 54 NR Personal construct 
therapy 
Other Grp 9 2 hrs No Anx, dep Gottschal
k-Glaser 
content 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
analysis 
scale 
Larson 2000 USA 41 56 I-IV Education, problem-
solving, relaxation, 
support 
Other Ind 2 1.5 hrs No Dep CES-D 
Lechner 
2014 
USA 114 51 0-IV CBSM CBT Grp 10 1.5 hrs Yes Dep, 
mood/ 
distress 
CES-D, 
POMS-SF 
Lee 2013 Korea 129 48 I-III Peer support Support Ind 6 Varied Yes Anx, dep HADS 
Lengacher 
2009 
USA 84 58 0-III MBSR Minfdulness Grp 6 2 hrs No Anx, dep CES-D, 
STAI 
Lewis 2015 USA 213 43 0-III Education, counselling PsyEd Ind 5 1.5 hrs No Anx, dep CES-D 
Maguire 
1980 
UK 152 NR  NR Counselling Support Ind NR NR No Anx, dep Present 
state 
examinati
on 
Manne 2005 USA 238 50 0-IIIa Communication, 
relaxation, stress 
management, problem 
solving 
CBT Cpl 6 1.5 hrs No Anx, 
mood/ 
distress 
MHI-18. 
IES 
Manne 2016 USA 302 55 0-IIIa Communication, 
relaxation, stress 
management, problem 
solving, cognitive 
restructuring 
CBT Cpl 8 1.5 hrs No Anx, 
mood/ 
distress 
MHI-38 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Marchioro 
1996 
Italy 36 NR  0-III Cognitive behavioural CBT Ind NR 50 mins No Dep BDI 
Marcus 
2010 
USA 304 NR  I-IIIa Counselling, relaxation Support Ind 16 45 mins No Dep CES-D 
McArdle 
1996 
UK 272 NR  NR Support, counselling Support Ind Varied Varied No Anx, dep HADS 
Mens 2015 USA 245 51 I-II 
or IV 
Peer support Support Grp 8 1 hrs No Dep CES-D 
Miyashita 
2005 
Japan 78 51 0-III SET Support Grp 1 1.5-2 hrs No Anx STAI-
state 
Napoles 
2015 
USA 151 51 0-III CBSM CBT Ind 9 1.5 hrs No Anx, 
mood/ 
distress 
BSI 
Naumann 
2012 
Australia 46 51 I-III Support, counselling, 
exercise 
Support Ind 8 1 hrs No Dep BDI 
Pelekasis 
2016 
Greece 61 56 I-IV CBT, guided imagery, 
dietary consulting, 
exercise, 
Other Ind 6 30 mins No Anx, dep DASS-21 
Qiu 2013 China 62 51 0-IV Cognitive behavioural CBT Grp 10 2 hrs Yes Anx, dep HAM-D, 
SAS 
Rissanen 
2015 
Sweden 155 58 I-III CBSM CBT Grp 10 2 hrs Yes Anx, dep, 
mood/ 
distress 
HADS, 
IES 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Samarel 
1997 
USA 181 53 I-II Support, stress 
management, 
communication, 
problem solving 
Support Grp 8 2 hrs No Mood/ 
distress 
POMS-
LASA 
Sandgren 
2000 
USA 62 52 I-II Support, problem 
solving, cognitive 
restructuring 
CBT Ind 10 30 mins  No Mood/ 
distress 
POMS 
Sandgren 
2003 
USA 235 55 I-III Education PsyEd Ind 5 (+1 
booster) 
30 mins No Anx, dep, 
mood/ 
distress 
POMS 
Savard 2005 Canada 54 54 I-III Cognitive behavioural CBT Grp 8 (+1 
optional 
booster) 
1.5 hrs No Anx, dep HADS 
Savard 2006 Canada 45 52 IV Cognitive behavioural CBT Ind 8 (+ 3 
booster) 
1-1.5 hrs Yes Anx, dep BDI, 
HAM-D, 
HADS 
Savard 2014 Canada 242 54 0-III Cognitive behavioural CBT Ind 6 50 mins No Anx, dep HADS 
Scheier 
2005 
USA 252 44 0-II Education PsyEd Grp 4 2 hrs No Dep CES-D 
Schnur 2009 USA 44 NR  0-III CBT, hypnosis CBT Ind NR Varied No anx, mood/ 
distress 
9 item 
mood 
report 
form, 
STAI, 
POM-SV 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Schover 
2011 
USA 300 54 NR education, peer 
counselling 
Support Ind 3 1-1.5 hrs No Mood/ 
distress 
BSI-18 
Simpson 
2001 
Canada 89 50 0-II PMR, hypnosis, stress 
management, CBT 
CBT Grp 6 1.5 hrs No Dep, 
mood/ 
distress 
BDI, 
POMS 
Spiegel 
1981 
USA 86 55 IV SET Support Grp >52 1.5 hrs No Anx, dep, 
mood/ 
distress 
POMS 
Stanton 
2005 
USA 558 58 I-II Education PsyEd Ind 2 Varied No Dep CES-D, 
IES-R 
Taylor 2003 USA 90 54 I-IIIa Education, relaxation, 
coping strategies, CBT,  
CBT Grp 8 2 hrs No Mood/ 
distress 
POMS, 
MHI, IES 
Vos 2007 Holland 87 49 0-III Experiential-existential 
therapy 
Other Grp 12 (+ 2 
follow-up) 
12 hrs No Mood/ 
distress 
POMS 
Wengstrom 
1999 
Sweden 134 60 0-IV Support Support Ind 5 30 mins No Mood/ 
distress 
IES 
Wurtzen 
2013 
Denmark 366 54 I-III MBSR Mindfulness Grp 8 (+silent 
retreat) 
2 hrs (+ 5 
hrs) 
No Anx, dep CES-D 
Yates 2005 Australia 110 49 I-II Education PsyEd Ind 3 10-20 mins No Anx, dep, 
mood/ 
distress 
HADS 
Zgaia 2016 Romania 102 59 I-III Autogenous training, 
counselling 
Support Ind 1 50 mins No Anx, dep Numerical 
rating 
scale 
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Source Country N  Age 
(mean) 
Stage Treatment components Treatment 
type 
Treatment 
format 
Treatment 
sessions 
Length of 
sessions 
Exclusively 
psychologically 
distressed 
patients 
Outcomes Outcome 
measures 
Notes.  Cpl = couple; Grp = group; Ind = individual CBT = cognitive behavioral therapy; CBSM = cognitive behavioral stress management; MBCR = mindfulness based cancer recovery; MBSR 
= mindfulness based stress reduction; BATD = behavioral activation treatment for depression; STPP = short-term psychodynamic psychotherapy; SET =  supportive expressive therapy; PMR = 
progressive muscle relaxation; PsyEd = psychoeducation; Anx = anxiety; Dep = depression; mins = minutes; hrs, hours; NR = not reported; HADS = Hospital Anxiety and Depression Scale; CES-
D = Center for Epidemiologic Studies Depression Scale; IES = Impact of Events Scale; IES-R = Impact of Events Scale – Revised; POMS = Profile of Mood States; POMS-SF = Profile of Mood 
States - Short Form; POMS-LASA = Profile of Mood States—Linear Analog Self-Assessment; BDI = Beck Depression Inventory; BAI = Beck Anxiety Inventory; STAI = State-Trait Anxiety 
Inventory; MHI = Mental Health Inventory; SAS =  Self-Rating Anxiety Scale; DASS = Depression, Anxiety, and Stress Scale; HAM-D = Hamilton Depression Rating Scale; SCL-90-R = Symptom 
Checklist-90-Revised; PAL-C = Profile of Adaptation to Life Clinical Scale; ABS = 40-item Affects Balance Scale; PANAS = Positive and Negative Affect Schedule; HAM-A = Hamilton Anxiety 
Rating Scale 
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3.3.1 Aim 1: Overall quality of trials  
The mean total quality score on the POMRF was 13.3 out of 38 with median 13 and 
IQR 6 (i.e. 35% of the maximum possible score; median 34%, IQR 16%). Only 12 
trials (13%) reached the criterion of 19, indicating that 79 trials (87%) were of 
inadequate quality. The mean total quality on the “generic design elements” subscale 
was 10.5 out of 26 with median 11 and IQR 3 (i.e. 40% of the maximum possible 
score; median 42%, IQR 12%), while the mean total quality on the “psychotherapy-
specific design elements” subscale was 2.8 out of 12 with median 2 and IQR 3 (i.e. 
23% of the maximum possible score; median 17%, IQR 25%). In general, therefore, 
quality was poor, particularly for design elements specific to psychotherapy RCTs. 
3.3.2 Aim 2: Quality of specific design elements  
Table 3.4 displays the individual item quality scores for each trial. Four generic design 
elements were particularly poorly implemented: representativeness of the sample 
(item 3), use of blind evaluators (item 7), control of concomitant treatments (item 18), 
and evaluation of clinical significance (item 21). These are evaluated in detail below, 
followed by the elements specific to psychotherapy RCTs.   
3.3.2.1 Generic design elements 
Representativeness of sample 
Of the 74 trials in which emotional distress was the primary outcome, only 11 (15%) 
specified as an inclusion criterion that patients were distressed. Eight defined distress 
as scoring above an established cut-off on a specific outcome measure, one defined 
distress as meeting diagnostic criteria for a depressive disorder, and two defined 
distress as scoring above an established cut-off on a specific outcome measure and 
meeting diagnostic criteria for a depressive disorder. 
Nine trials excluded patients with a mental health disorder but did not state what 
disorders these included; four excluded patients with clinical levels of emotional 
distress; three excluded patients with ‘severe’ mental health disorders but did not state 
what disorders these included; two excluded patients with ‘prior psychiatric 
morbidity’ but did not elaborate; two excluded patients with a prior history of 
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psychiatric treatment for a major depressive episode; one excluded patients with a 
prior history of hospitalisation for a mental health disorder; one excluded patients with 
current suicidal thoughts; and one excluded patients with previous suicidal thoughts. 
Of the 17 trials in which emotional distress was the secondary outcome, only three 
(18%) specified that to be included, patients must be experiencing the specific 
difficulty that the primary outcome measured; for example, requiring evidence of 
insomnia for inclusion in a trial in which the primary outcome was insomnia. 
Use of blind evaluators  
Only 14 trials (16%) reported using blinded assessors and none employed checks to 
ensure that the assessor was blind to the treatment condition. 
Control of concomitant treatments  
Only nine trials (10%) described controlling for concomitant treatments for emotional 
distress. Of these, two ensured that patients received no additional treatment 
(psychological or pharmacological); four excluded patients receiving additional 
psychological treatment (but not those receiving pharmacological treatment); the 
remaining three included patients taking anxiolytic or antidepressant medication 
provided the dose was stable (but did not exclude patients receiving additional 
psychological treatment). 
Clinical significance 
Only 10 trials (11%) evaluated the clinical significance of treatment effects. In six 
trials, clinical significance was defined as scoring below a pre-defined cut-off on a 
specific outcome measure; in three, it was defined as having no diagnosis of anxiety 
or depression according to DSM criteria; in another three, it was defined as making an 
arbitrary percentage reduction in score on a specific outcome measure; and in two, it 
was defined as making a reduction in score on a specific outcome measure based on 
data-informed reliable change index (RCI). All 10 trials used a different operational 
definition of clinical significance preventing assessment of the absolute efficacy 
across different treatments and trials.  
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3.3.2.2 Psychotherapy-specific design elements 
Manualised treatment 
Only 46 trials (51%) used a manual to standardise treatment. Of these, 19 referenced 
a published manual; six referred to an unpublished manual available on request; and 
21 referred to a “manual” or a “manualised treatment” without information on how to 
obtain it. An additional eight trials were ambiguous about whether a manual existed, 
for example reporting that treatment was “based on” or “modelled after” a specific 
manualised treatment. Three more trials reported the treatment was described 
elsewhere, but the referenced sources provided no information regarding a treatment 
manual.  
Therapist training  
Only 29 trials (32%) included therapists qualified to deliver psychotherapy. Of the 29 
trials including qualified therapists, only seven (8% of all trials) included therapists 
with supplementary training in the treatment being investigated. 
An additional 29 trials (32%) used therapists with training in the treatment being 
investigated, but these therapists either had little experience in psychotherapy, for 
example being “master's level registered nurse therapists”, or their clinical 
background was not reported. The amount of training these therapists received ranged 
from 6 hours to a ten-week long training course.  Of the remaining trials, 14 used 
therapists with little experience and without training in the treatment being evaluated; 
in nine it was merely stated that therapists were “trained” or “experienced”; and 10 
provided no information about therapist training. 
Checks for therapist adherence & competence 
Only 17 trials (15%) monitored therapist adherence and only five (4%) monitored 
therapist competence. An additional 12 reported monitoring treatment delivery but 
without specifying what aspects were monitored. 
Number of therapists 
Most trials (67%) included more than one therapist to deliver treatment. However, of 
these, 16 (18% of all trials) did not specify the number of therapists, although using 
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the plural “therapists”, and only six (7% of all trials) analysed the effect of therapist 
on outcome. 
Equality of therapy hours 
Eleven trials (12%) used only a WLC design. Of those using active controls or TAU, 
only 19 (21% of all trials) equalised the number of treatment hours between 
conditions. Of the remaining 61 trials, 26 had more than a 20% difference in treatment 
hours between conditions, 30 did not report the number of hours received in the control 
condition, and five did not report the number of hours received by either condition. 
3.3.3 Aim 3: Quality comparison with mental health populations  
To assess the quality of RCTs in mental health populations relative to RCTs in BCa, 
eight meta-analyses using the POMRF were identified addressing obsessive 
compulsive disorder (OCD) in children (Öst et al., 2016) and adults (Öst et al., 2015), 
anxiety disorders in children (Öst & Ollendick, 2017) and adults (Swain et al., 2013), 
depression in children (Arnberg & Öst, 2014) and military veterans (Hundt, Barrera, 
Robinson, & Cully, 2014), and across several mental health populations (e.g. anxiety, 
depression, borderline personality disorder; Öst, 2014; Sloan et al., 2017). Mean total 
quality scores ranged from 45 to 56% of the maximum possible, higher than the 
corresponding score in the present review (35% of the maximum, Table 3.5). Quality 
of generic and psychotherapy-specific design elements could not be compared because 
the mental health meta-analyses did not report individual item scores. 
3.3.4 Aim 4: Quality comparison by treatment type 
One-way ANOVAs revealed no significant difference in overall quality scores or 
generic subscale scores between different treatment types. A significant difference 
was seen for psychotherapy-specific subscale scores (Table 3.6). Post-hoc testing 
showed that MBT trials were of better quality than support, peer and “other” treatment 
trials. However, MBT trials still only had a mean quality score of 5.4 out of 12 (i.e. 
45% of the maximum possible score) on this subscale. 
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3.3.5 Aim 5: Quality trends over time  
The overall quality score modestly improved with year of publication 
(rho = 0.4, p < 0.01; Figure 3.2). However, the mean total quality of the 30 trials 
published in the last five years was still only 14.7 with median 14.5 and IQR 7 (i.e. 
38% of the maximum possible, median 34%, IQR 13%) and only six of these met our 
criterion for adequate quality. Generic design elements improved across publication 
year (rho = 0.48, p < 0.01) but psychotherapy-specific design elements did not 
(rho = 0.15, p = 0.15; Figure 3.3). 
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Table 3.4: POMRF scores for each included trial 
Author #1 #3 #5 #6 #7 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 
Total 
quality 
score 
Abad 2016 1 0 2 2 0 1 2 0 1 0 0 0 0 0 1 0 1 0 2 13 
Allard 2007 1 0 1 2 0 1 0 1 1 0 0 0 0 0 0 0 2 0 0 9 
Allen 2002 2 0 1 1 0 1 0 0 1 0 1 0 0 0 0 1 1 0 0 9 
Andersen 2004 2 0 2 2 0 1 0 1 2 0 1 1 1 0 0 1 1 0 0 15 
Anton 2015 1 1 2 0 0 1 2 0 1 0 0 0 0 0 0 0 1 0 0 9 
Antoni 2001 1 0 2 2 0 1 1 0 2 2 1 0 0 0 0 1 1 0 0 14 
Antoni 2006 2 0 2 1 0 1 1 0 1 2 1 0 0 0 0 2 1 0 0 14 
Antoni 2009 2 0 2 2 0 1 1 0 1 2 1 0 1 0 0 1 1 0 0 15 
Arving 2007 2 0 2 0 0 1 2 1 1 0 2 0 0 0 0 2 2 1 0 16 
Ashing 2014 2 2 2 2 0 1 0 0 0 0 1 0 1 0 0 0 1 1 0 13 
Badger 2007 1 0 2 2 0 1 1 0 1 0 1 1 0 0 0 0 2 0 0 12 
Badger 2013a 1 0 2 2 0 1 2 0 1 0 0 0 0 0 0 1 2 0 2 14 
Badger 2013b 2 0 2 1 0 1 2 0 1 0 0 0 2 0 0 1 2 0 2 16 
Baucom 2009 1 0 1 2 0 1 0 0 2 0 1 0 0 0 0 0 1 0 0 9 
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Author #1 #3 #5 #6 #7 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 
Total 
quality 
score 
Beutel 2014 1 1 2 1 1 1 0 2 1 2 1 1 0 0 1 2 2 1 0 20 
Bjornklett 2012 1 0 2 1 0 1 0 2 1 0 1 0 0 0 0 1 1 0 0 11 
Boesen 2011 1 0 2 1 0 1 0 0 2 0 1 1 0 0 0 1 1 0 0 11 
Bower 2015 1 0 2 0 0 1 0 2 1 0 0 0 0 0 0 1 2 0 2 12 
Bredal 2014 1 0 2 1 0 1 2 0 1 1 1 0 0 0 0 0 2 0 0 12 
Budin 2008 1 0 1 2 0 1 1 2 1 2 1 0 0 0 0 1 1 0 0 14 
Burton 1995 0 0 2 1 0 1 0 0 2 0 0 0 0 0 0 0 1 0 0 7 
Carlson 2013 1 2 2 0 1 1 2 1 0 2 1 1 0 0 0 1 2 0 2 19 
Chan 2006 1 0 2 0 0 1 2 0 1 2 0 0 0 0 0 0 1 0 2 12 
Christensen 1983 1 0 2 0 0 1 0 0 0 0 0 0 1 0 0 2 0 0 0 7 
Classen 2001 2 0 2 2 0 1 0 0 2 0 1 0 0 0 0 1 1 0 0 12 
Classen 2008 2 0 2 1 0 1 0 2 2 2 2 0 0 0 0 0 2 0 0 16 
Cohen 2007 1 0 1 2 1 1 2 0 1 0 0 0 0 0 0 1 2 0 2 14 
Cousson-Gelie 2011 1 0 2 2 0 1 2 1 0 0 1 1 0 0 0 0 2 0 2 15 
Creuss 2000 1 0 2 2 0 1 0 0 0 0 1 0 1 0 0 0 2 0 2 12 
Davis 1986 1 0 0 2 0 1 2 0 1 0 0 1 0 0 0 1 1 0 2 12 
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Author #1 #3 #5 #6 #7 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 
Total 
quality 
score 
Dirksen 2007 2 1 2 2 0 1 1 2 0 0 0 0 0 0 1 0 2 0 2 16 
Dolbeault 2009 1 0 2 1 0 1 0 0 1 2 1 1 0 0 0 1 2 0 2 15 
Dowlatabadi 2016 1 1 2 2 0 1 0 0 0 0 0 0 0 0 1 0 2 0 0 10 
Edelman 1999a 1 0 1 1 0 2 2 0 1 0 1 1 0 0 1 0 2 0 2 15 
Edelman 1999b 1 0 2 1 0 1 0 0 1 0 1 1 0 0 0 0 1 0 0 9 
Edmonds 2001 1 0 2 1 0 1 0 0 1 0 1 2 0 0 0 0 1 0 0 10 
Ferguson 2012 1 1 2 1 1 1 0 2 1 0 0 0 0 0 0 2 1 0 2 15 
Ferguson 2016 1 2 2 0 1 1 1 2 1 2 0 1 1 0 0 0 2 0 2 19 
Fillion 2008 1 0 1 2 0 1 0 2 1 0 1 0 2 0 0 0 2 0 0 13 
Fukui 2000 2 0 2 1 0 1 0 0 1 0 1 1 0 0 0 1 2 0 2 14 
Gaston 2000 1 0 2 1 0 1 0 1 0 0 0 0 0 0 0 0 2 0 0 8 
Giese-Davis 2016 2 0 2 2 0 1 0 1 1 2 1 1 0 0 0 2 1 0 0 16 
Goodwin 2001 1 0 2 0 0 1 0 1 0 2 1 2 0 0 0 1 2 0 0 13 
Gotay 2007 1 0 1 1 0 1 0 1 1 0 1 0 0 0 0 0 1 0 0 8 
Graves 2003 1 0 2 1 0 1 0 0 0 2 1 0 0 0 0 1 1 0 0 10 
Groarke 2012 2 0 2 2 0 1 0 1 2 1 0 1 0 0 0 1 2 0 0 15 
 63 
 
Author #1 #3 #5 #6 #7 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 
Total 
quality 
score 
Gudenkauf 2015 2 0 1 2 1 1 1 2 0 0 1 0 1 1 0 0 2 0 2 17 
Heiney 2003 1 0 2 2 0 1 0 0 1 0 1 1 0 0 0 2 2 0 0 13 
Henderson 2012 2 0 2 1 0 1 1 2 2 2 1 1 0 0 0 1 1 0 2 19 
Hoffman 2012 1 0 2 1 1 1 0 2 1 1 0 2 0 0 0 1 2 0 2 17 
Hopko 2011 2 2 2 2 0 2 2 2 2 2 1 0 2 2 1 1 2 1 2 30 
Kalaitzi 2007 0 0 2 1 0 1 0 0 0 0 0 0 0 0 0 2 1 0 0 7 
Kissane 2003 1 0 2 0 0 2 0 1 1 0 2 0 2 0 0 1 1 0 0 13 
Kissane 2007 2 0 2 0 0 1 0 2 2 2 1 1 2 2 0 1 1 1 0 20 
Lane 2005 1 0 2 1 0 1 0 0 1 0 0 1 0 0 0 2 2 0 2 13 
Larson 2000 0 0 2 0 0 1 0 0 0 0 1 1 0 0 0 0 1 0 0 6 
Lechner 2014 2 1 2 2 1 1 1 0 1 2 0 1 0 0 0 1 2 0 2 19 
Lee 2013 1 2 2 2 0 1 0 1 0 0 1 0 0 0 0 2 1 0 0 13 
Lengacher 2009 2 0 2 0 0 1 0 2 0 1 0 2 1 1 0 2 1 0 2 17 
Lewis 2015 1 0 1 2 1 1 1 1 1 0 1 0 0 0 0 2 2 0 0 14 
Maguire 1980 0 0 2 0 0 1 0 0 2 0 0 0 0 0 0 0 0 1 0 6 
Manne 2005 2 0 2 2 0 1 0 0 1 2 2 0 2 0 0 2 2 0 0 18 
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Author #1 #3 #5 #6 #7 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 
Total 
quality 
score 
Manne 2016 2 0 1 2 0 1 2 0 2 2 1 0 1 0 0 1 2 0 2 19 
Marchioro 1996 1 0 2 0 0 1 0 0 1 0 0 1 0 0 0 0 2 0 0 8 
Marcus 2010 2 0 1 1 0 1 0 0 1 0 1 0 0 0 0 0 1 0 0 8 
McArdle 1996 1 0 1 0 0 1 2 0 2 0 0 0 0 0 0 1 2 0 0 10 
Mens 2015 1 0 2 2 0 1 1 0 1 0 1 0 1 0 0 2 1 0 0 13 
Miyashita 2005 2 0 2 1 0 1 0 0 1 0 0 0 0 0 0 0 2 0 0 9 
Napoles 2015 2 0 1 2 1 1 0 0 1 0 1 0 0 0 0 1 2 0 0 12 
Naumann 2012 1 0 2 0 0 1 2 0 0 0 1 1 0 0 0 1 1 0 0 10 
Pelekasis 2016 1 0 2 2 0 1 1 0 0 0 1 0 0 0 2 0 1 0 0 11 
Qiu 2013 2 2 2 1 1 1 0 0 1 0 0 1 1 1 2 1 2 0 2 20 
Rissanen 2015 1 1 2 1 0 1 2 2 1 0 1 0 0 0 0 1 2 0 0 15 
Samarel 1997 1 0 1 1 0 0 2 0 1 0 2 0 0 0 0 1 2 0 2 13 
Sandgren 2000 1 0 2 2 0 1 0 0 1 0 1 0 0 0 0 0 2 0 0 10 
Sandgren 2003 1 0 2 2 0 1 0 0 1 0 1 0 0 0 0 0 1 0 0 9 
Savard 2005 2 1 2 1 0 1 0 2 2 0 0 1 0 0 1 1 2 1 2 19 
Savard 2006 2 2 2 0 1 1 0 0 1 1 1 2 0 0 1 1 2 1 2 20 
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Author #1 #3 #5 #6 #7 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 
Total 
quality 
score 
Savard 2014 1 2 2 1 0 1 1 2 2 0 1 1 1 1 0 2 2 1 0 21 
Scheier 2005 2 0 2 2 0 1 1 0 1 0 1 0 1 0 0 1 2 0 0 14 
Schnur 2009 1 0 2 2 1 1 0 2 1 0 1 1 0 0 0 0 1 0 0 13 
Schover 2011 1 0 1 0 0 1 1 0 2 0 2 0 0 0 0 0 0 0 0 8 
Simpson 2001 1 0 2 0 0 1 0 0 2 0 0 1 0 0 0 0 2 0 0 9 
Spiegel 1981 0 0 2 0 0 1 0 0 1 0 1 0 0 0 0 0 1 0 0 6 
Stanton 2005 1 0 2 1 0 1 1 2 1 0 1 0 1 1 0 2 1 0 0 15 
Taylor 2003 2 0 2 2 0 1 0 0 2 2 1 0 0 0 0 1 1 0 0 14 
Vos 2007 1 0 1 2 0 1 2 0 2 0 1 2 0 0 0 1 1 0 2 16 
Wengstrom 1999 1 0 2 2 0 1 1 0 1 0 1 0 0 0 0 2 2 0 0 13 
Wurtzen 2013 1 0 2 1 0 1 0 1 1 2 1 2 2 0 0 2 1 1 0 18 
Yates 2005 1 0 2 0 1 1 1 1 1 0 1 0 0 0 0 1 1 0 2 13 
Zgaia 2016 1 0 1 0 1 0 0 1 1 0 0 1 0 0 0 2 2 0 0 10 
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Table 3.5: Comparison of total quality scores on the POMRF of RCTs in this 
population with RCTs in mental health populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number 
of RCTs 
included 
Mean 
total 
score 
Maximum 
possible 
score 
Maximum 
possible 
score as a 
% 
Range 
of 
scores 
Range 
of 
scores 
as a % 
Anxiety disorders in children 23 21.6 44 49% - - 
Anxiety disorders in adults 4 20 44 45% 14-27 32-61% 
Depression in children 10 22 44 50% 8-30 18-69% 
Depression in military veterans 5 24 44 55% 15-32 34-63% 
Emotional distress in BCa 91 13.3 38 35% 6-30 16-79% 
Individuals with anxiety, 
depressive, or borderline 
personality disorders 
34 24 44 55% 14-34 32-77% 
Individuals with mental health 
conditions 
31 20.3 44 46% - - 
OCD in adults 37 23 44 52% 15-34 34-77% 
OCD in children 25 24.6 44 56% - - 
Note.  POMRF = psychotherapy outcome study methodology rating form; RCT = randomised 
controlled trial; BCa = breast cancer; OCD = obsessive compulsive disorder 
 67 
Table 3.6: Means (SDs) and F-values for the items on the POMRF for different 
treatment types 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: POMRF, psychotherapy outcome study methodology rating form. 
Figure 3.2: Scatterplot of total quality scores on the POMRF by year of 
publication 
 
CBT  
(n=40) 
Mindfulness 
(n=5) 
PsyEd 
(n=6) 
Support  
(n=21) 
Other  
(n=13) 
Peer-led  
(n=6) 
All 
trials 
(n=91) 
F-
value 
Total quality score 14.13 
(4.61) 
16.6 
 (2.7) 
13.17 
(0.75) 
12.14 
(3.86) 
12  
(3.96) 
11.66 
(3.14) 
13.27 1.78 
Subscale 1:  Generic 
design elements 
11.08 
(3.2) 
11.2  
(1.3) 
11  
(1.26) 
9.67  
(2.31) 
9.85 
(2.76) 
9.83 
(2.64) 
10.49 1.05 
Subscale 2: 
Psychotherapy-specific 
design elements  
3.05 
(1.99) 
5.4  
(2.07)a 
2.17  
(0.75) 
2.48 
(2.18)b 
2.15 
(1.77)b 
1.83 
(1.17)b 
2.78 2.81* 
Note. POMRF = psychotherapy outcome study methodology rating; PsyEd = psychoeducation; *P<0.01; a,bMeans with different 
superscript differ significantly 
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Abbreviations: POMRF, psychotherapy outcome study methodology rating form. 
Figure 3.3: Scatterplot of POMRF scores on generic design elements and 
psychotherapy-specific design elements by year of publication 
 
3.4 Discussion 
Findings from this study show that the methodological quality of RCTs for emotional 
distress in BCa is poor. Most RCTs were of inadequate quality and of lower quality 
than those in mental health. While quality modestly improved from 1980 to 2016, most 
of the more recently published RCTs were still poorly designed. 
Quality was particularly poor for design elements specific to psychotherapy RCTs. 
Moreover, while implementation of generic design elements improved over time, that 
of psychotherapy-specific ones did not. Design elements specific to psychotherapy 
RCTs were lacking in most trials, thereby compromising the internal validity of such 
trials. Only around one in 20 monitored therapist competence or analysed the effect of 
therapist on outcome; only around one in 10 employed therapists who were adequately 
trained in the treatments or monitored therapists' adherence to them; only around one 
in five compared conditions with an equal number of treatment hours; and barely half 
used a manual to standardise treatment. The purpose of these design elements is to 
ensure that a psychological treatment is implemented correctly. Because none of the 
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trials in this review adequately implemented all these elements, their findings provide 
unreliable information about the treatments the authors are claiming to evaluate.   
Although, in general, generic design elements were not as poorly conducted as those 
specific to psychotherapy RCTs, important ones were still neglected, thereby further 
compromising trials' internal and external validity. Only around one in 10 trials 
controlled for concomitant treatments, blinded assessors, specified as an inclusion 
criterion that participants were distressed, or evaluated the clinical significance of 
treatment effects. 
While all these areas represent significant deficits in the BCa literature, the latter two 
are particularly concerning. Consensus-based clinical practice guidelines specifically 
recommend the use of psychological treatments for BCa patients experiencing clinical 
levels of emotional distress (Coleman, Hession, & Connolly, 2011; Holland, 1999) 
and the standards by which a treatment is considered “evidence-based” in the United 
States recommend that trials provide an estimation of clinical significance (Chambless 
& Hollon, 1998; Tolin, McKay, Forman, Klonsky, & Thombs, 2015). If trials do not 
target patients with emotional distress, findings cannot be generalised to the 
population of patients to whom the treatments would be offered in practice: i.e. those 
with clinical levels of emotional distress. Additionally, if trialists do not report the 
clinical significance of treatment effects, it is difficult for researchers, clinicians, 
service providers and policy-makers to assess the practical relevance of findings. 
Determining and applying standardised criteria for the clinical significance of 
treatment effects would advance psychotherapy outcome research in BCa. The most 
established method for determining clinical significance is the approach developed by 
Jacobson and colleagues (Jacobson, Follette, & Revenstorf, 1984; Jacobson & Truax, 
1991; see chapter 4 for more details). 
The overall methodological quality of RCTs did not differ by type of treatment. For 
design elements specific to psychotherapy RCTs, quality did differ by type of 
treatment explored, with MBT trials achieving better quality scores than support, peer, 
and “other” treatment trials However, trials evaluating MBT were still of limited 
quality. Many of the trials provided insufficient details about treatment methods and 
procedures. Thus, it was not possible to categorise treatments by distinct treatment 
approaches, but only by broad categories of type of treatment. This highlights the 
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importance of studies clearly reporting the type of treatment used with clear and 
unambiguous descriptions of the treatments being compared. 
Although the methodological quality of RCTs modestly improved over time, the 
majority of the most recent RCTs were still of inadequate quality. Thus, there is clearly 
substantial room for improvement in the conduct of RCTs in this population. 
This review has some important limitations. The assessment of trial quality was 
limited to what was included in the published reports. As most journals impose word 
limits, authors may have excluded important information. Thus, some trials may have 
implemented unreported design elements. This review also relied on summary scores 
to quantify the overall quality of trials. Summary scores can be problematic as they 
can mask methodological strengths and weaknesses of a trial. Trials that differ in the 
conduct of individual design elements may still result in the same overall score. 
Finally, whether methodological quality differed amongst trials including patients at 
different points in the BCa trajectory was not evaluated because many trials included 
patients at multiple points in the disease trajectory.  
In conclusion, the current view that efficacious psychological treatment exists for 
emotional distress in BCa patients is based on poor quality RCTs. It does not follow 
that efficacious treatments do not exist, or that conclusions of previous meta-analyses 
are wrong. However, with increasing investment in, and growing priority of, 
psychological treatments for emotional distress in BCa (Hewitt, Herdman, & Holland, 
2004; Jassim et al., 2015) it is imperative that future psychotherapy RCTs are 
conducted with greater methodological rigour to make sure evidence-based 
practice occurs in clinical settings. Researchers need to ensure that the methodological 
issues presented in this review are adequately implemented in future trials. Trials need 
to include participants with clinical levels of emotional distress and report the clinical 
significance of treatment effects. Trialists must also consider the methodological 
challenges specific to psychotherapy RCTs, particularly manualisation.  
If relevant health policies are to be adequately empirically informed, meta-analyses 
must also account for important methodological issues presented in this review.  
However, no previous meta-analysis has focused specifically on clinically distressed 
patients, excluded non-manualised treatments or examined whether manualisation 
influenced treatment efficacy, or examined whether treatment effects are clinically 
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significant. Therefore, the practical relevance of previous meta-analysis is 
questionable. In chapter 5, a meta-analysis accounting for these methodological 
limitations is presented. First, however, the development of clinical significance is 
outlined, and a review and critique of a specific approach for evaluating clinical 
significance, known as the ‘Jacobson method’ is presented in chapter 4. 
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Chapter 4. Measuring Clinical Significance in Psychotherapy Outcome 
Research: A Review of Clinical Significance Methodology 
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4.1 Introduction 
Most psychotherapy outcome studies aim to demonstrate the superior efficacy of one 
treatment over alternative treatments or control conditions. This has typically been 
conveyed by comparing group means using inferential statistics (Ogles, Lunnen, & 
Bonesteel, 2001). Traditionally, effect sizes are used to express whether the average 
amount of change in one group is superior to that in another. An effect is deemed 
statistically significant if the magnitude of the mean difference is beyond the range of 
chance (conventionally set at p<0.05). The evaluation of effect sizes in psychotherapy 
outcome research has long been advocated (Cohen, 1995; Thompson, 2002); and the 
fifth edition of the APA publication manual stresses the importance of reporting effect 
sizes: “For the reader to fully understand the importance of your findings, it is almost 
always necessary to include some index of effect size” (APA Publication Manual, 2001 
pp. 25-26). Although effect sizes and associated tests of significance provide valuable 
group information, they provide no information about individual variability in 
treatment response.  Thus, it is possible to have a large effect size in favour of the 
treatment group but still have many or even the majority of treated patients present 
with substantial and impairing symptoms. Indeed, the size of an effect can often have 
no bearing on the clinical importance of a treatment. Jacobson and Truax (1991) used 
the following example to demonstrate how a large effect size can have no clinical 
importance: 
“If a treatment for obesity results in a mean weight loss of 2 lb and if subjects 
in a control group average zero weight loss, the effect size could be quite large 
if variability within the groups were low. Yet the large effect size would not 
render the results any less trivial from a clinical standpoint” (p. 12). 
Thus, while necessary, it is not enough to show that a treatment performs better than 
a control condition or another active treatment at the group level. An evaluation of 
clinical significance is needed to indicate the proportion of patients who benefit from 
treatment. 
Clinical significance has been operationalised in numerous ways, all with the aim of 
determining if a treatment results in a clinically meaningful change. The most 
established and widely used method for determining clinical significance in 
psychotherapy outcome research is the approach developed by Jacobson and 
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colleagues (Jacobson, Follette, & Revenstorf, 1984; Jacobson and Truax, 1991), 
referred to as the ‘Jacobson method’. This chapter provides a review of clinical 
significance from its development in behaviour analysis to the now widely used 
Jacobson method. Strengths and weakness of the Jacobson method and alternative 
methods are also considered. 
4.2 Development of clinical significance 
The current concept of clinical significance in psychotherapy outcome research stems 
from Risley’s seminal paper (1970) in the field of behaviour analysis. He proposed 
that treatment outcomes should be assessed according to both experimental and 
therapeutic criteria. The experimental criterion attempts to determine whether a 
treatment is responsible for behaviour change (i.e. by comparing behaviour during 
treatment with what it would be like without treatment); while the therapeutic criterion 
attempts to determine whether changes in behaviour are meaningful to the individual. 
Defining this therapeutic or ‘clinically significant’ criterion proved difficult. In some 
cases, the therapeutic criterion can be easily applied. For example, the elimination of 
seizures in a person with epilepsy would be universally accepted as clinically 
significant. However, a 30% reduction in seizures would likely represent a meaningful 
improvement but may not represent a clinically significant one. Thus, when treatment 
success is measured by the intensity or frequency of a behaviour (i.e. severity of 
emotional distress) defining what is clinically significant is much more difficult. 
In the 1970s, social validity (Kazdin, 1977; Wolf, 1978) emerged as a potential 
solution to this problem. Social validity was founded in applied behavioural analysis 
and refers to the social importance of treatment. Several facets of social importance 
can be distinguished but the focus here, and within the broader field of psychotherapy 
outcome research, is behaviour change. According to the social validity approach, 
what is deemed as clinically significant can be assessed in two specific ways: 1) 
subjective evaluation or 2) social comparison with well-functioning peers. 
The ‘subjective evaluation’ approach involves asking those in everyday contact with 
the treated patient to evaluate the treated patient’s behaviour. This enables the 
researcher to see if the patient has made changes that are observable by others. Strupp 
and Hadley (1977) extended the original method of subjective evaluation by 
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suggesting three specific perspectives be considered: 1) the patient themselves, 2) the 
therapist, and 3) those in everyday contact with the patient.  
The ‘social comparison’ approach involves a social comparison with a well-
functioning population. The underlying premise is that if a treatment has resulted in a 
clinically significant change then a patient’s post-treatment behaviour should be 
indistinguishable from that of well-functioning peers (Kazdin, 1977). This approach 
led to an increased recognition of the need to examine the clinical relevance of changes 
occurring during psychotherapy. The emerging consensus was that it would be useful 
to objectify what constitutes a return to functionality (Kazdin & Wilson, 1978). Initial 
definitions were either arbitrary (i.e. a 50% reduction in symptoms; Jansson & Öst, 
1982) or subjective (i.e. an unspecified level of functioning deemed clinically 
meaningful without a theoretical basis; Barlow & Mavissakalian, 1981).  An approach 
largely free from bias that could be applied to a wide range of psychological disorders 
and enable cross-study comparisons was therefore needed to overcome these 
heterogeneous and methodologically flawed definitions. Jacobson, Follette, and 
Revenstorf (1986) recognised this and presented a standardised method of defining 
what constitutes a return to functionality, now coined ‘clinical significance’.  
4.3 The Jacobson method of clinical significance  
Jacobson and colleagues (1984, 1991) believed that clinical significance should meet 
the standards of efficacy set by consumers (i.e. patients), clinicians and researchers. 
As patients, clinicians, and researchers often expect psychotherapy to remove the 
problem that patients bring to therapy, the central premise of the Jacobson method is 
that a clinically significant change should return patients to normal levels of 
functioning: “change in therapy is clinically significant when the client moves from 
the dysfunctional to the functional range during the course of therapy” (Jacobson et 
al., 1984, p. 340). The Jacobson method has two criteria. The first involves the 
calculation of a cut-off point on a well-validated outcome measure to determine if a 
patient’s posttreatment score has a greater probability of being drawn from a 
functional or dysfunctional population.  Second, the ‘reliable change index’ (RCI) 
determines if the extent of change from pre- to post-treatment is statistically reliable. 
This ensures that the pre- to post-treatment change score is not merely an artefact of 
measurement error. Applying these two criteria, patients can be classed into one of 
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four categories: i) ‘recovered’, if they make a statistically reliable change and move 
from a dysfunctional to a functional population; ii) ‘improved’, if they make a 
statistically reliable change but do not move from a dysfunctional to a functional 
population; iii) ‘unchanged’, if they do not make a statistically reliable change; and 
iv) ‘deteriorated’, if they make a statistically reliable change for the worse. 
Criterion 1: Cut-off point. There are three available methods for determining if a 
patient’s  level of functioning is within the functional range following treatment: (a) 
patient’s post-treatment score falls outside the range of dysfunctionality, defined as 
falling two or more standard deviations (SDs) beyond the mean of the dysfunctional 
population, in the direction of functionality; (b) patient’s post-treatment score is within 
the range of functionality, defined as  falling within two SDs of the mean of the 
functional population; and (c) patient’s post-treatment score has a greater probability 
of being drawn from the functional than the dysfunctional population. 
Based on hypothetical data, Jacobson and Truax (1991) clarified when each cut-off 
point is most suitable. When functional and dysfunctional distributions are 
overlapping, cut-off point (a) is the most stringent, cut-off point (b) is the most lenient, 
and cut-off point (c) falls in the middle of the two cut-offs. When functional and 
dysfunctional distributions are not overlapping, cut-off point (a) is the most lenient, 
cut-off point (b) is the most stringent and cut-off point (c) still falls in the middle of 
the two cut-offs. To calculate these cut-off points, normative data is required. Ideally 
normative data should be available for a functional as well as a dysfunctional 
population because if each study uses its own dysfunctional sample then each study 
will have a different cut-off point, making comparisons between studies difficult 
(Hollon & Flick, 1988; Wampold & Jenson, 1986). When appropriate normative data 
exists for a functional and dysfunctional population, cut-off point (c) is the method of 
choice. As it includes normative data from both functional and dysfunctional 
populations, it is the least arbitrary method. If normative functional data does not exist, 
only cut-off point (a) can be used; and if normative dysfunctional data does not exist, 
only cut-off point (b) can be used. 
Criterion 2: Reliable change index. Post-treatment scores may cross the cut-off point 
for functionality but the change in score may not be statistically reliable. For example, 
if the cut-off point on an outcome measure is 23 and a patient’s pre-treatment score 
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falls just outside this cut-off (i.e. a score of 24) but their post-treatment score falls just 
within (i.e. a score of 22) they would have crossed the cut-off point and be part of the 
functional population. However, a change score of two is unlikely to be statistically 
reliable. Thus, Jacobson et al. (1984) proposed an RCI which identifies the threshold 
beyond which symptoms must change on an outcome measure for it to be considered 
statistically reliable. Due to mathematical problems identified by Christensen and 
Mendoza (1986), the original formula was modified by Jacobson and Truax (1991). 
The modified RCI is calculated by dividing the difference between the post-treatment 
(xpost) and pre-treatment (xpre) scores by the standard error of differences (Sdiff): 
𝑅𝐶𝐼 =
(Xpost − xpre)
𝑆𝑑𝑖𝑓𝑓
 
The Sdiff can be calculated directly from the standard error of measurement (SE): 
𝑆𝑑𝑖𝑓𝑓 =  √2(𝑆𝐸)² 
The size of the SE hinges on the reliability (r) of the outcome measure.  
𝑆𝐸 = 𝑆𝐷√1 − 𝑟 
Thus, the more reliable a measure, the smaller the amount of change needed between 
pre- and post-treatment scores to achieve a statistically reliable change. While the type 
of reliability test was not specified by Jacobson et al. (1984, 1991), the use of internal 
consistency rather than test-retest reliability has since been recommended 
(Martinovich, Saunders, & Howard, 1996; Tingey, Lambert, Burlingame, & Hansen, 
1996a). This is because test-retest scores may reflect changes in score due to treatment 
opposed to measurement error. An RCI equal to or larger than ±1.96 is required for 
the change to be statistically reliable at p<0.05: 
𝑅𝐶𝐼 =
(Xpost−xpre)  
𝑆𝑑𝑖𝑓𝑓
 * 1.96 
4.4 Criticisms of the Jacobson method and proposed alternatives 
The Jacobson method has been criticised by several authors and in an attempt to 
provide more precise estimations of clinically significant change, alternative methods 
have been proposed. The most common criticism of the Jacobson method is not 
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considering regression towards the mean. Regression towards the mean is the 
phenomenon that extreme scores on the first measurement will likely be closer to the 
mean on the second measurement. Thus, patients with more extreme scores pre-
treatment (e.g. those with extreme anxiety or depression scores) are more likely to 
make a statistically reliable change by post-treatment.  
Alternative methods have been developed to try and deal with the issue of regression 
towards the mean. Hsu (1989) developed the Gullisken-Lord-Novick (GLN) method, 
which modifies the RCI formula to include estimates of the population mean which 
scores are expected to regress towards. However, population means and SDs are rarely 
available. Speer (1992) developed the Edwards-Nunnally (EN) method which places 
confidence intervals (CIs) around estimates of patients’ true pre-treatment scores and 
then calculates their post-treatment score based on this CI. Nunnally and Kotsch 
(1983) developed the Nunnally-Kotsch (NK) method which estimates patient’s true 
pre-treatment scores based on their observed pre-treatment scores. Lastly, Hageman 
and Arrindell (1999) developed the Hageman and Arrindell (HA) method which 
attempts to correct for regression towards the mean by modifying both the RCI and 
cut-off criteria. Similar to the EN method, the RCI is determined by including both 
pre- and post-treatment reliability in its calculation; while the calculation of the cut-
off point incorporates true score mean equivalents and reliability coefficients to 
account for measurement error. 
The Jacobson method has also been criticised for being too conservative. A severely 
dysfunctional patient could make a large amount of improvement but still fall within 
the dysfunctional population. Although such patients would be classed as ‘improved’, 
they would not be classed as having made a clinically meaningful change (i.e. 
‘recovered’). Tingey, Lambert, Burlingame, and Hansen (1996b) argue that a return 
to the functional population is not always a realistic goal. For example, it is impossible 
for physical therapy to cure Parkinson’s disease (PD). Thus, patients with PD will 
never be part of the functional population. Yet physical therapy may still facilitate 
numerous clinically meaningful changes for patients with PD. Similarly, patients with 
severe psychiatric disorders may never realistically fall within a functional population. 
Yet, most would agree it would be incorrect to assume that such patients can never 
make a clinically meaningful change. To overcome this problem, Tingey et al. (1996b) 
proposed using multiple samples on a continuum. They identified four separate 
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populations which patients could be classed: asymptomatic, normal, mild disturbance, 
and severe disturbance. Clinical significance requires movement into the adjacent 
population in the positive direction. Although this method would provide a more 
thorough understanding of individual change, this greater delineation in samples 
would require substantially more normative data, which is already sparse. Jacobson 
and colleagues (1999) did acknowledge the limitation of their method in not capturing 
all aspects of clinically meaningful change. However, they argued that the original 
purpose of operationalising clinically significant change was to meet the standards of 
efficacy set by consumers (i.e. patients), clinicians and researchers i.e. to remove the 
problem that patients brought to therapy (Martinovich et al., 1996). Nonetheless, this 
is still a valid criticism of the method. 
Another criticism of the Jacobson method, and the alternatives described above, is 
their sole reliance on change scores at two time points (i.e. pre- and post-treatment). 
Speer (1995) advocated for a multi-wave data approach to clinical significance using 
hierarchical linear modelling (HLM). The HLM method uses longitudinal data and 
growth-curve analysis to reflect the change that occurs from pre- to post-treatment 
more precisely. 
Several other methodological issues of the Jacobson method exist. First, when 
defining what constitutes a return to functionality, it is preferable to use normative 
data on a functional sample. However, defining what constitutes a functional sample 
is difficult. Jacobson and Revenstorf (1988) stated that while a functional sample 
should preferably not include patients who are dysfunctional, it should not exclude 
‘outliers’ of dysfunctional patients not receiving therapy. Likewise, Hollon and Flick 
(1988) proposed that representative functional samples should be based on an 
unscreened demographically normative population. However, it has been estimated 
that around 20% of the general population have clinical levels of psychopathology 
(Saunders, Howard, & Newman, 1988). This poses problems when suggesting that a 
clinically significant change signifies return to normal levels of functioning as such 
groups are likely to include a substantial proportion of dysfunctional individuals. 
Estimates based on unscreened populations will therefore provide a much more lenient 
evaluation of what constitutes a return to functionality. Thus, it is important that 
studies clearly define their functional sample: "it is essential that an investigator's 
perspective on what is normal be clearly articulated" (Saunders et al., 1988, p. 210). 
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Second, the Jacobson method assumes normal distributions. However, many of the 
outcome measures used in psychotherapy outcome research have a limited range 
leading to skewed distributions. Skewed distributions are more likely to cause 
problems when psychopathology measures are used on patients within the functional 
range (Seggar, Lambert, & Hansen, 2002). Both Tingey et al. (1996b) and Jacobson 
and Revenstorf (1988) recognised the potential problem of non-normal distributions 
but no solution has yet been provided. However, this is more of a limitation of 
available outcome measures opposed to the Jacobson method itself. 
Third, the Jacobson method is unable to adequately categorise change in patients who 
enter treatment already in the functional range (Lambert & Ogles, 2009). As these 
patients cannot move from a dysfunctional to a functional population, it is impossible 
for them to be classed as ‘recovered’. This is rarely the case as patients’ who are part 
of the functional population prior to treatment usually do not require such treatment. 
However, it is still possible to apply Jacobson’s second criterion (RCI) to these 
patients and evaluate whether they have made statistically reliable change. Therefore, 
these patients can still be classed as ‘improved’, ‘unchanged, or ‘deteriorated’. 
Finally, one of the main aims of developing the Jacobson method was to enable 
meaningful comparisons across studies. However, the Jacobson method can be applied 
to any outcome measure. Different outcome measures will obviously result in different 
cut-offs and RCIs. Therefore, the proportion of patients classed as having achieved 
clinically significant change will differ depending on the outcome measure used. For 
example, Ogles, Lambert, and Sawyer (1995) evaluated the clinical significance of 
CBT for patients with depression using the Jacobson method. They found that 
different measures produced differing results. At post-treatment, 28% of patients 
recovered according to the Beck Depression Inventory (BDI), while 45% recovered 
according to the Hamilton depression scale (HAM-D). This highlights the need to 
develop core outcome measures to be used within trials in a specific area. 
4.5 Convergences and divergences in classification between different methods 
Following the emergence of alternative clinical significance methods, it is important 
to consider whether different methods yield different results. Six empirical studies 
have investigated the convergences and divergences in classification between methods 
(Lambert & Ogles, 2009). Their findings will be discussed below. 
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Speer and Greenbaum (1995) compared rates of meaningful change amongst 73 
patients who were diagnosed with a range of psychological disorders based on five 
clinical significance methods: the Jacobson (RCI criterion only), EN, NK, GLN, and 
HLM methods. High rates of agreement in classification (78-81%) were found 
between methods, apart from the GLN method (51%). Speer and Greenbaum (1995) 
therefore recommended the use of the Jacobson method as it evades statistical issues 
associated with residualised true score adjustments, it is the most straight-forward 
method, and it is the most widely used method allowing comparisons across studies. 
They also concluded that regression towards the mean is not nearly as big of a problem 
as previously thought. 
McGlinchey and Jacobson (1999) compared the Jacobson and HA methods across 30 
couples receiving couple’s therapy. No substantial differences between methods 
emerged. As the HA method did not yield a more sensitive estimate of clinically 
significant change (the main reason for its development), McGlinchey and Jacobson 
(1999) concluded that the Jacobson method is preferable. 
McGlinchey, Atkins, and Jacobson (2002) compared rates of change amongst 129 
patients receiving psychological treatment for depression. The same five methods as 
Speer and Greenbaum (1995) were compared, apart from the NK method which was 
replaced by the HA method. No significant differences in classifications emerged 
between the different methods. As the methods were essentially equivalent, 
McGlinchey et al. (2002) supported the use of the Jacobson method as “it has yet to 
be rejected by an alternative method of superior performance” (p542). 
Bauer, Lambert, and Nielsen (2004) compared rates of change across the same five 
methods as McGlinchey et al. (2002) amongst 386 patients receiving psychological 
treatment across a range of psychological disorders. The average amount of agreement 
in classification between methods ranged from 71-85%. The HA method produced the 
most cautious recovery rates (12%) and the EN method the most lenient (21%). Due 
to its simplicity and because it provides a reasonable position between the extremes of 
the HA and EN methods, the Jacobson method was recommended. 
Atkins, Bedics, McGlinchey, and Beauchaine (2005) compared four methods: the 
Jacobson, GLN, EN, and HA methods. Unlike previous comparison studies, Atkins et 
al. (2005) used simulated data to explore differences between methods. Overall, there 
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was considerable agreement in classification between methods, especially when the 
reliability of the measure was high. The authors concluded that, as no one method 
could be preferred over another for statistical reasons, the Jacobson method is 
preferable because of its wide use and ease of computation.  
Ronk, Hooke, and Page (2012) compared five methods (the Jacobson, NK, EN, HA 
and GLN methods) across a wide range of outcome measures in inpatients (N=2,676) 
receiving psychological treatment for depression. High rates of agreement in 
classification (mean agreement 94%) were found between four of the five methods 
(the Jacobson, NK, EN, and GLN methods). The HA method had the least agreement 
in classification with other methods (mean agreement 81%). Interestingly, the 
outcome measure used to calculate clinical significance impacted patient classification 
much more than the clinical significance method. This further highlights the need to 
agree on valid and reliable core outcome measures to be used within trials in a specific 
area. The authors concluded that these findings do not allow any recommendations to 
be made regarding which method to use. 
4.6 The validity of different clinical significance classifications 
The previous section focused on the convergences and divergences in classification 
rates between methods. Across studies, generally high rates of agreement in 
classification between methods were found. Because of this, and due to its wide-use 
and ease of computation, five of the six studies recommended the Jacobson method. 
However, a higher rate of agreement in classification does not demonstrate higher 
accuracy in classification. For instance, if five of the six methods demonstrate that 
around 60% of patients ‘recovered’, and the remaining method demonstrates that only 
20% of patients ‘recovered’, this does not indicate that the latter method is of any less 
accuracy. It is important to consider whether methods are valid in their categorisation 
i.e. does a ‘recovered’ patient display characteristics expected from patients who have 
recovered. This is known as construct validity. Four empirical studies have 
investigated the construct validity of clinical significance methods - three focused 
solely on the Jacobson method, and one focused on both the Jacobson and HA 
methods. There findings will be discussed below. 
Ankuta and Abeles (1993) categorised 74 outpatients with varied psychological 
disorders according to the Jacobson method and compared classifications with 
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patient’s perceived satisfaction with therapy. Patients classed as ‘recovered’ reported 
higher levels of satisfaction than those not classed as ‘recovered’, providing important 
initial evidence of the construct validity of the Jacobson method.  
Lunnen and Ogles (1998) extended the evaluation of Ankuta and Abeles (1993) by 
examining the construct validity of the Jacobson method from multiple perspectives. 
They categorised 52 outpatients with a range of psychological disorders according to 
the Jacobson method (RCI criterion only) and compared classifications from the three 
perspectives proposed by Strupp and Hadley (1977): the patient, the therapist, and a 
significant other. Perceived change, therapeutic alliance and satisfaction with services 
were evaluated from the three perspectives. From both the patient and therapist’s 
perspective, patients classed as ‘improved’ showed higher levels of perceived change, 
therapeutic alliance, and satisfaction with therapy than those classed as ‘unchanged’ 
or ‘deteriorated’. There were no significant differences between those who remained 
‘unchanged’ or ‘deteriorated’ on any domain or from any perspectives. This 
demonstrates that the Jacobson method (RCI criterion) has good construct validity for 
defining patients as ‘improved’ but less construct validity for defining patients as 
‘deteriorated’. 
Newnham, Harwood, and Page (2007) compared patient classifications according to 
the Jacobson method with self-rated QoL and therapist-rated functioning amongst 
1,830 inpatients at a psychiatric hospital. Patients classed as ‘recovered’ and 
‘improved’ had both higher self-rated QoL and therapist rated functioning than those 
classed as ‘unchanged’ or ‘deteriorated’, providing further evidence for the construct 
validity of the Jacobson method. 
Ronk et al. (2016) evaluated the construct validity of the Jacobson and HA methods 
in classifying patients as ‘recovered’ amongst 119 patients recently discharged from a 
psychiatric hospital. ‘Recovery’ according to the Jacobson and HA methods were 
compared to three dimensions: consumer-based recovery, self-rated QoL, and 
readmission to a psychiatric unit. According to both clinical significance methods, 
patients classed as ‘recovered’ demonstrated higher levels of consumer-based 
recovery and self-rated QoL, and lower rates of hospital readmission than those not 
classed as ‘recovered’. This suggests that both the Jacobson and HA methods have 
good construct validity for defining patients as ‘recovered’. Since no meaningful 
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differences in capturing the construct of ‘recovery’ were found between methods, 
Ronk et al. (2016) supported the use of the Jacobson method due to its wide use and 
ease of computation. 
4.7 Conclusion 
While tests of statistical significance provide valuable group information, the practical 
relevance of this information is limited. An assessment of clinical significance is 
therefore needed to make meaningful inferences about the clinical impact of 
psychotherapy and provide a much clearer understanding of whether and how well a 
treatment ‘works’. The method of clinical significance proposed by Jacobson et al. 
(1984,1991) represents a meaningful and appropriate approach. While there are 
limitations of the Jacobson method, it has withstood vigorous debate and a superior 
method has yet to be established. It is also the most widely used method (Ogles et al., 
2001). Therefore, the Jacobson method seems the most appropriate and valid method 
for measuring clinical significance in psychotherapy outcome research.   
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5.1 Introduction 
Two Cochrane reviews (Jassim et al., 2015; Mustafa et al., 2013) and eight additional 
meta-analyses (Cobeanu & David, 2018; Duijts et al., 2011; Naaman et al., 2009; 
Tatrow & Montgomery, 2006; Xiao et al., 2017; Ye et al., 2018; Zhang et al., 2016; 
Zimmermann et al., 2007) of RCTs have concluded that efficacious psychological 
treatments for emotional distress in BCa exist. Consequently, healthcare policies and 
clinical practice guidelines internationally specify that psychological treatment should 
be available to BCa patients as part of their routine care throughout the disease 
trajectory (Dauchy et al., 2012; Holland et al., 2011; Howell et al., 2009; Li et al., 
2016; National Breast Cancer Centre, 2003; National Comprehensive Cancer 
Network, 2003; National Institute for Clinical Excellence, 2004; Page & Adler, 2008; 
Reese et al., 2017; Tit et al., 2017). 
However, study 2 challenged the conclusion that efficacious psychological treatments 
exist by exposing the poor quality of the trials. Two reasons why conclusions of 
previous meta-analyses are based on RCTs not relevant to clinical practice were 
identified. First, for a psychological treatment to be reproducible it must follow clear 
steps specified in a treatment manual (Westen, Novotny, & Thompson-Brenner, 
2004). Therefore, the standards by which a treatment is considered “evidence-based” 
for inclusion in clinical practice in the United States require that a treatment be 
manualised (Chambless & Hollon, 1998). However, only 51% of RCTs in BCa used 
a manual and no meta-analysis excluded non-manualised treatments or examined 
whether manualisation influenced treatment efficacy. Second, clinical practice 
guidelines recommend psychological treatment only for BCa patients who are 
clinically distressed (National Comprehensive Cancer Network, 2003). However, only 
15% of RCTs screened patients for distress, and no meta-analysis excluded non-
distressed patients or provided separate analyses specifically for those with distress, 
limiting the generalisability of their conclusions to the clinical setting. 
Moreover, previous meta-analyses are based solely on effect sizes. While effect sizes 
convey differences between conditions at the group level, they provide no information 
about individual variability in treatment response (Loerinc et al., 2015). This makes it 
difficult for researchers, clinicians, service providers and policy-makers to interpret 
the practical value of the treatments (Temple, Salmon, Tudur-Smith, Huntley, & 
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Fisher, 2018). To indicate the proportion of patients who benefit from treatment, and 
therefore its relevance to clinicians and services, an evaluation of clinical significance 
is needed. Unfortunately, in BCa, only 11% of RCTs and no meta-analyses have 
evaluated the clinical significance of treatments, making it difficult to interpret their 
practical value. When evaluating clinical significance, it is also important to assess 
‘deterioration’ i.e. significant worsening in symptoms. In mental health settings, 
around 5-15% of patients deteriorate in psychotherapy RCTs (Rozental, Magnusson, 
Boettcher, Andersson, & Carlbring, 2017).  
In addition, clinicians and service providers need two further kinds of information that 
meta-analyses have not yet provided. First, it is crucial to know the longer-term 
efficacy of psychological treatment (i.e. ≥6 months after completion of psychological 
treatment). Four previous meta-analyses evaluated longer-term effects (Cobeanu & 
David, 2018; Duijts et al., 2011; Jassim et al., 2015; Tatrow & Montgomery, 2006). 
However, three of these aggregated effects 0-12 months post-treatment (Duijts et al., 
2011; Jassim et al., 2015; Tatrow & Montgomery, 2006), and one aggregated effects 
3-12 months post-treatment (Cobeanu & David, 2018). Therefore, it is difficult to 
determine the durability of treatment gains. Second, whereas services need to know 
which types of psychological treatment are most efficacious, only three previous meta-
analyses examined this, with each reaching a different conclusion; Jassim et al. (2015), 
Zimmermann et al. (2007), and Naaman et al. (2009) concluded that, relative to control 
conditions, CBT, psychoeducation and supportive therapy were the most efficacious 
treatments, respectively. 
An individual patient data meta-analysis (IPD-MA) is therefore needed to overcome 
the limitations of previous meta-analyses. IPD-MAs are considered the ‘gold standard’ 
in meta-analysis techniques (Stewart & Parmar, 1993; Stewart & Tierney, 2002). 
Instead of using summary statistics from published RCTs, IPD-MA combines 
participant-level data from each relevant RCT into a common dataset. IPD-MA has 
three specific advantages over traditional meta-analysis (Stewart & Parmar, 1993). 
First, IPD-MA leads to more reliable analyses (Cooper & Patall, 2009; Stewart & 
Tierney, 2002; Tierney et al., 2015). Second, IPD-MA provides the opportunity for 
analyses which have not been reported in the included RCTs (Cooper & Patall, 2009). 
Crucially, this enables evaluation of treatment effects separately for distressed & non-
distressed patients, yet to be done in BCa. Finally, IPD-MA is needed to evaluate the 
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clinical significance of treatments, a major omission from previous meta-analyses. As 
detailed in chapter 4, the clinical significance approach developed by Jacobson and 
colleagues (Jacobson et al., 1984; Jacobson & Truax, 1991) has become the most 
widely used method but has never been applied in this population.  
The Jacobson method has two criteria. The first involves calculation of a cut-off point 
on a well-validated outcome measure to determine whether an individual's post-
treatment score has a greater probability of being drawn from a functional or 
dysfunctional population. Second the 'reliable change index' (RCI) determines if the 
extent of change from pre- to post-treatment is statistically reliable. Applying the two 
criteria from the Jacobson method, patients in RCTs can be classed into one of four 
categories: i) ‘recovered’, if they make a statistically reliable change and move from 
a dysfunctional to a functional population; ii) ‘improved’, if they make a statistically 
reliable change but do not move from a dysfunctional to a functional population; iii) 
‘unchanged’, if they do not make a statistically reliable change; and iv) ‘deteriorated’, 
if they make a statistically reliable change for the worse. Because most RCTs in BCa 
have been offered to patients irrespective of distress levels, many patients are likely to 
have been part of the functional population before treatment. Therefore, full 
assessment of clinical significance can only be applied to those who are distressed pre-
treatment. It is, however, still possible to evaluate whether non-distressed patients 
satisfy Jacobson’s second criterion and make a statistically reliable change. Therefore, 
these patients can be classed as ‘improved’, ‘unchanged’, or ‘deteriorated’. 
5.1.1 Aims of the present study  
The aim of the present study was to conduct an IPD-MA to evaluate the efficacy of 
manualised psychological treatments for emotional distress in BCa. To detect whether 
different methods of analysis suggested different conclusions, efficacy was evaluated 
using both IPD effect size analysis and Jacobson’s clinical significance analysis. These 
analyses were conducted for both the total sample (i.e. all patients irrespective of their 
pre-treatment distress levels) and the distressed sub-sample. For each analysis, 
efficacy was assessed at post-treatment and follow-up, and the influence of treatment 
type and methodological quality on outcome was investigated.  
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5.2 Method 
This review is reported according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement (Liberati et al., 2009). 
5.2.1 Eligibility criteria  
Eligibility criteria follow the PICOS framework (Liberati et al., 2009). 
Participants. Trials exclusively comprising adults aged 18 years or older with a 
histologically confirmed diagnosis of BCa.  
Interventions. Psychological interventions were defined as manualised treatments (i.e. 
trials referring to the use of a manual to standardise treatment) using psychological 
techniques. Trials evaluating complementary alternative medicines (i.e. yoga, 
hypnosis, reiki, logotherapy, art therapy, dance therapy) or treatments involving no 
interaction between therapist and patient (i.e. based explicitly on written or visual 
material) were excluded. 
Controls. Trials using either no treatment (usual care) or active (attention placebo) 
control groups. Trials comparing two or more specific psychological treatments 
without a control were excluded. 
Outcomes. The primary outcome was emotional distress defined as anxiety, 
depression, or general distress. The use of a common outcome measure with well-
established psychometric properties allows comparisons of clinically significant 
change between trials (Sheldrick, Kendall, & Heimberg, 2001). Therefore, included 
trials had to measure general distress using the Hospital Anxiety and Depression scale 
total (HADS-T; Zigmond & Snaith, 1983) or the Profile of Mood States Total Mood 
Disturbance (POMS-TMD; McNair, 1971), depression using the HADS depression 
subscale (HADS-D; Zigmond & Snaith, 1983) or the Centre for Epidemiological 
Studies Depression Scale (CES-D; Radloff, 1977), and anxiety using the HADS 
anxiety subscale (HADS-A; Zigmond & Snaith, 1983). These measures are the most 
widely used (Temple et al., 2018) and well-validated (Hann, Winter, & Jacobsen, 
1999; Johnston, Pollard, & Hennessey, 2000; Nyenhuis, Yamamoto, Luchetta, 
Terrien, & Parmentier, 1999) outcome measures in BCa RCTs.  
Studies. Only RCTs published in English in a peer-reviewed journal.  
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5.2.2 Search strategy & study selection 
PubMed, PsycINFO, Web of Science, Scopus, PsycARTICLE, and AMED were 
searched from their inception until 20th June 2018 using the same search strategy 
developed for study 2. The final search strategy used for each database is available in 
Appendix 2. Reference lists of both eligible RCTs and previous meta-analyses in BCa 
were hand-searched for additional studies.  
Initially, titles and abstracts of all papers were screened by one reviewer (JT) to 
remove duplicates and clearly irrelevant studies. To check for consistency in selection, 
a random 50% of abstracts and titles were independently assessed by a second 
reviewer (AB). At this stage, agreement between reviewers was high (81%). Most 
disagreements were due to one reviewer adopting an overly liberal approach. Next, 
full text articles of potentially relevant papers were independently assessed for 
inclusion by both reviewers (JT & AB). At this stage, agreement between reviewers 
was also high (92%). Following assessment of inter-rater agreement, discrepancies 
were resolved through discussion with a third reviewer (PF). 
5.2.3 Data extraction  
The corresponding authors of eligible trials were contacted by email and raw data on 
relevant outcome measures at pre-treatment, post-treatment and follow-up, plus 
treatment condition was requested. If corresponding authors did not respond after two 
weeks, a reminder email was sent. If there was still no response after an additional two 
weeks, all authors named on the paper of the eligible trial were contacted by email. If 
none of the authors responded within a month, a reminder email was sent to all authors.  
If there was still no response after an additional month, it was assumed that the IPD 
was unobtainable.  
Two reviewers (JT & CH) extracted data from published reports of eligible trials using 
a standardised data extraction protocol (see Appendix 3). Data extracted was year of 
publication; country of origin; number of patients randomly assigned to each 
condition; mean patient age in each condition; distribution of trajectory stage; 
distribution of tumour stage; choice of outcome measures; type of treatment and 
control conditions; mode of delivery of treatment and control conditions; and duration 
and number of sessions of treatment and control conditions. 
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5.2.4 Coding of treatment type 
Treatments were coded into five broad categories: ‘cognitive-behavioural-based 
treatments’ (CBT; treatments targeting specific thoughts or behaviours using 
cognitive behavioural techniques); ‘mindfulness-based treatments’ (MBT; treatments 
focusing on meditation, visualisation, and present-moment awareness); ‘psycho-
education’ (treatments primarily providing psychological education); ‘support’ 
(treatments emphasising a supportive environment by providing emotional or social 
support); or ‘other’ (treatments that either did not fit a defined category or combined 
different approaches without emphasising any one). The categorisation of treatments 
was discussed by three reviewers (JT, PF & CH) until consensus was reached.  These 
categories matched the categories used in study 2. 
5.2.5 Methodological quality 
Methodological quality was assessed by two reviewers (JT & CH) using a modified 
version (Temple et al., 2018) of the POMRF (Öst, 2008). This consists of 19 items 
each scored 0 (poor), 1 (fair), or 2 (good), producing a total score ranging from 0 to 
38, with higher scores indicating greater quality (see study 2 for more details on the 
POMRF). Interrater reliability between reviewers, assessed using the ICC, was 0.83 
(95% CI, 0.51–0.94) indicating good inter-rater reliability. Following calculation of 
the ICC, discrepancies were resolved by discussion with a third reviewer (PF).  
5.2.6 Identifying the distressed sub-sample 
Patients were included in the distressed sub-sample who scored above established cut-
offs for clinical levels of emotional distress pre-treatment:  HADS-A (≥8; Hinz & 
Brähler, 2011); CES-D (≥16; Radloff, 1977); HADS-D (≥8; Hinz & Brähler, 2011); 
HADS-T (≥13; Hinz & Brähler, 2011); or POMS-TMD (≥37; Cella et al., 1989; 
Classen et al., 2008).  
5.2.7 General analysis strategy 
Each outcome variable (anxiety, depression, and general distress) was examined 
separately, and included outcome data measured using different relevant measurement 
tools (i.e. HADS-D & CES-D for depression; and HADS-T & POMS-TMD for 
general distress) in the same analysis. Outcomes were examined at two time points: 
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post-treatment, defined as the earliest assessment point ≤8 weeks after treatment 
ended; and follow-up, defined as the earliest assessment point ≥6 months after 
treatment ended (the original plan was to evaluate treatment effects ≥12 months after 
treatment ended but only one trial provided such data). Both the IPD effect size 
analysis and Jacobson’s clinical significance analysis comprised three main elements: 
Effect size analysis 
1. Calculation of standardised mean difference (SMD) effect sizes in the total 
sample. 
2. Calculation of SMD effect sizes specifically in the distressed sub-sample. 
3. Evaluation of whether effect sizes varied with treatment type or 
methodological quality for the total sample and the distressed sub-sample. 
Clinical significance analysis 
1. Calculation of statistically reliable change in the total sample, using Jacobson’s 
second criterion (RCI). 
2. Calculation of statistically reliable change and recovery specifically amongst 
the distressed subsample, using Jacobson’s first and second criteria. 
3. Evaluation of whether the likelihood of achieving statistically reliable change 
or recovery varied with treatment type or methodological quality for the total 
sample and distressed sub-sample, respectively. 
5.2.8 Statistical analysis 
5.2.8.1 Preliminary analysis 
Not all eligible RCTs provided IPD. Therefore, pooled effect sizes of trials providing 
IPD were compared with those not providing IPD at post-treatment to assess whether 
effects were consistent. For the RCTs not providing IPD, effect sizes and 95% CIs 
were calculated using the data available from published reports. Differences were 
tested using Cochrane’s Q-test. Differences were also explored between trials 
providing IPD and those not providing IPD in sample characteristics, psychological 
treatment characteristics and methodological quality using chi-square tests and t-tests. 
Publication bias was assessed at post-treatment by inspecting funnel plots and using 
Egger’s test (Egger, Smith, Schneider, & Minder, 1997). 
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5.2.8.2 Effect size analysis 
Total sample. SMD effect sizes with 95% CIs were calculated using IPD by dividing 
the difference in mean value between treated and control patients by the pooled SD. 
SMDs were adjusted for small-sample bias using Hedges’ g (Hedges, 1989) and were 
pooled across trials using the inverse variance random effects model (DerSimonian & 
Laird, 1986). All SMDs were scaled so that positive values represented effects in 
favour of treated patients. Between-group SMD effect sizes of 0.2, 0.5 and 0.8 were 
considered small, medium and large, respectively (Cohen, 1988). In cases where trials 
had multiple treatment or control groups, each comparison was evaluated separately. 
However, as multiple comparisons from the same trial are not mutually independent, 
the number of patients in the relevant treatment or control group was divided equally 
between each comparison. Heterogeneity between studies was tested using Cochrane 
Q-test and the proportion of total variation that was due to heterogeneity expressed as 
the  I2 statistic, with values greater than 50% indicating at least moderate heterogeneity 
(Higgins, Thompson, Deeks, & Altman, 2003). Effect size analyses were conducted 
on a completer rather than an ITT basis because IPD was only received for treatment 
completers.  
Distressed subsample. The SMD effect size analysis techniques were identical to those 
used for the total sample. 
Influence of treatment type and methodological quality on treatment outcomes. These 
influences could only be explored at post-treatment because too few data were 
available at follow-up. Sub-group analyses were conducted using Cochrane’s Q test 
to explore whether treatment type influenced effect sizes, and weighted regression 
analyses to explore whether methodological quality influenced effect sizes. 
5.2.8.3 Clinical significance analysis 
Total sample. Using the RCI formula presented on page 77 and the data in Table 5.1, 
the RCI (Jacobson’s second criterion) was calculated separately for each outcome 
measure to determine the change in score that would be statistically reliable at p<0.05 
(Table 5.1). 
The proportions of patients classed as ‘improved’, ‘unchanged’, or ‘deteriorated’ 
following treatment, and 95% CIs, were calculated for each treatment and control 
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group. Proportions were pooled across trials using a random effects proportion meta-
analysis (DerSimonian & Laird, 1986). The Stuart-Ord (inverse double arcsine square 
root) method (Stuart & Ord, 1994) was used to stabilise variance among studies. 
Risk differences (RDs) with 95% CIs were then calculated to estimate the difference 
in improvement rates between treated and control patients. RDs were calculated by 
subtracting the proportion of patients who ‘improved’ in the control group from that 
in the treatment group. RDs were pooled across trials using the Mantel-Haenszel 
random effects model (Mantel & Haenszel, 1959). All RDs were scaled so that positive 
values represented effects in favour of treated patients. Tests of heterogeneity were 
conducted and trials with multiple comparisons were evaluated using the same 
procedures as in the effect size analysis. All RD analyses were conducted on a 
completer basis as explained above. 
Distressed sub-sample. In addition to the RCI, a cut-off point to determine whether a 
patient was more likely to be drawn from a functional or dysfunctional population was 
calculated separately for each outcome measure. As explained in chapter 4, three 
methods exist to determine this cut-off (Jacobson et al., 1984): (a) patients’ post-
treatment score falls outside the range of dysfunctionality, defined as falling two or 
more SDs beyond the mean of the dysfunctional population, in the direction of 
functionality; (b) patients’ post-treatment score is within the range of functionality, 
defined as  falling within two SDs of the mean of the functional population; and (c) 
patients’ post-treatment score has a greater probability of being drawn from the 
functional than the dysfunctional population (Jacobson et al., 1984). When normative 
data exists for both functional and dysfunctional populations, cut-off point (c) is the 
method of choice. Unfortunately, for the HADS, CES-D, and POMS, appropriate 
normative data for functional populations was not available. Thus, for the present 
study, only cut-off point (a) could be used. Table 5.1 shows the cut-off score required 
on each outcome measure to be within the range of the functional population. 
The proportions of patients classed as ‘recovered’, ‘improved’, ‘unchanged’, or 
‘deteriorated’ following treatment, and 95% CIs were calculated for each treatment 
and control group. Proportions were pooled across trials with the same techniques used 
for the total sample. Next, RDs with 95% CIs were calculated to estimate the 
difference in recovery rates between treated and control patients. RDs were calculated 
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by subtracting the incidence of ‘recovery’ in the control group from that in the 
treatment group. The model and procedures were identical to those used for the total 
sample analysis. 
Influence of treatment type and methodological quality on treatment outcomes. The 
same techniques as in the effect size analysis were used to explore whether RDs were 
influenced by treatment type or methodological quality. 
5.2.9 Statistical software 
Effect size and RD analyses were conducted using comprehensive meta-analysis, 
version 3.3.07; while proportion meta-analyses were conducted using StatsDirect, 
version 3.0.171. 
Table 5.1: Data used to determine the Reliable Change Index (RCI) and cut-off 
point on each outcome measure 
5.3 Results 
5.3.1 Study selection 
The database search retrieved 2,344 citations; 10 more were identified through hand 
searching. After removal of duplicates, 1,590 remained for screening based on title 
and abstract. Of these, 1,304 clearly did not meet inclusion criteria. Full text articles 
of the remaining 286 citations were retrieved and assessed. In total, 28 articles 
corresponding to 26 RCTs published between January 1980 and January 2018 were 
Outcome measure n1 M1 SD1 Sdiff Rxx RCI Cut-off point 
CES-D 351a 27.95 10.98 5.15 0.89 10 6 
HADS-D 522b 10.52 2.59 1.68 0.79 3 5 
POMS 397 66.83 24.75 11.07 0.9 22 17 
HADS-T 817b 19.86 5.27 2.79 0.86 5 9 
HADS-A 854b 11.45 2.9 1.74 0.82 3 6 
Note. n1= number of individuals scoring above established cut-offs for clinical levels of emotional distress pre-
treatment; M1= pre-treatment mean; SD1 = pre-treatment standard deviation; Sdiff = pre-treatment standard error 
of difference; Rxx = internal consistency; RCI = reliable change index at p<0.05; a we included pre-treatment 
scores on the CES-D (n=39) from one additional trial (Badger et al., 2013) for which we received IPD but 
excluded from the IPD-MA because there was no control condition, and one additional treatment group from 
Stanton et al. (2005) for which we received IPD (n=43) but excluded from the IPD-MA because it involved no 
interaction between therapist and patient (i.e. it was based exclusively on visual material); b we included pre-
treatment scores (n=76 for HADS-T & HADS-D; n=64 for HADS-A) from one additional trial (Rissanen, Nordin, 
Ahlgren, & Arving, 2015) for which we received IPD but excluded from the IPD-MA because there was no 
control condition 
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eligible. Seventeen (n=2,996) of the 26 (n=5,049) eligible RCTs provided IPD and 
were included. Figure 5.1 shows the study selection. A complete list of references of 
the included RCTs can be found in Appendix 6. 
5.3.2 Study and patient characteristics  
Table 5.2 describes the included RCTs. In total, 20 treatment and 18 control groups 
were included in our analyses. Nine treatments were categorised as CBT, four as 
‘other’, three as support, three as psychoeducation, and one as MBT. The mean 
duration of treatment was 14 hours (median 14; range 2-30) over nine sessions (median 
9; range 2-18). Of the 18 control groups, six were categorised as TAU, six as active 
controls, three as WLCs, two as educational material, and one as assessment only. The 
duration and number of sessions of control groups was only reported in 12 trials. Of 
these, the mean duration was seven hours (median 6; range 0-30) over three sessions 
(median 1; range 0-10). The mean post-treatment assessment took place 1 week after 
treatment ended (median 0; range 0-8). Of the twelve trials reporting follow-up data 
(i.e. the earliest assessment point ≥6 months after treatment ended), the mean follow-
up assessment took place 8 months after treatment ended (median 8; range 6-12). The 
mean total quality score on the POMRF was 16.5 out of 38, with median 16, and range 
9-29 (i.e. 43% of the maximum possible score, median 42%, range 24-76%). 
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Figure 5.1: Flow chart showing trial identification and selection 
Records identified through database searching  
(n=2,344) 
Web of Science (n=863) 
Scopus (n=874) 
PubMed (n=300) 
PsycINFO (n=282) 
PsycARTICLES (n=15) 
Records after duplicates removed  
(n=1,590) 
Records excluded  
(n=1,304) 
Full-text articles excluded, with reasons  
(n = 258) 
No Psychological treatment (n=56) 
Participants not exclusively breast cancer 
patients (n=39) 
Language not English (n=2) 
Not a randomized controlled trial (n=52) 
Emotional distress not primary outcome (n=24) 
Treatment not manualised (n=30)   
Secondary paper (n=18) 
Non-peer reviewed paper (n=16) 
No control group (n=4) 
No POMS, HADS, or CES-D (n=17) 
Additional records identified through other sources  
(n=10) 
Studies for which IPD was 
sought  
(n=26) (+2 follow-up papers) 
Studies for which IPD was 
provided (n=17) (+2 follow-up 
papers) 
Studies for which IPD was not provided  
(n=9) 
Could not contact (n=6) 
Did not have access to data (n=3) 
Records screened based on titles 
and abstracts  
(n=1,590) 
Full-text articles assessed for 
eligibility  
(n=286) 
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Table 5.2: Characteristics of trials included in the IPD-MA   
Author 
 
Sample 
size 
Treatment  Control Outcome 
measures 
Quality 
score 
Type of treatment Mode of 
delivery 
Total 
duration 
(hours) 
 Type of control Mode of 
delivery 
Total 
duration 
(hours) 
Andersen et al. 
(2004; 2007) 
227 Other Group 27  Assessment only - 0 POMS 15 
Antoni et al. 
(2001) 
136 CBT Group 20  Condensed version of active 
treatmenta 
Group 5-6 CES-D 14 
Beutel et al. 
(2014) 
156 Other Individual NRb  Offered referral to GP for 
psychological or 
pharmacological treatmentc 
- NRd HADS 20 
Bredal et al. 
(2014) 
367 Psychoeducation Group 10  Nurse-led supportc Group 6 HADS 12 
Carlson et al. 
(2013) 
271 MBT Group 21  Stress management seminara Group 6 POMS 19 
  Supportive therapy Group 18       
Classen et al. 
(2008) 
353 Support + 
education material 
Group 18  Education material - - HADS, 
POMSe 
16 
Desautels et al. 
(2018) 
62 CBT Individual 8  Wait-list control - 0 HADS 29 
      Bright light therapya Individual NR   
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Author 
 
Sample 
size 
Treatment  Control Outcome 
measures 
Quality 
score 
Type of treatment Mode of 
delivery 
Total 
duration 
(hours) 
 Type of control Mode of 
delivery 
Total 
duration 
(hours) 
Dirksen et al. 
(2007) 
81 CBT Group 5.5f 
 
 Educational components of 
active treatmenta 
Group 5.5f 
 
CES-D 16 
Graves et al. 
(2003) 
32 CBT Group 12  TAU from medical community 
+ educational materialc 
NR NR POMS 10 
Groarke et al. 
(2012) 
179 CBT Group 15  Support from oncology nursesc NR NR HADS 15 
Ho et al. 
(2016) 
157 Other Group 16  Self-help support groupa Group 16 HADS 18 
  Supportive therapy Group 16       
Lechner et al. 
(2014) 
114 CBT Group 15  Educational information 
delivered by therapista 
Group 15 CES-D 19 
Merckaert et 
al. (2016) 
159 CBT Group 30  Peer supportc Group 16 HADS 15 
Sandgren et al. 
(2003; 2007) 
237 Psychoeducation Telephone 3  Nurse help line was availablec Telephone NR POMS 9 
  Other Telephone 3  - - - -  
Savard et 
al. (2005) 
57 CBT Group 13.5  Wait-list control - 0 HADS 19 
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Author 
 
Sample 
size 
Treatment  Control Outcome 
measures 
Quality 
score 
Type of treatment Mode of 
delivery 
Total 
duration 
(hours) 
 Type of control Mode of 
delivery 
Total 
duration 
(hours) 
Savard et al. 
(2006) 
37 CBT Individual 11  Wait-list control - 0 HADS 20 
Stanton et al. 
(2005) 
371 Psychoeducation + 
education material 
Individual 1.8  Education material - - CES-D 15 
Note. Hyphen indicates not applicable; TAU = treatment as usual CBT = cognitive behavioural therapy; MBT = mindfulness-based therapy; NR = not reported; a active 
control; b number of sessions varied (mean 18, range 0-31); c treatment as usual; d number of sessions varied (mean 2.4, range 0-24); e Classen et al. (2008) provided IPD 
for general distress on both the HADS-T and POMS-TMD. We chose to use IPD for general distress on the POMS-TMD as this was their primary outcome measure; f 
session 1 = 2 hours, sessions 2-4 = ≤1 hour, sessions 5-6 = 15 minutes 
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Of the 17 trials (n=2,966) for which IPD was obtained, 1,518 (treatment=775; 
control=743), 2,209 (treatment=1,119; control=1,090) and 2,267 (treatment=1,296; 
control=971) patients, respectively, provided outcome data for anxiety on the HADS-
A (treatment=775; control=743), depression on the HADS-D (treatment=781; 
control=728) or CES-D (treatment=338; control=367), and general distress on the 
HADS-T (treatment=596; control=561) or POMS-TMD (treatment=700; 
control=410).  
For patients providing outcome data for anxiety, the weighted mean dropout rate in 
the treatment group was 8% (range: 0-29%) at post-treatment and 6% (range: 0-20%) 
at follow-up. This compared to 9% (range: 0-26%) and 13% (range: 8-17%) in the 
control group, respectively. For patients providing outcome data for depression, the 
weighted mean dropout rate in the treatment group was 8% (range: 0-29%) at post-
treatment and 9% (range: 0-27%) at follow-up. This compared to 9% (range: 0-26%) 
and 12% (range: 0-24%) in the control group, respectively. For patients providing 
outcome data for general distress, the weighted mean dropout rate in the treatment 
group was 12% (range: 0-53%) at post-treatment and 7% (range: 0-20) at follow-up. 
This compared to 10% (range: 0-65%) and 12% (range: 0-24%) in the control group, 
respectively. 
Of the 2,966 patients for which IPD was obtained, 1,451 (49% of the total sample) 
scored above the established cut-offs for clinical levels of emotional distress pre-
treatment and were therefore included in the distressed sub-sample. Of these patients, 
790 (treatment=399; control=391), 749 (treatment=390; control=359) and 1,023 
(treatment=590; control=433), respectively, scored above the established cut-offs for 
anxiety on the HADS-A (treatment=399; control=391), depression on the HADS-D 
(treatment=245; control=235) or CES-D (treatment=145; control=124), and general 
distress on the HADS-T (treatment=325; control=301) or POMS-TMD 
(treatment=265; control=132).  
5.3.3 Preliminary analysis   
Trials that provided IPD (n=17) and those that did not provide IPD (n=9) did not differ 
on any outcome at post-treatment (see Figure 5.2, 5.3 & 5.4) nor did they differ on 
sample characteristics, psychological treatment characteristics or methodological 
quality (see Table 5.3). Thus, results of the IPD-MA are unlikely to be biased by 
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excluding trials not providing IPD. Inspection of funnel plots revealed little to no 
asymmetry (see Appendix 7); this was confirmed by Egger’s regression test (all 
p>0.05). 
5.3.4 Effect size analysis 
Total sample. At post-treatment and follow-up, the difference between treated and 
control patients, as measured by the pooled SMD effect size, was not statistically 
significant for anxiety, depression or general distress (see Table 5.4 & 5.6). Moderate 
heterogeneity was indicated for depression at post-treatment (i2=58%) but not at 
follow-up. There was no evidence of heterogeneity for anxiety or general distress at 
post-treatment or at follow-up (see Appendix 8 for individual effect sizes for each 
trial). 
Distressed subsample. At post-treatment, a small but significant effect size in favour 
of treated patients was found for anxiety (k=11, g=0.24, p=0.04), depression (k=15, 
g=0.33, p<0.01) and general distress (k=16, g=0.26, p<0.01; see Table 5.7). At follow-
up, the difference between treated and control patients, as measured by the pooled 
SMD effect size, was no longer significantly different for anxiety, depression, or 
general distress (see Table 5.9). Moderate heterogeneity was indicated for anxiety at 
post-treatment (i2=51%) but not at follow-up. There was no evidence of heterogeneity 
for depression or general distress at post-treatment or follow-up (see Appendix 9 for 
individual effect sizes for each trial). 
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Note. BLT = bright light therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive therapy  
Figure 5.2: Comparison of effect sizes for trials providing IPD and those not providing IPD for anxiety at post-treatment 
 
Test for subgroup differences: Q = 1.05, df = 1 (p = 0.31) 
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Note. BLT = bright light therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive therapy 
Figure 5.3: Comparison of effect sizes for trials providing IPD and those not providing IPD for depression at post-treatment 
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive therapy; EE = emotional expression; 
PsyEd = psychoeducation 
 Figure 5.4: Comparison of effect sizes for trials providing IPD and those not providing IPD for general distress at post-treatment
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Table 5.3: Comparison of sample characteristics, psychological treatment 
characteristics and methodological quality of trials providing IPD and those not 
providing IPD  
Variable IPD provided 
(n=17) 
IPD not provided 
(n=9) 
IPD provided vs IPD 
not provided 
      statistical test p value 
Sample characteristics       
 
   Mean sample size 187 228 t(24)=-0.86 0.4 
   Mean age, years 53 53 t(24)=0.23 0.82 
Psychological treatment 
characteristics 
      
 
   Mean duration (hours) 14.4 15.5 t(26)=-0.5 0.62 
   Treatment type     x2(4)=8.27 0.08 
     CBT 9 2     
     Other 3 1     
     Psychoeducation 3 0     
     MBT 1 4     
     Supportive therapy 4 2     
  Treatment Format     x2(2)=0.34 0.84 
     Individual 4 1     
     Group 14 7     
     Telephone 2 1   
   Mean trial quality 16.5 14.3 t(24)=1.29 0.21 
Note. CBT = cognitive behavioural therapy; MBT = mindfulness-based therapy; t =   t-tests; x2 = 
chi-square tests 
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Table 5.4: Treatment effects at post-treatment (≤8 weeks after treatment) in the total sample  
  Effect sizes (g)  Risk differences for improvement 
Component  k n ga 95% CI p i2  Q (df) p  k n RDa 95% CI p i2  Q (df) p 
Anxiety 
Overall effect   11 1,372 0.12 [-0.02,0.25] 0.09 0.25  
 
  11 1,370 0.05 [-0.04,0.14] 0.29 0.68    
Treatment 
type 
        3.23 
(3) 
0.36         1.77 (3) 0.62 
CBT  6 469 0.16 [-0.14,0.45] 0.3 0.5  
 
  6 469 0.05 [-0.14,0.24] 0.61 0.8    
PsyEd  1 343 0.14 [-0.08,0.35] 0.21 0  
 
  1 343 0.03 [-0.07,0.13] 0.57 0    
Support  2 371 -0.03 [-0.23,0.18] 0.79 0  
 
  2 369 -0.01 [-0.09,0.07] 0.87 0    
Other  2 189 0.28 [ -0.01,0.57] 0.06 0  
 
  2 189 0.11 [-0.05,0.27] 0.18 0.3    
Depression 
Overall effect   15 1,967 0.13 [-0.01,0.28] 0.08 0.58  
 
  15 1,954 0.06 [0.01,0.1] 0.02* 0.41    
Treatment 
type 
        11.96 
(3) 
0.01*         4.79 (3) 0.19 
CBT  9 778 0.16 [0.02,0.31] 0.03* 0.03  
 
  9 777 0.08 [0.03,0.13] <0.01* 0    
PsyEd  2 629 -0.03 [-0.49,0.44] 0.91 0.88  
 
  2 619 0 [-0.06,0.07] 0.92 0.36    
Support  2 371 -0.16 [-0.37,0.04] 0.12 0  
 
  2 371 0 [-0.07,0.08] 0.91 0    
Other  2 189 0.47 [0.14,0.79] 0.01* 0.19  
 
  2 187 0.16 [-0.15,0.48] 0.31 0.86    
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  Effect sizes (g)  Risk differences for improvement 
Component  k n ga 95% CI p i2  Q (df) p  k n RDa 95% CI p i2  Q (df) p 
General distress 
Overall effect   17 1,968 0.11 [-0.00,0.23] 0.06 0.3  
 
  17 1,956 0.08 [0.03,0.13] <0.01* 0.34    
Treatment 
type 
        6.02 
(4) 
0.2         7.69 (4) 0.1 
CBT  7 482 0.18 [-0.07,0.43] 0.16 0.35  
 
  7 482 0.14 [0.07,0.21] <0.01* 0    
MBT  1 87 0.38 [-0.14,0.9] 0.15 0  
 
  1 87 0.03 [-0.22,0.27] 0.82 0    
PsyEd  2 436 0.14 [-0.05,0.34] 0.15 0  
 
  2 427 0.01 [-0.08,0.1] 0.78 0    
Support  3 462 -0.1 [-0.29,0.09] 0.32 0  
 
  3 461 0.02 [-0.06,0.1] 0.62 0    
Other  4 501 0.18 [-0.12,0.49] 0.24 0.62  
 
  4 499 0.1 [-0.05,0.25] 0.19 0.69    
Note. k = number of treatment/control group comparisons; n = number of patients; PsyEd = psychoeducation; GP = general practitioner; g = hedges’ g; RD = risk difference; CI = confidence 
interval; I2 = measure of heterogeneity; Q = Cochran Q statistic; DF = degrees of freedom; CBT = cognitive behavioural therapy; MBT= mindfulness-based therapy; support = supportive 
therapy; a effect sizes and risk differences were scaled so that positive values represented effects in favour of treatment; * = p<0.05 
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Table 5.5: The influence of methodological quality on treatment effects at post-
treatment (≤8 weeks after treatment) in the total sample 
 
 
Table 5.6: Treatment effects at follow-up (≥6 months after treatment) in the 
total sample  
  Effect sizes (g)  Risk differences for improvement 
Moderator 
variable 
 k β 95% CI p  k β 95% CI p 
Anxiety 
Methodological 
quality 
 11 0.01 [-0.03,0.04] 0.79  11 -0.02 [-0.04,0.01] 0.08 
Depression 
Methodological 
quality 
 15 0.05 [0.01,0.09] 0.01*  15 0.01 [-0.01,0.04] 0.17 
General distress 
Methodological 
quality 
 17 0.02 [-0.01,0.05] 0.1  17 0.01 [-0.01,0.02] 0.06 
Note.  k = number of treatment/control group comparisons; g = hedges’ g; RD = risk difference; 
CI = confidence interval; β = beta; * = p<0.05  
  Effect sizes (g)  Risk differences for improvement 
Outcome k n ga 95% CI p i2  k n RDa 95% CI p i2 
Anxiety  6 1,007 0.03 [-0.1,0.16] 0.64 0.02  6 1,005 0.02 [-0.04,0.08] 0.51 0.04 
Depression  9 1,483 0.02 [-0.12,0.15] 0.79 0.35  9 1,470 0.01 [-0.04,0.05] 0.82 0.23 
General 
distress  
8 1,392 0.02 [-0.09, 0.13] 0.67 0.3  9 1,381 -0.01 [-0.05, 0.04] 0.77 0 
Note. k = number of treatment/control group comparisons; n = number of patients; g = hedges’ g; RD = risk difference; 
CI = confidence interval; I2 = measure of heterogeneity; a effect sizes and risk differences were scaled so that positive 
values represented effects in favour of treatment 
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Table 5.7: Treatment effects at post-treatment (≤8 weeks after treatment) in the distressed sub-sample  
  Effect sizes (g)  Risk differences for recovery 
Component  k n ga 95% CI p i2  Q (df) p  k n RDa 95% CI p i2  Q (df) p 
Anxiety 
Overall effect   11 704 0.24 [0.00,0.47] 0.04* 0.51  
 
  11 704 0.13 [0.03,0.24] 0.01* 0.56    
Treatment 
type 
        3.71 (3) 0.3         2.51 (3) 0.47 
CBT  6 231 0.44 [-0.06,0.94] 0.08 0.57  
 
  6 231 0.19 [-0.01,0.4] 0.07 0.5  0.71  
PsyEd  1 196 0.11 [-0.17,0.39] 0.45 0  
 
  1 196 0.04 [-0.09,0.17] 0.55 0  0  
Support  2 146 -0.05 [-0.37,0.28] 0.77 0  
 
  2 146 0.06 [-0.08,0.19] 0.3 0  0  
Other  2 131 0.32 [-0.0.,0.66] 0.07 0  
 
  2 131 0.15 [0.02,0.27] 0.02* 0.67  0  
Depression 
Overall effect   15 639 0.33 [0.13,0.53] <0.01* 0.31  
 
  15 639 0.03 [-0.04,0.1] 0.39 0    
Treatment 
type 
        4.95 (3) 0.18         3.39 (3) 0.34 
CBT  9 293 0.34 [0.11,0.5] <0.01* 0  
 
  9 293 0.02 [-0.8,0.12] 0.67 0    
PsyEd  2 163 -0.01 [-0.32,0.3] 0.94 0  
 
  2 163 -0.01 [-0.14,0.12] 0.87 0    
Support  2 57 0.17 [-0.35,0.69] 0.54 0  
 
  2 57 -0.08 [-0.33,0.17] 0.53 0    
Other  2 126 1.12 [-0.22,2.46] 0.09 0.69  
 
  2 126 0.15 [-0.01,0.3] 0.06 0    
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  Effect sizes (g)  Risk differences for recovery 
Component  k n ga 95% CI p i2  Q (df) p  k n RDa 95% CI p i2  Q (df) p 
General distress 
Overall effect   16 865 0.26 [0.08,0.44] <0.01* 0.1  
 
  16 863 0.11 [0.06,0.17] <0.01
* 
0.04    
Treatment 
type 
        8.22 (4) 0.08         6.05 (4) 0.2 
CBT  6 215 0.56 [0.22,0.93] <0.01* 0.04  
 
  6 215 0.21 [0.11,0.32] <0.01
* 
0    
MBT  1 34 0.44 [-0.38,1.26] 0.29 0  
 
  1 34 0.05 [-0.36,0.47] 0.8 0    
PsyEd  2 194 0.12 [-0.16,0.41] 0.4 0  
 
  2 192 0.02 [-0.12,0.16] 0.76 0.07    
Support  3 163 -0.11 [-0.43,0.21] 0.5 0  
 
  3 163 0.04 [-0.13,0.22] 0.64 0.36    
Other  4 259 0.28 [-0.03,0.6] 0.08 0.09  
 
  4 259 0.11 [0.02,0.19] 0.01* 0    
Note. k = number of treatment/control group comparisons; n = number of patients; PsyEd = psychoeducation; g = hedges’ g; RD = risk difference; CI = confidence interval; I2 = measure 
of heterogeneity; Q = ratio of variation to within-study error; DF = degrees of freedom; CBT = cognitive behavioural therapy; MBT= mindfulness-based therapy; support = supportive 
therapy; a effect sizes and risk differences were scaled so that positive values represented effects in favour of treatment; * = p<0.05 
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Table 5.8: The influence of methodological quality on treatment outcome at 
post-treatment (≤8 weeks after treatment) in the distressed sub-sample  
  Effect sizes (g)  Risk differences for recovery 
Moderator 
variable 
 k β 95% CI p  k β 95% CI p 
Anxiety 
Methodological 
quality 
 11 0.01 [-0.04,0.06] 0.65  11 -0.01 [-0.03,0.02] 0.5 
Depression 
Methodological 
quality 
 15 0.04 [-0.01,0.08] 0.08  15 0.01 [-0.01,0.03] 0.36 
General distress 
Methodological 
quality 
 16 0.03 [-0.01,0.07] 0.05  16 0.01 [-0.01,0.02] 0.16 
Note.  k = number of treatment/control group comparisons; g = hedges’ g; RD = risk difference; 
CI = confidence interval; β = beta value 
 
Table 5.9: Treatment effects at follow-up (≥6 months after treatment) in the 
distressed sub-sample 
 
Influence of treatment type and methodological quality on treatment outcome. In 
the total sample, neither treatment type nor methodological quality was significantly 
related to variation in treatment effects for anxiety or general distress. Treatment type 
was significantly related to variation in treatment effects for depression  (k=15, 
Q=11.96, df=3, p=0.01): significant effects in favour of  treated patients were found 
for CBT (k=9, g=0.16, p=0.03) and ‘other’ treatments (k=2, g=0.47, p=0.01) but not 
  Effect sizes (g) 
 
Risk differences for recovery 
Outcome k n ga 95% CI p i2 
 
k n RDa 95% CI p i2 
Anxiety 6 457 -0.07 [-0.25,0.12] 0.48 0 
 
6 457 -0.04 [-0.12,0.05] 0.41 0 
Depression  9 423 0.04 [-0.23,0.32] 0.76 0.45 
 
9 423 -0.02 [-0.13,0.09] 0.71 0.23 
General 
distress  
9 548 0.13 [-0.04, 0.29] 0.15 0 
 
9 548 0.03 [-0.03, 0.09] 0.36 0 
Note. k = number of treatment/control group comparisons; n = number of patients; g = hedges’ g; RD = risk difference; 
CI = confidence interval; I2 = measure of heterogeneity; a effect sizes and risk differences were scaled so that positive 
values represented effects in favour of treatment 
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psychoeducation (k=2, g=-0.03, p=0.91) or support (k=2, g=-0.16, p=0.12).  
Methodological quality was also related to variation in treatment effects for depression 
(k=15, β =0.05, p=0.01), with higher quality studies having larger effects (see Table 
5.4 & 5.5). Amongst the distressed subsample, neither treatment type nor 
methodological quality was related to variation in effect sizes for anxiety, depression, 
or general distress (see Table 5.7 & 5.8).  
Summary. In the total sample, no treatment effects were found for anxiety, depression 
or general distress at post-treatment or follow-up. In the distressed sub-sample, 
treatment effects were found for anxiety, depression and general distress at post-
treatment but not at follow-up. The only influence of treatment type and 
methodological quality on outcome was for depression in the total sample.  
5.3.5 Clinical significance analysis  
Total sample. Table 5.10 shows the pooled proportion of treated and control patients 
allocated to each reliable change category for each outcome variable at post-treatment 
and follow-up (see Appendix 10 for proportions for each trial). At post-treatment, 
across outcomes, few treated and control patients ‘deteriorated’ (treatment=9-11%; 
control=12-15%), a large minority ‘improved’ (treatment=26-34%; control=19-27%), 
and most remained ‘unchanged’ (treatment=55-64%; control=58-69%). At follow-up, 
the proportion of treated and control patients classed as ‘deteriorated’ was slightly 
higher than the proportions at post-treatment (treatment=9-21%, control=11-18%). 
The proportion of treated patients classed as ‘unchanged’ (52-68%) and ‘improved’ 
(24-34%) were comparable to post-treatment. However, compared to post-treatment, 
fewer control patients were classed as ‘unchanged’ (52-65%) and more as ‘improved’ 
(23-35%).  
At post-treatment, a significant RD in favour of treated patients was found for 
depression (k=15, RD=0.06, p=0.02) and general distress (k=17, RD=0.08, p<0.01). 
This indicates that, on average, 6% and 8% more treated patients compared to control 
patients ‘improved’ for depression and general distress, respectively. The RD 
comparing improvement between treated and control patients was not statistically 
significant for anxiety (see Table 5.4).  At follow-up, RDs comparing improvement 
between treated and control patients were not significantly different for anxiety, 
depression or general distress (see Table 5.6). Moderate heterogeneity was indicated 
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for anxiety at post-treatment (i2=68%) but not at follow-up. There was no evidence of 
heterogeneity for depression or general distress at post-treatment or follow-up (see 
Appendix 11 for individual RDs for improvement for each trial). 
Distressed subsample. Table 5.11 shows the pooled proportion of treated and control 
patients allocated to each Jacobson outcome category at post-treatment and follow-up 
(see Appendix 12 for proportions for each trial). At post-treatment, across outcomes, 
a small minority of treated and control patients ‘deteriorated’ (treatment=6-8%; 
control=7-12%), a larger minority ‘improved’ (treatment=17-26%; control=16-24%), 
around one quarter to one third ‘recovered’ (treatment=28-32%; control=17-27%), 
and a large proportion remained ‘unchanged’ (treatment=37-45%; control=50-51%). 
At follow-up, the proportions of treated and control patients who ‘deteriorated’ 
(treatment=5-11%; control=8-12%) were similar to those at post-treatment. The 
proportion of treated patients who remained ‘unchanged’ (41-47%), ‘improved’ (15-
24%), and ‘recovered’ (24-33%) were also similar to those at post-treatment. 
However, compared to post-treatment, fewer control patients remained ‘unchanged', 
(36-43%), and more ‘improved’ (15-28%) and ‘recovered’ (24-34%). 
At post-treatment, a significant RD in favour of treated patients was found for general 
distress (k=16, RD=0.11, p<0.01) and anxiety (k=11, RD=0.13, p=0.01). This 
indicates that, on average, 11% and 13% more treated patients compared to control 
patients recovered from general distress and anxiety, respectively. The RD comparing 
recovery between treated and control patients was not significantly different for 
depression (see Table 5.7). At follow-up, RDs comparing recovery between treated 
and control patients were not significantly different for anxiety, depression, or general 
distress (see Table 5.9). Moderate heterogeneity was indicated for anxiety at post-
treatment (i2=56%) but not at follow-up. There was no evidence of heterogeneity for 
depression or general distress at post-treatment or follow-up (see Appendix 13 for 
individual RDs for recovery for each trial). 
Influence of treatment type and methodological quality. Neither treatment type nor 
methodological quality was significantly related to variation in RDs for improvement 
in the total sample (see Table 5.4 & 5.5) or recovery amongst the distressed sub-
sample (see Table 5.7 & 5.8). 
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Summary. In the total sample, by contrast with the effect size analysis, significant 
RDs for improvement in favour of treated patients were found for depression and 
general distress at post-treatment. However, consistent with the effect size analysis, 
RDs for improvement were not statistically significant at follow-up. Similarly, in the 
distressed sub-sample, significant RDs for recovery in favour of treated patients for 
anxiety and general distress at post-treatment did not persist to follow-up. Neither 
treatment type nor methodological quality influenced RDs. 
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Table 5.10: Classification of patients at post-treatment (≤8 weeks after treatment) and follow-up (≥6 months after treatment) according 
to Jacobson’s second criterion (RCI) in the total samplea 
   Post-treatment (%) 
 
Follow-up (%) 
Condition  n Deteriorated Unchanged Improved 
 
n Deteriorated Unchanged Improved 
Anxiety 
Treatment 
95% CI 
 700 11 
(7-15) 
58 
(50-66) 
31 
(23-39) 
 
524 14 
(10-18) 
52 
(40-64) 
34 
(20-50) 
Control 
95% CI 
 672 15 
(11-19) 
58 
(49-67) 
27 
(19-36) 
 
481 13 
(9-18) 
52 
(40-63) 
35 
(22-51) 
Depression 
Treatment 
95% CI 
 992 9 
(6-13) 
64 
(57-72) 
26 
(18-35) 
 
757 9 
(7-11) 
68 
(58-77) 
24 
(16-33) 
Control 
95% CI 
 964 12 
(9-14) 
69 
(60-76) 
19 
(14-25) 
 
713 11 
(9-14) 
65 
(54-76) 
23 
(14-34) 
General distress 
Treatment 
95% CI 
 1122 11 
(8-14) 
55 
(48-62) 
34 
(27-42) 
 
787 21 
(8-35) 
52 
(40-62) 
27 
(15-39) 
Control 
95% CI 
 837 12 
(9-15) 
62 
(56-69) 
26 
(19-33) 
 
596 18 
(7-29) 
52 
(42-60) 
30 
(17-42) 
Note. n = number of patients; RCI = reliable change index at P<0.05; CI = confidence interval; a percentages have been calculated by pooling arm level data across trials to 
provide information about the actual percentage estimates. However, to interpret direct comparative results of improvement rates between treatment and control groups the 
reader should refer to the risk difference analyses presented in tables 5.3 & 5.5 
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Table 5.11: Classification of patients at post-treatment (≤8 weeks after treatment) and follow-up (≥6 months after treatment) according 
to Jacobson’s first and second (RCI) criteria in the distressed sub-samplea  
   Post-treatment (%) 
 
Follow-up (%) 
Condition  n Deteriorated Unchanged Improved Recovered 
 
n Deteriorated Unchanged Improved Recovered 
Anxiety 
Treatment 
95% CI 
 353 8 
(4-12) 
44 
(36-51) 
17 
(13-22) 
32 
(25-39) 
 
218 11 
(6-17) 
41 
(25-57) 
18 
(13-25) 
31 
(18-47) 
Control 
95% CI 
 353 12 
(8-14) 
51 
(37-62) 
18 
(11-24) 
19 
(13-27) 
 
211 9 
(4-14) 
43 
(30-56) 
15 
(10-20) 
34 
(21-49) 
Depression 
Treatment 
95% CI 
 334 6 
(3-8) 
45 
(34-56) 
18 
(12-25) 
32 
(20-45) 
 
225 5 
(2-7) 
47 
(32-62) 
15 
(7-25) 
33 
(12-58) 
Control  305 7 51 16 27 
 
199 8 41 19 31 
95% CI   (4-11) (45-60) (11-21) (16-39)   (4-12) (23-56) (11-27) (9-59) 
General distress 
Treatment 
95% CI 
 497 8 
(6-12) 
37 
(30-45) 
26 
(19-33) 
28 
(24-33) 
 
310 8 
(3-12) 
44 
(32-55) 
24 
(17-19) 
24 
(11-39) 
Control 
95% CI 
 369 10 
(7-13) 
50 
(42-58) 
24 
(17-33) 
17 
(11-24) 
 
235 12 
(5-20) 
36 
(24-48) 
28 
(22-33) 
24 
(9-40) 
Note. n = number of patients; RCI = reliable change index at p<0.05; CI = confidence interval; a percentages have been calculated by pooling arm level data across trials to 
provide information about the actual percentage estimates. However, to interpret direct comparative results of recovery rates between treatment and control groups the reader 
should refer to the risk difference analyses presented in tables 5.6 & 5.8. 
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5.4 Discussion 
An IPD-MA was conducted to evaluate the efficacy of manualised psychological 
treatments for emotional distress in BCa in two different ways: effect size analysis and 
clinical significance analysis. When all patients were included in the analysis, 
irrespective of their levels of distress before treatment, the two methods converged on 
a disappointing picture. Despite evidence from the clinical significance analysis of 
benefits for depression and general distress immediately post-treatment, no advantage 
from treatment remained relative to control conditions after a mean of 8 months 
follow-up. When the subset of patients who were clinically distressed before treatment 
were examined, findings remained disappointing. Despite evidence from both 
analyses of benefits for anxiety and general distress at post-treatment, and evidence 
from the effect size analysis of benefits also for depression at post-treatment, there 
were no benefits for treatment relative to control conditions for any form of emotional 
distress at follow-up.  
While the two methods of analysis largely converged, findings from the clinical 
significance analysis added a realistic indication of the practical significance of 
statistically significant findings. Despite statistically significant evidence that 
treatment improved outcomes at post-treatment, the clinical significance analysis 
showed that benefits were very small. In the total sample, only 6-8% more treated than 
control patients improved on measures of depression and general distress. In the 
distressed sub-sample, only 11-13% more treated than control patients recovered on 
measures of anxiety and general distress. Overall, regardless of whether patients 
received treatment or control conditions, the proportion recovering was low; across 
outcomes at post-treatment, only 28-32% of treated patients recovered compared to 
17-27% of controls At follow-up, the proportion recovering remained low: only 24-
31% of treated patients and 24-34% of controls recovered.  
Apart from isolated findings in the effect size analysis for depression in the total 
sample; that higher-quality trials had larger effects, and that CBT and ‘other’ 
treatments were the only treatment types to have significant effect sizes favouring 
treated over control patients, neither methodological quality nor treatment type 
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influenced treatment outcome. As these findings were not borne out in the clinical 
significance analysis, their robustness is questionable. 
Findings from the effect size analysis in the total sample at post-treatment can be 
directly compared to those of previous meta-analyses. Findings presented here differ 
from those (Cobeanu & David, 2018; Duijts et al., 2011; Jassim et al., 2015; Mustafa 
et al., 2013; Naaman et al., 2009; Tatrow & Montgomery, 2006; Xiao et al., 2017; Ye 
et al., 2018; Zhang et al., 2016; Zimmermann et al., 2007). Previous meta-analyses 
found significant controlled effect sizes favouring treated patients relative to control 
patients, ranging from small to large (0.26-1.11).  However, controlled effect sizes 
comparing treated and control patients in the analysis presented in this study were non-
significant. This divergence might reflect the type of RCTs included. By contrast with 
previous meta-analyses, only manualised psychological treatments were included in 
this study.  Moreover, the divergence of conclusions drawn from this IPD-MA and 
those of previous meta-analyses reflects additional ways in which methods differed. 
Specifically, by contrast with previous meta-analyses, in this IPD-MA the clinical 
significance of psychological treatments was evaluated, and their longer-term efficacy 
was evaluated. Separate analyses were also provided for patients with clinical levels 
of emotional distress - the group for whom clinical practice guidelines explicitly 
recommend psychological treatment (National Comprehensive Cancer Network, 
2003). Based on these crucial methodological differences, the conclusion of previous 
meta-analyses that efficacious psychological treatments for emotional distress in BCa 
exist cannot be supported, as these conclusions are based on patients and findings not 
relevant to clinical practice.  
This meta-analysis has limitations. First, not all eligible RCTs were included as 
authors of only 17 of the 26 eligible RCTs provided IPD, potentially compromising 
the generalisability of the results. However, no differences were found in effect sizes 
between the 17 included RCTs and the 9 not included, suggesting that the included 
RCTs were representative of published trials. Second, the included RCTs reported 
limited long-term follow-up data. Therefore, the longer-term benefits of treatment 
could only be considered around 8 months after treatment completion. Third, RCTs 
not published in English language were excluded. Therefore, relevant RCTs may have 
been omitted. Fourth, moderate heterogeneity was identified for anxiety at post-
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treatment which could not be explained by methodological quality or treatment type. 
Thus, heterogeneity must be due to other characteristics which were not explored. For 
instance, included RCTs were diverse with regards to the point in the disease trajectory 
at which patients received psychological treatment (i.e. soon after diagnosis, during 
medical treatment, or in survivorship). When requesting IPD, this information was not 
asked for and it could not be extracted from published reports because most RCTs 
aggregated patients at different points in the disease trajectory. Finally, this IPD-MA 
may have overestimated the efficacy of psychological treatments because analyses 
were only based on treatment completers, discounting patients who may have been 
non-compliant to treatment because of treatment failure. Notably larger effects have 
been found for trials conducted on a completer basis compared to an ITT basis 
(Cuijpers et al., 2010). However, dropout rates in this IPD-MA were relatively small 
(~10%) and distributed equally across conditions. 
Healthcare policies currently specify that psychological treatment should be available 
to BCa patients as part of their routine care (Holland et al., 2011; Page & Adler, 2008; 
Tit et al., 2017). However, in light of the findings in this IPD-MA of the minimal and 
temporary benefit of treatment, its clinical utility is questionable. If BCa patients were 
aware of the small benefit psychological treatment offers, they might choose not to 
commit to psychotherapy, especially considering the commitment of time and 
personal involvement it requires.  It could be argued that there is little point in 
providing BCa patients with these psychological treatments when other options, such 
as support from oncology nurses, are just as beneficial.  
One possible explanation for these poor outcomes is that treatments were inadequately 
implemented. Although only trials that used manualised treatments were included, 
most trials did not use certified trained therapists or monitor therapists’ adherence or 
competence to treatment. These design elements are essential to ensure that treatment 
was implemented as designed (Temple et al., 2018). 
An alternative explanation for these poor outcomes might be that current therapeutic 
approaches are unsuitable for BCa patients. Nine of the 20 treatments were based on 
CBT, of which the central premise is that unrealistic appraisals of events initiate and 
maintain emotional distress. CBT therefore commonly seeks to reduce distress by 
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testing the reality of unrealistic thoughts (Bennett-Levy et al., 2004). However, 
thoughts and concerns troubling BCa patients are often not unrealistic (e.g. ‘my cancer 
may return’ or ‘my cancer is putting a financial strain on my family’). Thus, 
challenging such thoughts may be inappropriate in BCa. Evaluating alternative 
psychotherapeutic approaches that do not focus on challenging the content of negative 
thoughts but instead the processes which lead individuals to respond negatively to such 
thoughts may be more suitable in BCa. An additional advantage of focusing on 
psychological processes is that it offers the potential to address comorbid problems. 
This could benefit BCa patients, who often present with mixed symptoms of anxiety, 
depression and general distress. 
In conclusion, approximately 70% of BCa patients remain distressed following 
completion of psychological treatment. While patients receiving them are slightly 
more likely to recover than those receiving a control condition in the immediate short-
term, they are no more likely to recover after around 8 months. More efficacious 
psychological treatments are urgently needed for BCa patients with emotional distress. 
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Chapter 6. Alternative Psychotherapeutic Approaches for Understanding 
Emotional Distress in Breast Cancer - The Intolerance of Uncertainty Model 
and the Self-Regulatory Executive Function (S-REF) Model 
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6.1 Introduction 
Study 3 showed that current psychological treatments do not alleviate emotional 
distress in most BCa patients. Most of the psychological treatments evaluated in study 
3 were either non-theory based or based on the central premise of the cognitive model 
(Beck, 1967, 1976), that is, that individual’s appraisal of a situation, rather than the 
situation itself, determines the behaviours and emotions that follow. In other words, 
an event leads to a thought (or appraisal), which leads to an emotional response. Thus, 
according to the cognitive model, negative appraisals of situations and events (e.g. 
negative thoughts about BCa and its consequences) initiate and maintain emotional 
distress. Negative thoughts about BCa and its consequences are associated with 
current (Cook et al., 2015a) and future distress in BCa patients (Cook et al., 2015b; 
Millar et al., 2005). However, most if not all BCa patients experience negative 
thoughts. Yet, not all BCa patients become distressed. Thus, psychological 
mechanisms not accounted for by the cognitive model may underlie emotional distress 
in BCa patients.  
Two potential mechanisms underlying emotional distress in BCa are worry and 
rumination, both of which are common among BCa patients. Worry has been defined 
as “a chain of thoughts and images, negatively affect-laden, and relatively 
uncontrollable” (Borkovec, Robinson, Pruzinsky, & DePree, 1983, p. 10) and has 
typically been examined in the anxiety literature. Rumination has been defined as 
“behaviors and thoughts that focus one’s attention on one’s depressive symptoms and 
on the implications of these symptoms” (Nolen-Hoeksema, 1991, p. 569) and has 
typically been examined in the depression literature. The main distinction between 
worry and rumination has been their temporal focus (i.e. worry is more future-oriented 
and rumination is more past-oriented; Borkovec, Ray, & Stober, 1998; Papageorgiou 
& Wells, 2004). However, both types of repetitive thinking share common processes 
and are highly correlated (Fresco, Frankel, Mennin, Turk, & Heimberg, 2002; Muris, 
Roelofs, Rassin, Franken, & Mayer, 2005; Segerstrom, Tsao, Alden, & Craske, 2000). 
Worry and rumination are also similarly related to anxiety and depression (D’Hudson 
& Saling, 2010; Fresco et al., 2002; Goring & Papageorgiou, 2008; Nolen-Hoeksema, 
2000; Rood, Roelofs, Bögels, & Alloy, 2010; Segerstrom et al., 2000). Consequently, 
worry and rumination have been conceptualised as part of a broader transdiagnostic 
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construct labelled ‘repetitive negative thinking’ (RNT; Harvey, Watkins, & Mansell, 
2004). RNT is associated with emotional distress in numerous clinical and non-clinical 
populations (Mahoney, McEvoy, & Moulds, 2012; McEvoy, Mahoney, & Moulds, 
2010; McEvoy et al., 2017; Spinhoven, Drost, van Hemert, & Penninx, 2015); and 
RNT in the form of worry and rumination is associated with emotional distress in BCa 
(Chan, Ho, Tedeschi, & Leung, 2011; Gibbons, Groarke, & Sweeney, 2016; Lo-Fo-
Wong et al., 2016; Soo & Sherman, 2015). However, the cognitive model, which most 
treatments in BCa are based on, does not attempt to explain what causes and maintains 
RNT. 
Two psychological models that could account for RNT and subsequent emotional 
distress in BCa are the intolerance of uncertainty (IU) model (Dugas et al., 1998) and 
the Self-Regulatory Executive Function (S-REF) model (Wells & Matthews, 1994, 
1996). 
6.2 Intolerance of uncertainty model 
The IU model (Dugas et al., 1998) was developed to explain the persistence of worry 
in generalised anxiety disorder (GAD). More recently, the IU model has been 
conceptualised as a transdiagnostic model which explains the development and 
maintenance of RNT and emotional distress across a range of mental and physical 
health populations (Mahoney & McEvoy, 2012; McEvoy & Mahoney, 2012). 
The IU model has four components: IU; positive beliefs about worry; negative 
problem orientation; and cognitive avoidance. IU, the core component of the model, 
refers to a dispositional characteristic resulting from dysfunctional cognitive beliefs 
surrounding uncertain situations (Dugas, Buhr, & Ladouceur, 2004). Examples of 
these beliefs include “uncertainty makes me anxious”, “uncertainty stops me from 
functioning”, and “uncertainty makes life intolerable”. Individuals with high levels of 
IU perceive future uncertain events as unacceptable and intolerable, regardless of the 
probability of the event.  
The IU model posits that IU directly leads to RNT by enhancing cognitive 
interpretational biases whereas the other three components (positive beliefs about 
worry; negative problem orientation; and cognitive avoidance) contribute to RNT via 
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indirect pathways. Positive beliefs about worry refer to beliefs that worrying will 
enable coping and prevent the occurrence of future unwanted events (e.g. “worrying 
will help me stop an event from occurring”; Dugas et al., 1998; Freeston, Rhéaume, 
Letarte, Dugas, & Ladouceur, 1994; Koerner & Dugas, 2006). Positive beliefs about 
worry can be maintained and strengthened through both positive reinforcement (e.g. 
worrying provides a solution to an uncertain situation) and negative reinforcement 
(e.g. worrying is followed by the absence of an uncertain situation occurring), leading 
to enhanced levels of RNT.  
RNT and subsequent distress leads to negative problem orientation and cognitive 
avoidance (Behar, DiMarco, Hekler, Mohlman, & Staples, 2009). Negative problem 
orientation refers to a lack of problem-solving confidence. Negative problem 
orientation leads to limited attempts to deal with difficult situations, which perpetuates 
false beliefs about problem-solving abilities and exacerbates RNT. Cognitive 
avoidance, drawn from Borkovecs’s avoidance theory (Borkovec, 1994; Borkovec, 
Alcaine, & Behar, 2004) refers to a variety of automatic and cognitive strategies to 
avoid or supress distressing thoughts and images. Examples of these strategies in BCa 
include supressing thoughts about BCa recurrence, replacing negative images of BCa 
with positive or neutral images, and avoiding BCa follow-up appointments. These 
strategies ultimately backfire and maintain and exacerbate RNT and subsequent 
distress by enhancing the strength and frequency of distressing thoughts and images 
(Borkovec & Roemer, 1995; Dugas et al., 1998).  
6.2.1 Empirical support for the intolerance of uncertainty model 
IU significantly predicts emotional distress and RNT in the form of worry and 
rumination in a range of clinical populations (Carleton, 2012; McEvoy & Mahoney, 
2012). IU has also been shown to have the strongest association with worry over and 
above other components in the IU model (positive beliefs about worry, negative 
problem orientation, and cognitive avoidance; Lachance, Ladouceur, & Dugas, 1999; 
Laugesen, Dugas, & Bukowski, 2003; Robichaud, Dugas, & Conway, 2003). 
Moreover, in a series of experimental studies, increasing levels of IU using different 
manipulation tasks led to higher levels of worry and distress (Buhr & Dugas, 2009; 
Ladouceur, Gosselin, & Dugas, 2000; Rosen & Knäuper, 2009). Although the vast 
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majority of research investigating the IU model has occurred outside the realm of 
psycho-oncology, preliminary evidence also indicates that IU is associated with worry 
in BCa survivors (Costa-Requena, Rodríguez, Fernández, Palomera, & Gil, 2011), and 
emotional distress in breast (Costa-Requena et al., 2011; Taha, Matheson, & Anisman, 
2012), prostate (Eisenberg et al., 2015), and lung (Kurita, Garon, Stanton, & 
Meyerowitz, 2013) cancer survivors.  
6.3 The Self-Regulatory Executive Function (S-REF) model  
The S-REF model (Wells & Matthews, 1994, 1996) is a transdiagnostic model which 
explains the development and maintenance of emotional distress across a range of 
mental and physical health populations. According to the S-REF model, stored 
metacognitive beliefs (i.e. beliefs about thinking), opposed to cognitive beliefs, 
underlie RNT and persistent emotional distress. 
The S-REF model posits that stored metacognitive beliefs activate a negative and 
sustained response style called the cognitive attentional syndrome (CAS). The CAS 
consists of RNT, fixating attention on potential signs of threat (e.g.  constantly 
scanning for symptoms of BCa and being hypervigilant to negative BCa thoughts) and 
the use of maladaptive coping strategies (e.g. avoiding reminders of BCa, constantly 
seeking reassurance that BCa has not returned, and distracting attention away from 
negative thoughts about BCa). The CAS prolongs and intensifies distress via several 
pathways. For example, RNT increases the frequency and strength of negative 
thoughts; fixating attention on threat increases intrusive mental experiences and 
maintains the sense of threat; and the use of maladaptive coping strategies interferes 
with normal cognitive processes and prevents the opportunity to discover that 
cognitive beliefs are often erroneous. These strategies increase engagement in RNT 
and ultimately exacerbate emotional distress. 
A wide range of metacognitive beliefs are specified in the S-REF model but five have 
been the primary focus of research: positive metacognitive, negative metacognitive 
beliefs, need to control thoughts, cognitive self-consciousness, and cognitive 
confidence. Positive metacognitive beliefs refer to beliefs about the benefits of or need 
to engage in RNT (e.g. “I must ruminate in order to find an answer to my sadness”). 
Negative metacognitive beliefs refer to beliefs about the uncontrollability and danger 
 127 
 
of RNT (e.g. “my worrying is uncontrollable”). The need to control thoughts refers to 
the extent to which one believes that certain thoughts should be suppressed (e.g. “I 
need to control my thoughts at all times”). Cognitive self-consciousness refers to the 
tendency to self-monitor thoughts and focus attention inwards (e.g. “I pay close 
attention to the way my mind works and constantly examine my thoughts”). Cognitive 
confidence refers to the amount of confidence in one’s own cognitive functioning (e.g., 
“I constantly doubt my own memory”). These stored metacognitive beliefs predispose 
individuals to engage in CAS activity. Once activated, the CAS strengthens stored 
metacognitive beliefs by increasing accessibility to information that supports them. 
This further strengthens CAS activity such as RNT, which in-turn further exacerbates 
emotional distress. 
6.3.1 Empirical support for the S-REF model 
Metacognitive beliefs significantly predict emotional distress and RNT in the form of 
worry and rumination in a range of clinical and non-clinical populations (Wells, 2000, 
2009; Wells & Fisher, 2015). Evidence also supports the central prediction of the S-
REF model; that metacognitive beliefs give rise to RNT which in-turn leads to 
emotional distress (Wells, 2000, 2009; Wells & Fisher, 2015). While most empirical 
support for the model has occurred outside the realm of psycho-oncology, evidence of 
the model’s utility for understanding RNT and emotional distress in cancer is 
beginning to emerge. Metacognitive beliefs are associated with worry in breast and 
prostate cancer survivors (Cook et al., 2015a; Thewes, Bell, & Butow, 2013); and 
emotional distress in breast, prostate, colon (Cook et al., 2015a, 2015b; Quattropani, 
Lenzo, Mucciardi, & Toffle, 2015), and adolescent and young adult (Fisher et al., 
2018) cancer survivors. 
6.4 Summary  
Both the IU model and the S-REF model suggest processes underlying RNT and 
emotional distress in BCa. Although both models overlap to some extent (i.e. positive 
beliefs about worry), the fundamental hypothesised causal psychological processes are 
distinct. As both models focus on a process underlying distress, they offer the potential 
for a transdiagnostic treatment approach, which may be more appropriate to BCa 
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patients who often present with mixed symptoms of anxiety, depression, trauma, and 
general distress.  
6.5 Conclusion  
There is preliminary evidence that both IU and metacognitive beliefs are associated 
with emotional distress in BCa survivors. However, the role of these constructs for 
explaining RNT has only partially been explored and no study to date has investigated 
the role of IU and metacognitive beliefs in BCa within the same study. Thus, it is 
unclear whether IU or metacognitive beliefs uniquely predict RNT and distress after 
controlling for each other. In the few studies in non-BCa populations investigating 
metacognitive beliefs and IU concurrently, metacognitive beliefs have consistently 
emerged as a stronger predictor of RNT and distress (Fergus & Wheless, 2018; 
Gerlach, Andor, & Patzelt, 2008; Khawaja & McMahon, 2011; Thielsch, Andor, & 
Ehring, 2015a, 2015b). It is not yet known whether the same finding would occur in 
BCa populations. 
Moreover, all but one of the previous studies investigating metacognitive beliefs and 
IU in BCa has been cross-sectional, precluding the study of temporal precedence. 
Therefore, it is impossible to conclude whether IU and/or metacognitive beliefs are a 
cause, rather than a consequence of RNT and distress. In the one prospective study 
(Cook et al., 2015b), retrospective self-report measures were used to explore 
engagement in RNT and distress over the preceding week or month. However, such 
methods are often inaccurate due to recall biases (Fahrenberg, Myrtek, Pawlik, & 
Perrez, 2007; Hassan, 2006). For example, individuals are more likely to recall 
experiences that occurred more recently; and that are consistent with their current 
mood (Gorin & Stone, 2001; Hufford, Shiffman, Paty, & Stone, 2001). The risk of 
inaccuracy or bias is increased because emotional distress and engagement in RNT 
fluctuate over short intervals such as hours and days (Moberly & Watkins, 2008).  
To overcome the difficulties associated with traditional retrospective self-report 
measures and to take account of short-term variability in RNT and distress in BCa, an 
alternative methodology that captures RNT and emotional distress shortly after being 
experienced is needed. One approach is experience sampling methodology (ESM), 
described in the following chapter. 
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Chapter 7. An Overview of Experience Sampling Methodology 
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7.1 Introduction 
Most prospective research in psychology has focused on relationships between 
psychological constructs at two or three occasions often weeks or months apart. 
However, there is an increased awareness that psychological models of emotional 
distress are essentially dynamic (Bentall, 2004) leading to large variation in 
psychological constructs over short intervals. A growing number of researchers have 
therefore advocated for an alternative methodology that accounts for variability over 
short periods of time (Csikszentmihalyi & Larson, 2014). A method known as 
experience sampling methodology (ESM) was therefore devised. ESM, also referred 
to as ecological momentary assessment (EMA), is a longitudinal research method that 
involves asking participants to complete a short assessment about their current or 
recent experiences several times each day in everyday settings (Csikszentmihalyi & 
Larson, 1987; Stone & Shiffman, 1994). ESM has been used in numerous mental and 
physical health populations in both children and adults (Broen et al., 2016; 
Csikszentmihalyi & Larson, 2014; Curran, Beacham, & Andrykowski, 2004; Mujagic 
et al., 2015; Myin-Germeys et al., 2009). 
7.2 Advantages of ESM 
As ESM enables individual’s current or recent experiences to be continuously 
captured as they fluctuate in everyday settings, it provides a rich ecological data set 
and enables dynamic relationships between variables to be evaluated in much more 
detail (Aldao, 2013; Gratz & Roemer, 2004; Myin-Germeys et al., 2009). It also 
minimises the likelihood of recall biases which are prevalent in traditional 
retrospective self-report measures (Dupuy, Beaudoin, Rhéaume, Ladouceur, & Dugas, 
2001). For example, individuals are more likely to recall experiences that occurred 
more recently; and that are consistent with their current mood (Gorin & Stone, 2001; 
Hufford et al., 2001). Moreover, individuals experiencing psychological morbidity are 
more likely to recall emotionally negative rather than positive experiences during 
retrospective assessments (Fritzsche et al., 2010; Lepage, Sergerie, Pelletier, & 
Harvey, 2007). 
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7.3 Disadvantages of ESM 
There are two main limitations of ESM: it can be perceived as intrusive and time-
consuming by participants, leading to selection and sample biases (Cerin, Szabo, & 
Williams, 2001); and it increases the chance of participant reactivity due to multiple 
assessments and frequent observation. Participant reactivity refers to when 
participants’ experiences or behaviors change due to their awareness of being 
observed (Parsons, 1974).  Careful design and piloting of an ESM study is necessary 
to overcome these limitations. 
7.4 Designing an ESM study 
When designing an ESM study, the following need to be considered; sampling 
procedure, development of the ESM assessment, ESM equipment, recruitment 
process, and piloting of the ESM study. 
7.4.1 Sampling procedure  
Two main ESM sampling procedures exist: event-contingent sampling and signal-
contingent sampling. In event-contingent sampling, participants are prompted to 
complete an assessment following every occurrence of an event of interest. This type 
of sampling is useful when the experience of interest revolves around a certain event 
(e.g. smoking). In signal-contingent sampling, participants are prompted to complete 
assessments at certain times each day. As this procedure provides a broader assessment 
of daily life, it is the preferred procedure in ESM studies (Palmier‐Claus et al., 2011). 
Signal-contingent sampling can be split into two further categories: fixed and random 
sampling. Fixed sampling involves prompting participants to complete assessments at 
the same times each day. With fixed sampling, it is easier to conduct time-related 
statistical analysis. However, it has the potential for participants to become aware of 
when they will be prompted, potentially resulting in participants changing their routine 
in anticipation of an upcoming prompt or thinking about their responses prior to being 
prompted. Random sampling, on the other hand, involves prompting participants to 
complete assessments at random times each day. This has the advantage of preventing 
participants from being prepared for upcoming assessments. However, it may result in 
long periods of time with no assessment followed by numerous assessments in quick 
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succession, representing only a small part of daily variance. This issue can be resolved 
by using pseudo-random sampling, in which participants are prompted to complete 
assessments at random points within fixed time intervals (e.g. a random prompt within 
every 2-hour block of time).  
It is also important to consider how often and for how long participants will be 
prompted to complete ESM assessments. This largely depends on the amount of data 
required to achieve a representative picture of the constructs being investigated. More 
prompts (and therefore more assessments) do not necessarily result in more data, as 
an overload of prompts may result in less compliance and higher dropout rates 
(Palmier‐Claus et al., 2011). There is no “gold standard” for the frequency and length 
of time to prompt participants, However, ESM studies have ranged from 1-14 prompts 
per day over a period of 1-90 days (Exler et al., 2017; Kimhy et al., 2006; Sullivan, 
Khondkaryan, Dos Santos, & Peters, 2011; Wijesekera et al., 2018).  
7.4.2 Development of the ESM assessment 
The central component of any ESM study is the questions included in the ESM 
assessment (Palmier‐Claus et al., 2011). A typical ESM assessment contains a 
collection of questions gathering information about participant’s current or recent 
thoughts, feelings or experiences using simple, unambiguous questions such as “how 
happy do you feel right now?”, “just before the beep, how much were you worrying?” 
or “since the last beep, how sad have you felt?”. As the aim is to capture current or 
recent experiences opposed to retrospective experiences, the wording of questions in 
ESM assessments fundamentally differ from those used in standard retrospective 
questionnaires. The development of an ESM assessment is often guided by global 
questionnaires but worded differently to be applicable in everyday life. For example, 
the following question from the HADS “I feel tense or wound up” could be changed 
to “since the last beep, I have felt tense or wound up”. The time taken to complete an 
ESM assessment should not exceed 2–3 minutes (Myin‐Germeys et al., 2018). 
Responses to questions can be obtained using open-ended formats or numerical scales. 
While open-ended responses can be informative, they take considerably longer to 
complete. Therefore, ESM responses are typically obtained using numerical scales. 
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7.4.3 Choosing equipment: Paper & pen vs electronic methods 
ESM was originally administered using paper-pen methods, which involves asking 
participants to carry around a paper-based pack of ESM assessments, and a signalling 
device with pre-programmed ‘beeps’ (usually a wristwatch). Participants are typically 
asked to complete a paper-based assessment when prompted by the preprogramed 
‘beep’ on a wristwatch (paper-based ESM). However, paper-based ESM cannot 
ascertain that participants complete assessments when prompted. Thus, participants 
may forward- or back-log their responses (e.g. a participant may have a busy day and 
forget to complete the ESM assessments when prompted and instead complete them 
all at the end of the day), invalidating the aim of ESM to capture current or recent 
experiences as they fluctuate over time. Furthermore, carrying around a collection of 
paper-based ESM assessments is often made obvious to others, inviting questions and 
adding to participant burden (Thomas & Azmitia, 2016).  
Electronic methods of administering ESM have therefore been developed, with the use 
of palmtop computers becoming extremely popular. The main advantage of ‘palmtop 
ESM’ is that assessments can be accurately ‘time-stamped’, making it possible to 
know when each assessment is completed. Thus, assessments not completed in a 
permitted time-frame can be discarded, solving the issue of forward- or back-logging. 
Electronic methods also have higher compliance rates than paper-pen methods. Stone, 
Shiffman, Schwartz, Broderick, and Hufford (2002) conducted an ESM study 
comparing paper-pen and palmtop methods. To assess paper-pen compliance, ESM 
paper assessment packs were fitted with photo-sensors that recorded the opening of 
the booklet - a prerequisite to completing an ESM assessment. Patients were instructed 
to only complete ESM assessments within 30 minutes of the prompt. The palmtop 
ESM software was programmed to only enable participants to complete assessments 
within this 30-minute window, ensuring that only relevant assessments were 
completed. Stone et al. (2002) found that participants completed the majority of ESM 
assessments using both the paper-pen (90%) and palmtop (94%) method. However, 
when compliance with the paper-pen method was verified by the photo-sensor, 
completion was much lower (11%).  
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While palmtop ESM is an improvement on paper-based ESM, palmtops are expensive 
and largely outdated making it difficult for researchers to find appropriate devices 
(Burgin, Silvia, Eddington, & Kwapil, 2013). Moreover, they still have to be carried 
around, adding to participant burden. Consequently, numerous smartphone 
applications (apps) have been developed for use in ESM studies (e.g. ClinTouch; 
MovisensXS; P.A.C.O; PIEL survey; metric-wire) and are quickly becoming the most 
preferred ESM data-collection method (Berkel, Ferreira, & Kostakos, 2017). This 
‘smartphone ESM’ approach holds all the advantages of palmtop ESM methods but 
adds no physical burden and is a cheaper option.  
7.4.4 Pilot testing of ESM 
Researchers are strongly advised to pilot ESM studies before starting recruitment 
(Palmier‐Claus et al., 2011), with Hektner, Schmidt, and Csikszentmihalyi (2007, p. 
52) stating that “it would be difficult to overstate the importance of pilot testing when 
doing an ESM study”. Piloting is not only important to ensure that the newly 
developed ESM assessments are understandable but also to ensure that the prompting 
schedule chosen is not too invasive and that the ESM equipment works without any 
errors (e.g. to check prompts are ‘released’ in the correct time frames or to check the 
prompts are audible to patients). Ideally, ESM studies should initially be piloted on a 
member of the research team followed by a small number of individuals who are in 
close contact with the chosen population (Hektner et al., 2007). 
7.4.5 Recruiting participants into an ESM study 
Considering the perceived invasive nature of ESM, recruiting participants into ESM 
studies can be difficult. ESM studies often have high participant dropout rates with 
only the most motivated taking part, leading to potential sample biases (Cerin et al., 
2001). Despite high dropout rates, ESM studies have been able to recruit sample sizes 
ranging from 5–145 participants (Delle Fave & Massimini, 2004; Ruscio et al., 2015). 
To increase participant recruitment and compliance, it is highly recommended that, 
upon recruitment to the study, the researcher meets with the participants for an 
orientation session (typically lasting around 45 minutes to an hour; Hektner et al., 
2007). During this session, the researcher should explain the ESM procedure to the 
participant, ensure that the participant understands all the questions in the ESM 
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assessment, train the participant to correctly use the ESM equipment, and allow the 
participant to complete some practice ESM assessments.  
7.5 Data analysis in ESM 
An important assumption of many statistical analyses is that data points are 
independent of one another (i.e. two individual data points are assumed not to be 
related to one another). In reality, this assumption is often violated. For example, when 
examining the effects of revision on test results, you might expect students from the 
same school to have similar results. This type of data is referred to as “nested” data. 
Not controlling for “nested” data can significantly bias results (Goldberg, 1992). As 
several measurements are taken from each participant over several days, ESM, by 
convention, involves “nested” data. Measurements are likely to be more comparable 
within-person opposed to between-person. Measurements may also be more 
comparable within days opposed to between days. Thus, ESM is nested at three levels: 
Level 1 (the lowest level) represents each individual ESM assessment; level 2 
represents each day; and level 3 represents each participant. This multilevel data 
structure is presented in Figure 7.1. To deal with this multilevel structure, ESM data 
can be aggregated for each participant. This involves combining participants’ 
individual questionnaire responses to give an overall score. However, this removes the 
multi-level structure of the ESM data, thus limiting the potential to explore within-
person variability (one of the main advantages of ESM). Alternatively, a technique 
known as “multilevel modelling” (MLM) can be used. MLM enables the estimation 
of the amount of variation at each level and maintains the multilevel structure of the 
data. Considering, the nested nature of ESM, small sample sizes still result in a very 
rich dataset. For example, if 20 participants completed 10 questionnaires a day for six 
days, it would result in 1,200 data points (20 participants x 10 questionnaires x 6 days). 
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Figure 7.1: Multilevel structure of ESM data 
 
7.6 Summary  
This chapter has presented an overview of important practical issues that need to be 
considered when designing and implementing an ESM study. Taking these 
considerations into account and considering the advantages of smartphone ESM, the 
following chapter will describe a smartphone ESM study conducted to explore the role 
of IU and metacognitive beliefs model in the development and maintenance of RNT 
and emotional distress in BCa survivors. The feasibility of conducting a smartphone 
ESM study in BCa survivors was also tested. 
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Chapter 8. Study 4: An Experience Sampling Methodology Study of Emotional 
Distress in Breast Cancer Survivors - The Role of Metacognitive Beliefs and 
Intolerance of Uncertainty 
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8.1 Introduction 
There is preliminary evidence that both IU and metacognitive beliefs are associated 
with emotional distress in BCa survivors. However, as highlighted in chapter 6, the 
role of these constructs for explaining RNT has only partially been explored and no 
study to date has investigated the role of IU and metacognitive beliefs in BCa within 
the same study. Moreover, all previous studies have relied solely on traditional 
retrospective self-report measures, which are often inaccurate due to recall biases 
(Fahrenberg, Myrtek, Pawlik, & Perrez, 2007; Hassan, 2006). Smartphone ESM can 
overcome these limitations. 
Smartphone ESM has been used in numerous physical and mental health populations 
(Band, Barrowclough, Caldwell, Emsley, & Wearden, 2017; Palmier-Claus et al., 
2012; Palmier‐Claus et al., 2014; Seidel et al., 2016; van der Velden, Mulders, 
Drukker, Kuijf, & Leentjens, 2018; Westermann et al., 2017). Yet, only one 
smartphone ESM study has been conducted in BCa (focusing specifically on sleep 
disturbance and mood in patients receiving chemotherapy; Min et al., 2014), but none 
have been conducted in BCa survivors.  
Therefore, the aims of this study were two-fold. The first was to assess the feasibility 
of using smartphone ESM in BCa survivors. This aim was exploratory and intended 
to help in designing future ESM studies. Specifically, we examined how representative 
recruited patients were of the study population, the degree of attrition, and the extent 
of compliance with the requirements of the study. The second aim was, using 
smartphone ESM, to explore whether IU and/or metacognitive beliefs uniquely predict 
anxiety, depression and RNT. As baseline anxiety, depression and RNT predict future 
anxiety, depression and RNT, respectively (Cook, Salmon, Hayes, Byrne, & Fisher, 
2018; Thielsch et al., 2015a; Weber & Exner, 2013) baseline measures of these 
constructs, along with demographic variables, were included as covariates. 
Specifically, we hypothesised that: 1) IU and metacognitive beliefs would predict 
anxiety, depression and RNT; 2) IU and metacognitive beliefs would be better 
predictors of anxiety, depression and RNT than known covariates; and 3) 
metacognitive beliefs would predict anxiety, depression and RNT over and above IU. 
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8.2 Method 
8.2.1 Design  
We used a prospective cohort design. Independent variables were metacognitive 
beliefs and IU; covariates were demographic variables and baseline anxiety, 
depression and RNT; dependent variables were anxiety, depression, and RNT. 
Independent variables and relevant covariates were assessed at baseline using 
traditional self-report measures. Dependent variables were assessed using ESM. There 
is little theoretical guidance on the appropriate frequency and duration of an ESM 
study. Therefore, based on previous ESM studies (Marco & Suls, 1993; Myin-
Germeys, Krabbendam, Jolles, Delespaul, & van Os, 2002), ESM assessments 
occurred six times daily for eight consecutive days.  
8.2.2 Participants 
Inclusion criteria were: diagnosis of BCa, completion of adjuvant therapy (excluding 
hormone replacement therapy), access to a smartphone with an android or IOS 
operating system, aged 18 years or older, and ability to speak and understand English. 
Patients considered by the clinical team or researcher to be too distressed or confused 
to give informed consent were excluded. The study was approved by the NHS North 
West Greater Manchester East ethics committee (15/NW/0925). 
8.2.3 ESM protocol 
ESM assessments were delivered by an app downloaded onto participants’ 
smartphones. The Participation in Everyday Life Survey application (PIEL app; 
www.pielsurvey.org) was used for iOS devices and the MovisensXs app 
(www.movisens.com) was used for android devices. Participants were ‘prompted’ to 
complete each ESM assessment by a pre-programmed ‘beep’ within the app. To 
capture sufficient variability in daily experiences, prompts were delivered at pseudo-
randomised intervals with a minimum of 60 minutes between each prompt. If an 
assessment was not completed within 15 minutes of the prompt, it was no longer 
accessible. The time-frame during which participants were prompted was 
individualised by programming the app to only prompt participants during their 
average waking hours.  
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8.2.4 Procedure 
Patients were recruited through a post-treatment BCa clinic at a National Health 
Service (NHS) teaching hospital in North-West England between September 2016 and 
July 2017. Clinical staff identified potentially eligible patients from their medical 
records and sent them a recruitment letter and information sheet which they received, 
along with their appointment letter, 3-4 months prior to their appointment. 
Immediately following their appointment, patients were asked by the BCa nurse 
conducting the appointment whether they had access to a smartphone, and if so, would 
they like to speak to the researcher (JT) to learn more about the study. Those who 
agreed met with the researcher who answered questions, screened for eligibility, and 
obtained written informed consent from those who agreed to participate. Participants 
then completed the baseline questionnaires in the clinic. Following this, the ESM app 
was downloaded onto each participant’s smartphone and programmed to begin on an 
agreed date within the following seven days. The ESM assessments continued for 
eight consecutive days. On the second day of the ESM schedule, participants were 
contacted by the researcher (JT) to ensure that the app was functional and that they 
still wanted to participate. 
8.2.5 Measures  
8.2.5.1 Independent variables 
Metacognitive beliefs were assessed using the metacognitions questionnaire-30 
(MCQ-30; Wells & Cartwright-Hatton, 2004). The scale contains 30 items measuring 
five metacognitive beliefs: positive metacognitive beliefs about the benefits of or need 
to engage in RNT; negative metacognitive beliefs about the uncontrollability and 
danger of RNT; the need to control thoughts; cognitive self-consciousness; and lack 
of cognitive confidence. Each subscale yields a total score ranging from 6 to 24 with 
higher scores indicating greater conviction in metacognitive beliefs. The MCQ-30 has 
been validated for use with cancer patients (Cook, Salmon, Dunn, & Fisher, 2014). In 
the current sample, Cronbach’s α of MCQ-30 subscales ranged from 0.73 (‘need to 
control thoughts’) to 0.9 (‘cognitive confidence’) indicating adequate to excellent 
internal consistency.  
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IU was assessed using the Intolerance of Uncertainty Scale (IUS; Buhr & Dugas, 
2002). The IUS is a 27-item self-report questionnaire measuring ones’ emotional, 
cognitive and behavioural reactions to uncertain situations. Total scores range from 27 
to 135 with higher scoring indicating greater IU. The scale has been validated in BCa 
(Costa-Requena et al., 2011) and has excellent internal consistency in the current 
sample (Cronbach’s α: 0.96). 
8.2.5.2 Covariates 
Demographic and clinical data was collected by self-report. Data collected were age 
at diagnosis, tumour stage at diagnosis, employment status, living alone or not, and 
time since finishing adjuvant therapy. 
Baseline anxiety and depression were assessed using the Hospital Anxiety and 
Depression Scale (HADS; Zigmond & Snaith, 1983). The HADS is a 14-item self-
report questionnaire measuring anxiety (7 items) and depression (7 items). Each 
subscale is scored from 0 to 21, with higher scores indicating greater anxiety or 
depression. The HADS is one of the most well-validated outcome measures of anxiety 
and depression in BCa populations (Hann et al., 1999; Hashim, 2016; Villoria & Lara, 
2018). In the current sample, both subscales have good internal consistency 
(Cronbach’s α: 0.88 for anxiety; 0.81 for depression). 
Because no RNT scale has yet been validated in BCa or a similar population, baseline 
RNT was assessed as two separate variables: worry and rumination. Worry was 
assessed using the Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, 
& Borkovec, 1990), a 16-item self-report questionnaire measuring the intensity and 
excessiveness of worry independent of worry content. The scale yields a total score of 
16 to 80 with higher scores indicating greater worry. The PSWQ has good internal 
consistency in cancer populations (e.g. Lehto & Cimprich, 2009) and has good test-
retest reliability (Meyer et al., 1990). The scale has excellent internal consistency in 
the current sample (Cronbach’s α: 0.93). Rumination was assessed using the 
ruminative response scale (RRS; Nolen-Hoeksema, 1991), a 22-item self-report scale. 
Scores range from 22 to 88 with higher scores indicating higher levels of rumination. 
The scale has good internal consistency in cancer populations (e.g. Schellekens et al., 
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2017) and has excellent internal consistency in the current sample (Cronbach’s α: 
0.95).  
8.2.5.3 Dependent variables (ESM assessment) 
The ESM assessment included three questions – one for each dependent variable; 
anxiety, depression, and RNT (see Figure 8.1). To limit potential recall biases and 
capture data representative of participant’s daily experiences, questions in the ESM 
assessment began with the phrase “since the last beep”. The questions relating to 
anxiety and depression were similar to those used in previous ESM assessments 
(Bylsma, Taylor-Clift, & Rottenberg, 2011; Hartley, Haddock, Vasconcelos e Sa, 
Emsley, & Barrowclough, 2014; Moberly & Watkins, 2008; Peeters, Nicolson, 
Berkhof, Delespaul, & deVries, 2003). The question relating to RNT was adapted from 
the Cognitive Attentional Syndrome Scale (CAS-I; Wells, 2009), a retrospective self-
report measure that assesses, along with other constructs, RNT. 
8.2.6 Patient and public involvement 
Feedback regarding the ESM design was informally obtained from a group of BCa 
survivors who were members of a local cancer support group.  This feedback led to 
significant revisions of the ESM assessment, including rephrasing questions so that 
they were preceded by “since the last beep” opposed to “just before the beep” as 
patients felt it was difficult to pin-point their exact feelings immediately prior to the 
‘beep’. The number of questions in the ESM assessment was also reduced as 
participants felt it was originally too burdensome.  
8.2.7 Pilot testing 
As described in chapter 7, pilot testing newly developed ESM assessments and 
software is strongly advised (Palmier‐Claus et al., 2011). Thus, the ESM procedure 
was informally piloted on a member of the research team. Technical issues relating to 
the delivery of the ESM assessment on the smartphone app were resolved accordingly 
(i.e. the sampling schedule initially reset every time the smartphone was turned off). 
Following this, the ESM procedure was informally piloted on six BCa nurses at the 
participating NHS hospital. Further technical issues were dealt with (i.e. initially, the 
volume of ‘prompts’ could not be muted, causing unwanted disruption during the 
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nurses’ schedules). Moreover, it indicated that the average time it took them to 
complete the ESM questionnaire was 90 seconds, falling within the 2-3 minute range 
recommended (Palmier‐Claus et al., 2011). 
8.2.8 Feasibility 
8.2.8.1 Attrition 
We calculated the proportion of patients who agreed to meet with the researcher, 
consented to take part, and dropped out after giving consent.   
8.2.8.2 Sample representativeness 
We compared the education level, ethnicity, marital status, and employment status of 
our sample with a sample of cancer patients (n=229) recruited from the same hospital, 
who took part in a recent cross-sectional study exploring worry and distress using 
traditional retrospective self-report measures (Cook et al., 2015a).  
One potential barrier to using smartphone ESM in BCa survivors is smartphone 
accessibility. Most BCa patients (80%) are aged 50 years or older, with a median age 
of 62 (Horner et al., 2009). However, only 55% of people aged between 55-64, and 
only 18% of people aged 65 or older own a smartphone in the UK (Ofcom, 2018). 
Thus, to explore representativeness of the sample age, the median age of our sample 
was compared to the median age of BCa patients according to statistics from the 
National Cancer Institute (Horner et al., 2009).  
8.2.8.3 Compliance 
We calculated the number of ESM assessments completed per participant. In line with 
previous ESM studies (e.g. Hare, Gracey, & Wood, 2016; Moberly & Watkins, 2008; 
Myin-Germeys, van Os, Schwartz, Stone, & Delespaul, 2001), minimum compliance 
was defined as completion of at least one third of assessments. Level of compliance 
was also compared to that in a smartphone ESM study that used a similar ESM 
schedule (i.e. four times a day for seven consecutive days) and indicated response rates 
in samples from four distinct populations: schizophrenia, substance dependence, 
anxiety disorders, and a non-clinical sample (Johnson et al., 2009). 
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Figure 8.1: Summary of ESM procedure and details of ESM assessment 
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8.2.9 Statistical analysis 
8.2.9.1 Hypothesis 1 & 2 
Data obtained by ESM is nested within three levels: assessments (level 1) nested 
within days (level 2) nested within individuals (level 3). Therefore, multilevel models 
of longitudinal data were used to test the hypotheses. Multilevel models can include 
both fixed effects (which take the same value across all individuals, days and 
assessments) and random effects which allow scores to differ between individuals, 
days, and assessments). Days were coded sequentially (e.g. 1 represents day 1) and 
assessments were coded in hours (e.g. 9.5 represents 9.30am). To improve the chance 
of a well-specified multilevel model, Diggle et al. (2002) recommend a procedure that 
firstly establishes an appropriate random effects structure for the model, then 
establishes appropriate fixed effects to include. This procedure was conducted 
separately for each dependent variable (i.e. anxiety, depression and RNT). Firstly, a 
model containing all possible fixed effects (i.e. independent variables and covariates) 
was fitted (excluding interactions between fixed effects) using restricted maximum 
likelihood techniques. Various models with different random effects structures were 
compared, from inclusion of no random effects, random intercepts at either the 
individual or day level, or both, and the addition of a random assessment time term  at 
either the day level (to explain differences in responses to assessments within 
individuals over the course of a day; e.g. patient 1 might have responses that fall more 
quickly over the course of day 1 than day 2) and at the individual level (to explain 
differences in responses to assessments between individuals over the course of a day 
i.e. patient 1 might have responses that fall more quicker over certain days  than patient 
2), or both. The model reporting the lowest Akaike’s Information Criterion (AIC; 
Akaike, 1974) was selected as the model of best fit. Fixed effects were then examined 
and sequentially removed in a backwards selection process using likelihood ratio tests. 
Fixed effects were removed from the model in order of least significant, until all terms 
remaining in the model were significant. P values of less than 0.05 were used to 
measure significance of the overall model. However, 95% confidence intervals (CIs) 
were used to measure the significance of individual fixed effects as p values for 
individual fixed effects in longitudinal multi-level models are not recommended 
(Bates, Mächler, Bolker, & Walker, 2015). Fixed effects were identified as non-
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significant if their 95% CIs contained zero. Fixed terms for intercept and assessment 
time (i.e. timing of each individual assessment) were always included in the model. 
95% CIs were calculated using bootstrapping procedures based on 500 bootstraps. 
Fixed effects examined for inclusion in each model are presented in Table 8.1. 
8.2.9.2 Hypothesis 3 
To explore whether metacognitive beliefs predict anxiety, depression and RNT over 
and above IU, IU was controlled for in the model (i.e. the model of best fit). However, 
to be able to control for IU in the model, IU has to be present. Thus, in situations where 
IU was not present in the model, the analysis was re-ran and IU was ‘forced’ into the 
model to allow it to be controlled.  
8.2.10 Missing data 
In line with previous ESM studies (Hare et al., 2016; Moberly & Watkins, 2008; Myin-
Germeys et al., 2001), participants who completed less than a third of assessments 
were excluded from the analysis.  Missing data for baseline measures (i.e. independent 
variables and covariates) were imputed using the ‘MICE’ package in R (Zhang, 2016). 
All analyses were performed in R [3] version 3.5.0, using packages lme4 (Bates et al., 
2015).  
8.3 Results 
8.3.1 Sample characteristics 
Forty-five of the 51 patients who took part in the study completed at least a third of 
the ESM assessments and were included in the analysis. There were no significant 
differences between completers (n=45) and non-completers (n=6) on clinical or 
demographic characteristics. The baseline clinical and demographic characteristics of 
the final sample (n=45) are shown in Table 8.2.  
 
 
 
 147 
 
Table 8.1: Fixed effects entered into multilevel models for each dependent 
variable 
 
Fixed effects (independent variables & 
covariates) 
Dependent variables 
 Anxiety Depression RNT 
(Intercept)    
Assessment start time    
Anxiety    
Depression    
Worry    
Rumination    
Intolerance of uncertainty    
Positive metacognitive beliefs about the 
benefits of or need to engage in RNT 
   
Negative metacognitive beliefs about the 
uncontrollability and danger of RNT 
   
Cognitive confidence    
Need to control thoughts    
Cognitive self-consciousness    
Age    
Employment statusa    
Living alone or not     
Tumour stage at diagnosisb     
Time since finishing primary adjuvant 
therapy 
   
Note. RNT = repetitive negative thinking a coded as employed vs. unemployed; 
b coded as non-metastatic vs. metastatic  
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8.3.2 Feasibility  
8.3.2.1 Attrition 
Of the 189 patients invited to participate, 81 (37.6%) agreed to meet with the 
researcher, 51 (26.9% of those approached and 62.9% of those who met with the 
researcher) consented to take part and completed baseline questionnaires, and none 
dropped out after consenting. 
Sample representativeness  
Most participants were White Caucasian (84.4%), had a school qualification or higher 
(91.1%), were married, in a civil partnership or cohabiting (73.3%), and were 
employed (66.7%). This compared to the comparator sample (Cook et al., 2015a) as 
follows: 98% White Caucasian, 58% had a school qualification or higher, 66% 
married, in a civil partnership or cohabiting, and 38% employed. The median age of 
our sample was 58 (range 35-81), slightly lower than the median age of 62 of the 
general BCa population (Horner et al., 2009).  
8.3.2.2 Compliance 
The compliance rate was high (88.2% of patients). After removing patients who did 
not meet the compliance criterion, mean compliance rates were 64.8%, (SD=16%). 
This compared to mean compliance rates of 83% (SD=16%) in non-clinical patients, 
80% (SD=18%) in patients with substance dependence, 73% (SD=18%) in patients 
with anxiety disorders, and 69% (SD=16%) in patients with schizophrenia (Johnson 
et al., 2009).   
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Table 8.2: Clinical and demographic sample characteristics at baseline 
Total number of participants  45 
Median age [min, max] 58 [35,81] 
Median age at diagnosis [min,max] 56 [30,79] 
Median Days since finishing primary adjuvant therapy 
[min,max] 
127 [9,1538] 
Median baseline anxiety [min,max] 6.0 [0,20] 
Median baseline depression [min,max] 3.0 [0,18] 
Gender (%)  
Male  1 (2.2) 
Female 44 (97.8) 
Employment (%)  
Employed 30 (66.7) 
Unemployed  15 (33.3) 
Living Arrangements (%)  
Living alone 7 (15.6) 
Not living alone 37 (82.2) 
Highest Qualification (%)  
None 4 (8.9) 
School qualification or higher 41 (91.1) 
Marital Status (%)  
Married/civil partnership/cohabiting 33 (73.3) 
Single/divorced/separated/widowed 12 (26.7) 
Current BCa episode was a recurrence (%)  
Yes 4 (8.9) 
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No 40 (88.9) 
Tumour Stage at diagnosis (%)  
Non-metastatic 42 (93.3) 
Metastatic 1 (2.2) 
Not reported 2 (4.4) 
Adjuvant therapy (%)  
Chemotherapy  
  Yes 17 (37.8) 
  No 27 (60.0) 
Radiotherapy  
  Yes 30 (66.7) 
  No 14 (31.1) 
Ethnicity (%)  
White Caucasian 38 (84.4) 
Other 7 (25.6) 
 
8.3.3 Hypothesis 1 & 2 
Anxiety. The model of best fit (i.e. the model reporting the lowest AIC) for anxiety 
included a random intercept and random assessment time term at the day level, and a 
random intercept and random assessment time term at the individual level. This 
indicates that there was significant variation in anxiety scores both within and between 
individuals over the course of each day. After accounting for the intercept and 
assessment time, baseline anxiety (ß=0.09) was the only variable to significantly 
predict anxiety (Table 8.3). 
Depression. The model of best fit for depression included a random intercept and 
random assessment time term at the day level, and a random intercept and random 
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assessment time term at the individual level. This indicates that there was significant 
variation in depression scores both within and between individuals over the course of 
each day. After accounting for the intercept and assessment time, baseline depression 
(ß=0.09) was the only variable to significantly predict depression (Table 8.4). 
RNT. The model of best fit for RNT included a random intercept and random 
assessment time term at the day level, and a random intercept and random assessment 
time term at the individual level. This indicates that there was significant variation in 
RNT scores both within and between individuals over the course of each day. After 
accounting for the intercept and assessment time, negative metacognitive beliefs about 
the uncontrollability and danger of RNT (ß=0.07) was the only variable to 
significantly predict RNT (Table 8.5). 
8.3.4 Hypothesis 3 
As negative metacognitive beliefs about the uncontrollability and danger of RNT but 
not IU predicted RNT, the analysis was re-ran forcing IU into the model. After 
accounting for the intercept and assessment time at the day level and individual level, 
negative metacognitive beliefs about the uncontrollability and danger of RNT 
significantly predicted RNT (ß=0.06) over and above IU. All other variables were non-
significant predictors of RNT (Table 8.6). 
 
 Table 8.3: Final multilevel model of anxiety  
 
 
 
 
 
 
 
Fixed effects ß (95% CI) 
(Intercept) 0.62 (0.28,0.95)* 
Assessment start time -0.03 (-0.04,-0.02)*  
Baseline anxiety  0.09 (0.05,0.13)* 
Note.  ß = beta; CI = 95% confidence interval; *= significant i.e. 95% 
confidence intervals do not contain zero 
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 Table 8.4: Final multilevel model of depression 
 
 
 
 
 
 
 Table 8.5: Final multilevel model of repetitive negative thinking (RNT) 
 
Table 8.6: Final multilevel model of repetitive negative thinking (RNT) with the 
forced entry of intolerance of uncertainty (IU) 
 
 
 
 
 
 
 
Fixed effects ß (95% CI) 
(Intercept) 0.61 (0.34,0.87)* 
Assessment start time -0.02 (-0.04,-0.01)*  
Baseline depression  0.09 (0.05,0.14)* 
Note.  ß = beta; CI = confidence interval; *= significant i.e. 95% 
confidence intervals do not contain zero 
Fixed effects ß (95% CI) 
(Intercept) 0.61 (0.18,1.04)* 
Assessment start time -0.03 (-0.04,-0.02)*  
Negative metacognitive beliefs about the 
uncontrollability and danger of RNT 
0.07 (0.03,0.1)* 
Note.  RNT; repetitive negative thinking; ß = beta; CI = confidence interval; *= 
significant i.e. 95% confidence intervals do not contain zero 
Fixed effects ß (95% CI) 
(Intercept) 0.59 (0.14,1.04)* 
Assessment start time -0.03 (-0.04,-0.02)* 
Intolerance of uncertainty 0.00 (-0.01. 0.01) 
Negative metacognitive beliefs about the 
uncontrollability and danger of RNT 
0.06 (0.0,0.12)* 
Note.  RNT; repetitive negative thinking; ß = beta; CI = confidence 
interval; *= significant i.e. 95% confidence intervals do not contain zero 
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8.4 Discussion 
The first aim of this study was to examine the feasibility of conducting a smartphone 
ESM study in a population of BCa survivors. The findings are promising. Most 
patients complied with the ESM schedule, and mean compliance rates were 
comparable to those in other populations using smartphone ESM (Johnson et al., 
2009). Moreover, the sample was representative of BCa patients with regards to most 
demographic variables. The mean age was similar to the general BCa population 
(Horner et al., 2009); and the ethnicity and marital status were similar to those in a 
previous study of cancer patients in the same hospital (Cook et al., 2015a). However, 
more patients were employed and had more years of education than those in the 
previous study (Cook et al., 2015a). While attrition before consent was modest, no 
attrition occurred after consent.  
The second aim was to explore whether IU and/or metacognitive beliefs predict 
anxiety, depression and RNT in BCa survivors. Negative metacognitive beliefs about 
the uncontrollability and danger of RNT were a better predictor of RNT than IU and 
known covariates. Moreover, negative metacognitive about the uncontrollability and 
danger of RNT remained a significant predictor of RNT even after controlling for IU. 
This is in line with the central tenet of the S-REF model that proposes that, while all 
metacognitive beliefs are important in the development and maintenance of emotional 
distress, negative metacognitive beliefs about the uncontrollability and danger of RNT 
are of more direct importance and can be viewed as the ‘turbocharger’ behind 
emotional distress (Wells & Matthews, 1994, 1996). In clinical and non-clinical 
populations, negative metacognitive beliefs about the uncontrollability and danger of 
RNT have also emerged as the strongest predictor of RNT and account for additional 
variance in predicting RNT beyond the effects of IU (Fergus & Wheless, 2018; 
Gerlach et al., 2008; Khawaja & McMahon, 2011; Thielsch et al., 2015a, 2015b). 
Surprisingly, however, neither metacognitive beliefs nor IU predicted anxiety or 
depression. The only variables to predict anxiety or depression were baseline anxiety 
and depression, respectively. This does not support the study hypotheses and is 
inconsistent with previous cross-sectional (Cook et al., 2015a; Costa-Requena et al., 
2011; Quattropani et al., 2015; Taha et al., 2012) and prospective (Cook et al., 2015b) 
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findings in BCa using traditional retrospective self-report measures. One potential 
reason for this finding is that the theoretical explanations of the S-REF model and IU 
model are insufficient for understanding emotional distress in BCa survivors. As most 
previous studies in BCa have been cross-sectional, it may be that metacognitive beliefs 
and IU are a consequence rather than cause of emotional distress. However, this does 
not explain the findings of Cook et al. (2015b) in which metacognitive beliefs 
prospectively predicted distress in BCa. Instead, it is possible that the S-REF model 
applies to BCa survivors’ long-term retrospective recall of distress, but not their real-
life distress as explored in this study. However, this seems unlikely (for the S-REF 
model) because metacognitive beliefs predicted RNT, which has repeatedly been 
shown to underlie emotional distress (Bar-Haim, Lamy, Pergamin, Bakermans-
Kranenburg, & Van Ijzendoorn, 2007; Calmes & Roberts, 2007; Mogg & Bradley, 
1998; Muris & van der Heiden, 2006; Wells, 2000). 
Other potential reasons why neither metacognitive beliefs nor IU predicted anxiety or 
depression are suggested by the low levels of distress reported by the sample and the 
inclusion of baseline distress as a predictor variable. First, the low levels of distress 
reported by the sample may have resulted in insufficient variance in distress levels. 
Moreover, as the S-REF model and IU model were developed to explain distress in 
clinically distressed populations, IU and metacognitive beliefs should (according to 
theory) be stronger predictors of anxiety and depression in a more distressed sample. 
Second, because of the inevitable correlation between baseline distress and future 
distress, the variance in baseline distress that arises from metacognitive beliefs and IU 
is likely to account for most of the variance in future distress. Thus, controlling for 
baseline distress leaves minimal variance left to account for. This may mask the effects 
of important psychological processes that underlie distress, such as metacognitive 
beliefs and IU. 
Several limitations of this study need to be considered. First, most patients reported 
low levels of anxiety and depression. Thus, findings should not be generalised to 
clinically distressed BCa patients without further investigation. Second, although 
ESM was used to capture recent experiences, the questions within the ESM assessment 
were still retrospective (i.e. “since the last beep”). Thus, while recall biases are less 
likely due to the shorter time between experiences and reporting of those experiences, 
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they cannot be excluded. Further studies should use purely momentary questions (i.e. 
“just before the beep”). Third, although dependent variables were assessed using ESM, 
independent variables were assessed using only traditional retrospective self-report 
questionnaires. Further studies should assess both dependent and independent 
variables using ESM to reduce recall biases and enable testing through lagged 
predictive analyses leading to more conclusive findings regarding temporal 
precedence. 
In summary, although metacognitive beliefs and IU did not predict anxiety and 
depression, negative metacognitive beliefs about the uncontrollability and danger of 
RNT were the strongest predictor of RNT even after controlling for IU, partially 
supporting the applicability of the S-REF model in BCa survivors. However, to pursue 
the findings of this study and determine reasons for the failure of IU and metacognitive 
beliefs to predict emotional distress, replication in a more distressed sample is needed. 
Our results suggest that conducting a smartphone ESM study in a population of BCa 
survivors is feasible. Though, further exploration of differences in employment rates 
and level of education between BCa patients who take part in studies using 
retrospective methods and those using ESM would be beneficial. Overall, smartphone 
ESM provides a promising new direction to help understand the psychological 
processes involved in the development and maintenance of emotional distress in BCa 
survivors.  
 
 
 
 
 
 
 
 
 156 
 
Chapter 9. General Discussion and Conclusions 
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9.1 Introduction 
There were two broad aims of this thesis; first, to advance knowledge and 
understanding regarding the efficacy of psychological treatments for emotional 
distress in BCa; and second, to develop a better understanding of the psychological 
processes associated with the development and maintenance of emotional distress in 
BCa survivors. To achieve these aims, three main studies were conducted. Each will 
now be discussed in turn. 
9.2 A Systematic Review of the Quality of Randomised Controlled Trials of 
Psychological Treatments for Emotional Distress in Breast Cancer 
Previous meta-analyses conclude that efficacious psychological treatments for 
emotional distress in BCa exist. These conclusions inform health care policies and 
clinical practice guidelines internationally which specify that psychological treatments 
should be available to BCa patients as part of their routine care (Dauchy et al., 2012; 
Holland et al., 2011; Howell et al., 2009; Li et al., 2016; National Breast Cancer 
Centre, 2003; National Comprehensive Cancer Network, 2003; National Institute for 
Clinical Excellence, 2004; Page & Adler, 2008; Reese et al., 2017; Tit et al., 2017). 
However, confidence in these conclusions can only be confirmed if the RCTs they are 
based on are of good quality. Therefore, a systematic review of the methodological 
quality of RCTs of psychological treatments for emotional distress in BCa was 
conducted. Overall, methodological quality was low. Generic design elements were 
limited in most trials: only 15% speciﬁed as an inclusion criterion that participants 
were distressed; only 10% controlled for concomitant treatments; and only 11% 
reported the clinical signiﬁcance of ﬁndings. Design elements speciﬁc to 
psychotherapy RCTs were also implemented poorly: only 51% used treatment 
manuals; only 8% used certiﬁed trained therapists; and monitoring of adherence and 
competence occurred in only 15% and 4%, respectively. Thus, the current view that 
efficacious psychological treatments exist for emotional distress in BCa patients is 
based on poor quality RCTs. If relevant health policies are to be adequately 
empirically informed, meta-analyses and future RCTs must account for important 
methodological issues presented in this review. 
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9.3 Do Manualised Psychological Treatments Alleviate Emotional Distress in 
Breast Cancer Patients? An Individual Patient Data Meta-Analysis 
As no previous meta-analysis focused specifically on clinically distressed patients, 
excluded non-manualised treatments, or evaluated the clinical significance of 
treatments, the practical relevance of their findings is questionable. Consequently, an 
IPD-MA of RCTs of manualised psychological treatments for emotional distress in 
BCa was conducted. Treatment efficacy was evaluated using both effect size analysis 
and, for the first time in BCa, clinical significance analysis. Analyses were conducted 
for the total sample (including distressed and non-distressed patients), and the 
clinically distressed sub-sample. In the total sample, the two methods of analysis 
converged on a disappointing picture. Controlled effect sizes were non-significant; 
and the likelihood of improving was only 6-8% higher for treated than control patients 
at post-treatment, and no higher at follow-up. Findings remained disappointing in the 
distressed sub-sample. Despite benefits from both analyses at post-treatment, there 
were no benefits for treated patients relative to controls at follow-up. Moreover, the 
clinical significance analysis showed that post-treatment benefits were very small: 
only 28-32% of treated patients recovered compared to 17-27% of controls. These 
findings show that psychological treatments do not alleviate emotional distress for 
most BCa patients. Thus, the general conclusion that efficacious psychological 
treatments for emotional distress in BCa exist appears to be wrong. The clinical utility 
of implementing these treatments into routine practice is questionable. More 
efficacious psychological treatments are urgently needed for BCa patients with 
emotional distress. 
9.4 An Experience Sampling Methodology Study of Emotional Distress in Breast 
Cancer Survivors - The Role of Metacognitive Beliefs and Intolerance of 
Uncertainty  
Having identified the urgent need to develop more efficacious psychological 
treatments for BCa patients with emotional distress, the second aim of this thesis was 
to develop a better understanding of the psychological processes associated with the 
development and maintenance of emotional distress in BCa survivors. To do this, a 
smartphone ESM study explored whether the core components of the S-REF model 
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(metacognitive beliefs) and/or the IU model (intolerance of uncertainty) predicted 
RNT and emotional distress in BCa survivors. As this was the first smartphone ESM 
study in BCa survivors, the feasibility of conducting a smartphone ESM study in this 
population was also tested. In line with the S-REF model, negative metacognitive 
beliefs about the uncontrollability and danger of RNT were the strongest predictor of 
RNT and were a better predictor of RNT than IU and known covariates. Moreover, 
negative metacognitive beliefs about the uncontrollability and danger of RNT 
remained a significant predictor of RNT even after controlling for IU. Unexpectedly, 
neither metacognitive beliefs nor IU predicted anxiety or depression. This is 
incongruent with the central prediction of both the S-REF model and IU model. This 
may suggest that the S-REF and IU model are insufficient for understanding emotional 
distress in BCa survivors. However, due to the low levels of distress reported by the 
sample, further investigation is needed to clarify this. The low rate of attrition, the high 
compliance, and the representativeness of the sample in this study indicate that 
conducting a smartphone ESM study in BCa survivors is highly feasible. This provides 
an alternative and promising new approach of understanding emotional distress in BCa 
survivors.  
9.5 Limitations of the thesis 
While limitations of the included studies have been documented in their respective 
chapters, some deserve further attention.  
9.5.1 The quality scale used in study 2 
The first issue relates to the quality scale used in study 2. Although the POMRF has 
been used to assess the quality of psychotherapy RCTs in numerous mental and 
physical health populations (Arnberg & Öst, 2014; Öst, 2008, 2014; Öst et al., 2015; 
Öst & Ollendick, 2017; Öst et al., 2016; Sloan et al., 2017; Swain et al., 2015; Swain 
et al., 2013), little is known about the scale’s psychometric properties. Ensuring a 
quality scale is valid and reliable minimises the likelihood of errors when determining 
the quality of a scientific literature (Olivo et al., 2008). While the inter-rater reliability 
of the POMRF has been confirmed in this thesis and by others (Öst, 2008), the 
criterion, content, face, and construct validity of the POMRF has not. This is a 
limitation of most quality tools (Olivo et al., 2008). As the scale was developed by a 
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group of experts in psychotherapy outcome research, one would assume the tool would 
have reasonable face and content validity. Nonetheless, this tool needs to be validated 
to increase confidence in conclusions regarding trial quality. 
Another issue relates to the items included in the POMRF. As discussed in chapter 2, 
methodological quality is a multidimensional construct. Thus, there will always be 
differing opinions on which items should be included in a quality scale. Any 
conclusions made based on the findings from study 2 can only relate to the aspects of 
quality assessed by the POMRF.  
Finally, many items in the POMRF are ambiguous in their scoring criteria. This opens 
the possibility to differing opinions of what is required for a specific score. Although 
inter-rater reliability between reviewers was high, standardisation of scoring, for 
example, devising a manual with examples for each item, analogous to the 
“explanation and elaboration” document provided by CONSORT (Boutron, Moher, 
Altman, Schulz, & Ravaud, 2008) would likely further help this situation.   
9.5.2 Cut-off points used to define functionality in study 3 
An important limitation of study 3 relates to the calculation of the cut-off point used 
to define patients as part of a functional population post-treatment. As described in 
chapter 4, when using the Jacobson clinical significance method, there are three 
available methods for defining this cut-off point. Cut-off point (c) is the least arbitrary 
method as it is based on the relative probability of a patient's post treatment score 
belonging to either the functional or dysfunctional population. However, as 
appropriate normative data on functional populations were not available on the 
outcome measures used in study 3, only cut-off point (a) could be used (i.e. patient’s 
post-treatment score falls outside the range of dysfunctionality, defined as falling two 
or more SDs beyond the mean of the dysfunctional population, in the direction of 
functionality). As described in chapter 4, cut-off point (a) may under- or over-estimate 
the score required for a patient to be classed as part of the functional population 
depending on the overlapping distribution between functional and dysfunctional 
populations. If the functional and dysfunctional distributions overlap, cut-off point (a) 
will be conservative. If they do not overlap, cut-off point (a) will be lenient. Without 
access to normative functional data, the extent of this overlap remains unknown.  
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9.5.3 Generalisability of findings from study 3 
Another issue relates to the RCTs included in study 3. As only 17 of the 26 eligible 
RCTs provided IPD, not all eligible trials were included in the analysis, potentially 
compromising the generalisability of the results. However, no difference in controlled 
effect sizes were found between the 17 included RCTs and the 9 not included, 
suggesting that the included RCTs are representative of eligible published trials. 
Furthermore, to allow comparisons of clinically significant change between RCTs and 
provide greater confidence in results, only RCTs using the HADS, CES-D or POMS, 
the most widely used (Temple et al., 2018) and well-validated (Hann et al., 1999; 
Johnston et al., 2000; Nyenhuis et al., 1999) outcome measures in BCa, were included. 
This could also potentially compromise the generalisability of results, as not all RCTs 
evaluating manualised psychological treatments were included.  
In contrast, although inclusion was restricted to RCTs using the HADS, CESD, or 
POMS, outcome data measured using different relevant measurement tools (i.e. 
HADS-D & CES-D for depression; and HADS-T & POMS-TMD for general distress) 
were still included. Not all measures are equal in their psychometric properties, 
including responsiveness to change. Therefore, the proportion of patients classed as 
having achieved reliable or clinically significant change may differ depending on the 
outcome measure used.  
9.5.4 Clinical diversity of findings from study 3 
RCTs included in study 3 were diverse with regards to at what point in the disease 
trajectory patients received psychological treatment (i.e. soon after diagnosis, during 
medical treatment, and survivorship). Treatments have been shown to work differently 
depending on the point in the disease trajectory that patients receive them 
(Zimmermann et al., 2007). PTSD literature has also suggested that early intervention 
can do more harm than good (Litz et al., 2002; Rose et al., 2003). Therefore, it may 
not be appropriate to aggregate across patients receiving treatment at different points 
in the disease trajectory. Unfortunately, when requesting IPD, participants’ trajectory 
stage was not requested, and this information could not be extracted from published 
reports as most RCTs included patients at different points in the disease trajectory. 
Therefore, the influence of trajectory stage on outcome could not be explored. 
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However, for most outcomes, heterogeneity between trials was low suggesting that 
trajectory stage did not have much influence on treatment outcome.  
Included RCTs were also diverse with regards to the type of psychological treatment 
used. To account for this, the influence of treatment type on outcome was investigated. 
However, as most treatments were broadly defined and involved a combination of two 
or more approaches, treatment groups had to be categorised using broad definitions. 
Grouping treatments that have important differences in rationale and procedures might 
obscure differences between treatments. For example, at post-treatment, the overall 
RD for recovery in depression for CBT was 0.02. However, RDs for individual CBT 
trials ranged from -0.08 (Groarke, Curtis, & Kerin, 2013) to 0.33 (Savard, Simard, 
Ivers, & Morin, 2005). To account for this variability, findings for each trial are 
presented individually in Appendix 8-13.   
9.5.5 ESM assessment used in study 4 
An important limitation of study 4 is the potential of measurement reactivity 
associated with asking participants to complete the same questionnaire multiple times. 
Although research has found reactivity to be fairly low in ESM studies (Cruise, 
Broderick, Porter, Kaell, & Stone, 1996; Ebner-Priemer & Sawitzki, 2007) it cannot 
be ruled out. Persistently asking patients to answer questions about their thoughts and 
feelings may lead to an increased focus of attention on their thoughts and feelings. 
According to the S-REF model, this is one of the exact processes believed to cause 
and maintain engagement in RNT and subsequent distress. Although the potential of 
measurement reactivity is inherent with all ESM studies, it is still important to consider 
when reflecting on the findings. 
A final issue in study 4 relates to the questions used in the ESM assessment. Assessing 
the validity and reliability of ESM assessments is difficult (Palmier‐Claus et al., 2011). 
The aim of ESM is to accurately capture recent or current experiences that may be 
have been missed or falsely reported when using traditional retrospective 
questionnaires. Thus, it makes little sense to attempt to validate ESM assessments by 
comparing ESM responses to those in traditional retrospective questionnaires. Another 
aim of ESM is to capture experiences as they fluctuate over time. Thus, it also makes 
little sense to assess the reliability (i.e. stability over time) of an ESM assessment. To 
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account for these difficulties, questions included in the ESM assessment in study 4 
were informed by previous ESM assessments, feedback regarding the questions was 
obtained from a group of BCa survivors, and the questions were piloted in a group of 
BCa nurses. 
9.6 Future research 
While study 4 provides valuable first evidence to support the utility of the S-REF 
model for predicting RNT in BCa survivors, it did not provide support for the utility 
of the S-REF model in predicting distress. To determine whether this is because the 
S-REF model is insufficient for understanding distress in BCa survivors, or instead 
due to the low levels of distress amongst the sample, replication in a more distressed 
sample is needed. Moreover, as the smartphone ESM study focused only on BCa 
survivors who had completed treatment, the study needs to be replicated in a more 
heterogeneous sample to establish the generalisability of findings and the feasibility 
of smartphone ESM in BCa patients at other points in the disease trajectory. 
In study 3, around 10% of treated and control patients in the total sample (i.e. 
distressed and non-distressed patients) deteriorated. While analyses were conducted 
on the sub-sample of patients who were distressed pre-treatment, analyses were not 
conducted on the sub-sample who were not distressed pre-treatment. However, around 
half of patients included in study 3 were not distressed (which was unsurprising as 
study 2 found that only 11% of RCTs screen for distress). From an ethical perspective, 
an evaluation of the proportion of non-distressed patients deteriorating is needed to 
ensure that providing psychological treatment to BCa patients with little distress 
(common amongst RCTs in this population) does not cause more harm than good. 
More generally, future research should follow the Medical Research Council (MRC) 
framework for the development and evaluation of complex interventions (Craig et al., 
2008), considered best practice for intervention development. The MRC framework 
proposes a systematic approach to the development of interventions that are supported 
by the best available evidence and appropriate theory. The framework includes four 
phases (Figure 9.2): 
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Phase 1: Development 
The first phase of the MRC framework involves identifying what is already known 
about other interventions in the field to ensure new interventions are warranted. If no 
recent high-quality systematic review of the relevant literature exists, one should be 
conducted. Following this, it is important to explore the literature to ensure a 
theoretical basis exists for the proposed intervention. The clinical utility of the 
proposed theoretical model should then be tested and modelled through empirical 
studies. 
Phase 2 
Once the utility of the theoretical model guiding the intervention has been confirmed, 
the feasibility of the intervention and the proposed methods to evaluate it should then 
be tested.  This includes testing procedures for their acceptability, estimating the likely 
rates of participant recruitment and retention, testing the quality of intervention 
delivery, and identifying any adverse events.  
Phase 3 
Phase three involves evaluating the efficacy of the proposed intervention. This ideally 
involves conducting an RCT. Conducting a process evaluation and/or an economic 
evaluation is also advised to help assess therapist adherence and competence to the 
intervention and provide important information regarding its cost-effectiveness.  
Phase 4 
The final phase involves translating the intervention into routine practice. This should 
be informed by the work carried out in all previous phases. Findings from the previous 
phases, both positive and negative, should be disseminated. A detailed description of 
the intervention should also be made available to allow replication. This phase also 
requires long-term follow-up of previous trials to determine whether short-term 
changes persist.  
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Figure 9.1: Key elements of the MRC development and evaluation process 
The work in this thesis fulfils most of the aims in phase one - two high quality 
systematic reviews and an IPD-MA were conducted to identify whether efficacious 
psychological treatments for emotional distress in BCa exist; the literature was then 
searched to identify the evidence-base supporting the mechanisms of change proposed 
by the S-REF model and the IU model; and a smartphone ESM study was conducted 
to test the utility of the S-REF model and the IU model for predicting RNT and 
emotional distress in BCa survivors.  
Future research should therefore continue to test the utility of the S-REF model and 
IU model for emotional distress in BCa or, after exploring the literature to ensure a 
theoretical basis for an alternative model exists, test the utility of an alternative model 
through a series of empirical studies. Once the psychological processes involved in 
the development and maintenance of emotional distress in BCa have been identified 
and findings have been replicated (as causality is never derived from a single study 
but through a variety of studies using different methods), therapeutic approaches 
targeting the identified processes should be tested by following phases 2-4 of the MRC 
framework. 
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Appendix 1: Final search strategy used to search electronic databases (study 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 194 
 
Appendix 1A: Search strategy for PubMed 
Number Term 
1 Review* OR meta* 
2 “Psychotherapy”[Mesh] OR “psychotherapy” OR “psychological 
therapy” OR “counselling” OR “counselling” OR “psychological 
intervention” OR “cognitive behavioural therapy”  OR “group therapy” 
OR “psychosocial therapy” OR “psychological treatment” OR 
“individual therapy” OR “psychotherapeutic” OR “CBT” 
3 “Breast Neoplasms”[mesh] OR “breast neoplasms” OR “breast cancer” 
4 “Depression”[Mesh] OR “depressive disorder”[Mesh] OR “depressive 
disorder” OR “anx*”[Mesh] Or “anxiety disorders”[Mesh] OR 
“anxiety disorders” OR “anxiety” OR “depress*” OR “emotional 
distress” OR “psychological distress” 
5 1 AND 2 AND 3 AND 4  
6 Limit to English language 
Abbreviations: MeSH, Medical Subject Headings; mh, Mesh Heading; Tiab, Title 
or Abstract; SH, Subject Heading 
 
Appendix 1B: Search strategy for PsycINFO, Web of Science, Scopus, and the 
Cochrane Database of Systematic Reviews. 
Number Term 
1 Review* OR meta* 
2 “Psychotherapy” OR “psychological therapy” OR “counseling” OR 
“counselling” OR “psychological intervention” OR “cognitive 
behavioural therapy” OR “group therapy” OR “psychosocial therapy” 
OR “psychological treatment” OR “individual therapy” OR 
“psychotherapeutic” OR “CBT” 
3 “Breast neoplasm*” OR “breast cancer” 
4 “Depress*” OR “depressive disorder” OR “anx*” OR “anxiety 
disorder*” OR “emotional distress” OR “psychological distress” 
5 1 AND 2 AND 3 AND 4 
6 Limit to English language 
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Appendix 2: Final search strategy used to search electronic databases for study 
2 & 3 
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Appendix 2A: Search strategy for PubMed 
 
 
 
 
 
 
 
 
 
Number Term 
1 Randomized controlled trial[pt] OR controlled clinical trial[pt] OR 
randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR 
randomly[tiab] OR trial[tiab] OR groups[tiab] NOT (animals [mh] NOT 
humans [mh] 
2 “Psychotherapy”[Mesh] OR “psychotherapy” OR “psychological 
therapy” OR “counselling” OR “counselling” OR “psychological 
intervention” OR “cognitive behavioural therapy”  OR “group therapy” 
OR “psychosocial therapy” OR “psychological treatment” OR 
“individual therapy” OR “psychotherapeutic” OR “CBT” 
3 “Breast Neoplasms”[mesh] OR “breast neoplasms” OR “breast cancer” 
4 “Depression”[Mesh] OR “depressive disorder”[Mesh] OR “depressive 
disorder” OR “anx*”[Mesh] Or “anxiety disorders”[Mesh] OR “anxiety 
disorders” OR “anxiety” OR “depress*” OR “emotional distress” OR 
“psychological distress” 
5 “gene therapy” OR “genetic*” 
6 1 AND 2 AND 3 AND 4 NOT 5 
7 Limit to English language 
Abbreviations: MeSH, Medical Subject Headings; mh, Mesh Heading; Tiab, Title 
or Abstract; SH, Subject Heading 
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Appendix 2B: Search strategy for PsycINFO, Web of Science, Scopus, PsycARTICLE, 
and AMED 
Number Term 
1 “Psychotherapy” OR “psychological therapy” OR “counseling” OR 
“counselling” OR “psychological intervention” OR “cognitive 
behavioural therapy” OR “group therapy” OR “psychosocial therapy” 
OR “psychological treatment” OR “individual therapy” OR 
“psychotherapeutic” OR “CBT” 
2 “Breast neoplasm*” OR “breast cancer” 
3 “Depression” OR “depressive disorder” OR “anxiety” OR “anxiety 
disorder*” OR “emotional distress” OR “psychological distress” 
4 “gene therapy” OR “genetic*” 
5 1 AND 2 AND 3 NOT 4 
6 Limit to English language 
Abbreviations: MeSH, Medical Subject Headings; mh, Mesh Heading; Tiab, Title 
or Abstract; SH, Subject Heading 
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Appendix 3: 
Standardised data extraction tool used to extract data from included studies 
(study 2 & 3) 
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Review Title:  
Study authors:  
Name of review author completing this form: 
Date form completed:  
 
STUDY METHODS   
 
POPULATION AND SETTING 
Inclusion criteria   
Exclusion criteria  
Method/s of recruitment of participants 
(How were potential participants 
approached and invited to participate?) 
 
 
Aim of intervention (what was the problem 
that this intervention was designed to 
address?) 
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PARTICIPANTS 
 Description as stated in report/paper 
Total no. randomised (overall and per group)  
Number Invited to participate, eligible, 
excluded, refused to take part 
 
 
Number post randomisation (excluded, 
withdrawn, lost to follow-up) 
 
Age: range, mean and SD (Overall and per 
group, if available) 
 
 
 
Race/Ethnicity (Overall and per group, if 
available) 
 
 
Stage of disease  
(Overall and per group, if available: Also if 
certain stages are part of inclusion criteria) 
 
Treatment status (Overall and per group, if 
available) 
 
Did participants need to score above a 
particular distress threshold? If so, how 
was this justified?  
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Psychological comorbidities: e.g. PTSD along 
with anxiety (Overall and per group, if 
available) 
 
Non-psychological comorbidities e.g. Other 
cancer along with BCa cancer (Overall and 
per group, if available) 
 
 
INTERVENTION 1 
 Description as stated in 
report/paper 
Intervention type (e.g. CBT, psychoeducation etc)  
Format (group/ individual)   
Number and length of sessions  
 Delivery method (phone, internet, in person etc)  
INTERVENTION 2 (Or control) – copy and paste table for however many more 
groups 
 Description as stated in 
report/paper 
Control type (e.g. TAU, WLC, no treatment) If 
TAU – describe what this was 
 
Format (group/ individual)   
Number and length of sessions  
 Delivery method (phone, internet, in person etc)  
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OUTCOMES 
 Description as stated in 
report/paper 
Methods of assessing outcome measures (e.g., 
questionnaire or interview) 
 
 
Primary outcome(s) 
 
 
Secondary outcome (s)  
Distress outcome (e.g. anxiety, depression, mood)  
Distress measure  
27. Statistical significance between groups on 
distress outcome (if this is not primary 
outcome)? 
 
Yes – in favour of treatment 
No  
Yes- in favour of comparison 
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Appendix 4: 
Psychotherapy outcome study methodology rating form (POMRF) 
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Note: If not enough information is given regarding a specific item a rating of 0 is given. 
   
1. Clarity of sample description 
0 Poor Vague description of sample (e.g. only mentioned whether patients 
were diagnosed with the disorder). 
 
1 Fair Fair description of sample (e.g. mentioned inclusion/exclusion 
criteria, demographics, etc.). 
 
2 Good Good description of sample (e.g. mentioned inclusion/exclusion 
criteria, demographics, and the prevalence of comorbid disorders). 
   
2. Severity/chronicity of the disorder 
0 Poor Severity/chronicity was not reported and/or subsyndromal patients 
were included in the sample. 
 
1 Fair All patients met the criteria for the disorder. Sample includes acute 
(<1 yr) and/or low severity. 
 
2 Good Sample consisted entirely of chronic (>1 yr) patients of at least 
moderate severity. 
   
3. Representativeness of sample 
0 Poor Sample is very different from patients seeking treatment for the 
disorder (e.g. there are excessively strict exclusion criteria). 
 
1 Fair Sample is somewhat representative of patients seeking treatment 
for the disorder (e.g. patients were only excluded if they met 
criteria for other major disorders). 
 
2 Good Sample is very representative of patients seeking treatment for the 
disorder (e.g. authors made efforts to ensure representativeness of 
sample). 
   
4. Reliability of the diagnosis in question 
0 Poor The diagnostic process was not reported, or not assessed with 
structured interviews by a trained interviewer. 
 
1 Fair The diagnosis was assessed with structured interview by a trained 
interviewer. 
2 Good The diagnosis was assessed with structured interview by a trained 
interviewer and adequate inter-rater reliability was demonstrated 
(e.g. kappa coefficient). 
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5. Specificity of outcome measures 
0 Poor Very broad outcome measures, not specific to the disorder (e.g. 
SCL-90R total score). 
1 Fair Moderately specific outcome measures 
2 Good Specific outcome measures, such as a measure for each symptom 
cluster. 
   
6. Reliability and validity of outcome measures 
0 Poor Measures have unknown psychometric properties, or properties 
that fail to meet current standards of acceptability. 
 
1 Fair Some, but not all measures have known or adequate psychometric 
properties. 
2 Good All measures have good psychometric properties. The outcome 
measures are the best available for the authors’ purpose. 
   
7. Use of blind evaluators 
0 Poor Blind assessor was not used (e.g. assessor was the therapist, 
assessor was not blind to treatment condition, or the authors do not 
specify). 
 
1 Fair Blind assessor was used, but no checks were used to assess the 
blind. 
2 Good Blind assessor was used in correct fashion. Checks were used to 
assess whether the assessor was aware of treatment condition. 
   
8. Assessor training 
0 Poor Assessor training and accuracy are not specified, or are 
unacceptable. 
1 Fair Minimum criterion for assessor training is specified (e.g. assessor 
has had specific training in the use of the outcome measure), but 
accuracy is not monitored or reported. 
2 Good Minimum criterion of assessor training is specified. Inter-rater 
reliability was checked, and/or assessment procedures were 
calibrated during the study to prevent evaluator drift. 
   
9. Assignment to treatment 
0 Poor Biased assignment, e.g. patients selected their own therapy or were 
assigned in another non-random fashion, or there is only one 
group. 
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1 Fair Random or stratified assignment. There may be some systematic 
bias but not enough to pose a serious threat to internal validity. 
There may be therapist by treatment confounds. N may be too 
small to protect against bias. 
2 Good Random or stratified assignment, and patients are randomly 
assigned to therapists within condition. When theoretically 
different treatments are used, each treatment is provided by a large 
enough number of different therapists. N is large enough to protect 
against bias. 
   
10. Design 
0 Poor Active treatment vs. WLC, or briefly described TAU. 
1 Fair Active treatment vs. TAU with good description, or placebo 
condition. 
2 Good Active treatment vs. another previously empirically documented 
active treatment. 
   
11. Power analysis 
0 Poor No power analysis was made prior to the initiation of the study. 
1 Fair A power analysis based on an estimated effect size was used. 
2 Good A data-informed power analysis was made and the sample size was 
decided accordingly. 
   
12. Assessment points 
0 Poor Only pre- and post-treatment, or pre- and follow-up. 
1 Fair Pre-, post-, and follow-up <1 year. 
2 Good Pre-, post-, and follow-up⩾1 year. 
   
13. Manualised, replicable, specific treatment programs 
0 Poor Description of treatment procedure is unclear, and treatment is not 
based on a publicly available, detailed treatment manual. Patients 
may be receiving multiple forms of treatment at once in an 
uncontrolled manner. 
 
1 Fair Treatment is not designed for the disorder, or description of the 
treatment is generally clear and based on a publicly available, 
detailed treatment manual, but there are some ambiguities about 
the procedure. Patients may have received additional forms of 
treatment, but this is balanced between groups or otherwise 
controlled. 
 
 207 
 
2 Good Treatment is designed for the disorder. A detailed treatment 
manual is available, and/or treatment is explained in sufficient 
detail for replication. No ambiguities about the treatment 
procedure. Patients receive only the treatment in question. 
   
14. Number of therapists 
0 Poor Only one therapist, i.e. complete confounding between therapy and 
therapist. 
1 Fair At least two therapists, but the effect of therapist on outcome is not 
analysed. 
2 Good Three, or more therapists, and the effect of therapist on outcome is 
analysed. 
   
15. Therapist training/experience 
0 Poor Very limited clinical experience of the treatment and/or disorder 
(e.g. students). 
1 Fair Some clinical experience of the treatment and/or disorder. 
2 Good Long clinical experience of the treatment and the disorder (e.g. 
practicing therapists). 
   
16. Checks for therapist adherence 
0 Poor No checks were made to assure that the intervention was consistent 
with protocol. 
1 Fair Some checks were made (e.g. assessed a proportion of therapy 
tapes). 
2 Good Frequent checks were made (e.g. weekly supervision of each 
session using a detailed rating form). 
   
17. Checks for therapist competence 
0 Poor No checks were made to assure that the intervention was delivered 
competently. 
1 Fair Some checks were made (e.g. assessed a proportion of therapy 
tapes). 
2 Good Frequent checks were made (e.g. weekly supervision of each 
session using a detailed rating form). 
   
18. Control of concomitant treatments (e.g. medications) 
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0 Poor No attempt to control for concomitant treatments, or no 
information about concomitant treatments provided. Patients may 
have been receiving other forms of treatment in addition to the 
study treatment. 
 
1 Fair Asked patients to keep medications stable and/or to discontinue 
other psychological therapies during the treatment. 
 
2 Good Ensured that patients did not receive any other treatments (medical 
or psychological) during the study. 
   
19. Handling of attrition 
0 Poor Proportions of attrition are not described, or described but no 
dropout analysis is performed. 
1 Fair Proportions of attrition are described, and dropout analysis or 
intent-to-treat analysis is performed. 
2 Good No attrition, or proportions of attrition are described, dropout 
analysis is performed, and results are presented as intent-to-treat 
analysis. 
   
20. Statistical analyses and presentation of results 
0 Poor Inadequate statistical methods are used and/or data are not fully 
presented. 
1 Fair Adequate statistical methods are used but data are not fully 
presented. 
2 Good Adequate statistical methods are used and data are presented 
with M and SD. 
   
21. Clinical significance 
0 Poor No presentation of clinical significance was done. 
1 Fair An arbitrary criterion for clinical significance was used and the 
conditions were compared regarding percent clinically improved. 
 
2 Good Jacobson's criteria for clinical significance were used and presented 
for a selection (or all) of the outcome measures, and conditions 
were compared regarding percent clinically improved. 
   
22. Equality of therapy hours (for non-WLC designs only) 
0 Poor Conditions differ markedly (⩾20% difference in therapy hours). 
1 Fair Conditions differ somewhat (10–19% difference in therapy hours). 
2 Good Conditions do not differ (<10% difference in therapy hours). 
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Funnel plots of effect sizes against standard error data from eligible published 
trials (study 3) 
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Figure 7A:  Funnel plot of effect sizes against standard error for anxiety using 
data from eligible published trials at post-treatment 
 
 
 
Figure 7B: Funnel plot of effect sizes against standard error for depression using 
data from eligible published trials at post-treatment 
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Figure 7C: Funnel plot of effect sizes against standard error for general distress 
using data from eligible published trials at post-treatment 
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Appendix 8: 
Treatment effects at post-treatment and follow-up for anxiety, depression and 
general distress in the total sample based on effect sizes (study 3) 
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Note. BLT = bright light therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive therapy 
Figure 8A: Forest plot of effect sizes for anxiety at post treatment in the total sample 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Beutel et al. 2014 58 59 0.23 -0.13 0.59 0.21
Bredal et al. 2014 173 170 0.14 -0.08 0.35 0.21
Classen et al. 2008 148 151 -0.03 -0.25 0.20 0.82
Desautels et al. 2018 - BLT 22 12 -0.51 -1.21 0.18 0.15
Desautels 2018 et al. - WLC 10 12 0.78 -0.06 1.62 0.07
Groarke et al. 2012 92 87 0.19 -0.10 0.48 0.20
Ho et al. 2016 - BMS 25 47 0.38 -0.11 0.86 0.13
Ho et al. 2016 et al. - support 25 47 -0.03 -0.51 0.45 0.90
Merckeart et al. 2016 77 82 -0.07 -0.38 0.24 0.67
Savard et al. 2005 29 19 0.21 -0.36 0.78 0.46
Savard et al. 2006 12 15 0.76 -0.01 1.52 0.05
671 701 0.12 -0.02 0.25 0.09
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy 
Figure 8B: Forest plot of effect sizes for depression at post treatment in the total sample 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Antoni et al. 2001 72 55 0.13 -0.22 0.48 0.47
Beutel et al. 2014 58 59 0.60 0.23 0.97 0.00
Bredal et al. 2014 163 179 0.21 -0.01 0.42 0.06
Classen et al. 2008 148 151 -0.18 -0.40 0.05 0.13
Desautels et al. 2018 - BLT 22 12 0.80 0.09 1.52 0.03
Desautels et al. 2018 - WLC 10 12 1.03 0.17 1.90 0.02
Dirksen et al. 2008 38 34 0.16 -0.30 0.62 0.50
Groarke et al. 2013 92 87 0.08 -0.21 0.37 0.59
Ho et al.  2016 - BMS 25 47 0.26 -0.22 0.74 0.30
Ho et al. 2016 - support 25 47 -0.08 -0.56 0.40 0.73
Lechner et al. 2014 57 53 0.10 -0.27 0.47 0.59
Merckeart et al. 2016 77 82 0.10 -0.21 0.41 0.54
Savard et al. 2005 29 19 -0.00 -0.57 0.56 0.99
Savard et al. 2006 12 15 0.35 -0.39 1.09 0.35
Stanton et al. 2005 142 145 -0.27 -0.50 -0.03 0.02
970 997 0.13 -0.01 0.28 0.08
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy; EE = emotional expression; PsyEd = psychoeducation  
Figure 8C: Forest plot of effect sizes for general distress at post treatment in the total sample 
Study name Sample size Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Andersen et al. 2004 90 106 -0.15 -0.43 0.13 0.29
Beutel et al. 2014 58 59 0.45 0.08 0.81 0.02
Bredal et al. 2014 160 169 0.14 -0.08 0.36 0.21
Carlson et al. 2013 - MBT 18 69 0.38 -0.14 0.90 0.15
Carlson et al. 2013 - support 18 73 -0.12 -0.63 0.39 0.65
Classen et al. 2008 148 151 -0.10 -0.33 0.13 0.38
Desautels et al. 2018 - BLT 22 12 0.16 -0.53 0.85 0.65
Desautels et al. 2018 - WLC 10 12 1.01 0.15 1.87 0.02
Graves et al. 2003 6 7 -0.77 -1.83 0.29 0.15
Groarke et al. 2013 92 87 0.17 -0.13 0.46 0.26
Ho et al. 2016 - BMS 25 47 0.38 -0.10 0.86 0.12
Ho et al. 2016 - support 25 47 -0.06 -0.54 0.42 0.80
Merckeart et al. 2016 77 82 0.01 -0.30 0.32 0.96
Sandgren et al. 2003 - EE 26 90 0.16 -0.27 0.59 0.47
Sandgren et al. 2003 - PsyEd 26 81 0.16 -0.28 0.60 0.47
Savard et al. 2005 29 19 0.16 -0.41 0.73 0.59
Savard et al. 2006 12 15 0.65 -0.11 1.40 0.09
842 1126 0.11 -0.00 0.23 0.06
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note; BMS = body mind spirit; support = supportive therapy 
Figure 8D: Forest plot of effect sizes for anxiety at follow-up in the total sample 
 
 
Note. BMS = body mind spirit; support = supportive therapy 
Figure 8E: Forest plot of effect sizes for depression at follow-up in the total 
sample 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Bredal et al. 2014 171 176 0.10 -0.11 0.31 0.37
Classen et al. 2008 145 141 -0.09 -0.32 0.14 0.45
Desautels et al. 2018 25 27 0.16 -0.37 0.70 0.55
Groarke et al. 2012 92 87 -0.12 -0.42 0.17 0.40
Ho et al. 2016 - BMS 24 48 0.40 -0.09 0.89 0.11
Ho et al. 2016 - support 24 47 0.14 -0.35 0.63 0.58
481 526 0.03 -0.10 0.16 0.64
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
Control Tx g limit limit p-Value
Antoni et al. 2001 59 49 0.19 -0.19 0.57 0.33
Bredal et al. 2014 159 179 0.02 -0.19 0.24 0.83
Classen et al. 2008 145 141 -0.09 -0.32 0.14 0.45
Desautels et al. 2018 25 27 0.47 -0.07 1.02 0.09
Groarke et al. 2013 92 87 0.04 -0.25 0.33 0.79
Ho et al. 2016 - BMS 24 48 0.25 -0.23 0.74 0.30
Ho et al. 2016 - support 24 47 0.15 -0.34 0.64 0.55
Lechner et al. 2014 56 52 0.07 -0.31 0.44 0.72
Stanton et al. 2005 136 133 -0.30 -0.54 -0.06 0.01
720 763 0.02 -0.12 0.15 0.79
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note.  BMS = body mind spirit; support = supportive therapy; EE = emotional 
expression; PsyEd = psychoeducation 
Figure 8F: Forest plot of effect sizes for general distress at follow-up in the total 
sample 
 
 
 
 
 
 
 
 
 
 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Andersen et al. 2004 86 97 -0.13 -0.42 0.16 0.37
Bredal et al. 2014 158 174 0.03 -0.19 0.24 0.81
Classen et al. 2008 145 141 -0.10 -0.33 0.13 0.41
Desautels et al. 2018 25 27 0.40 -0.14 0.95 0.14
Groarke et al. 2013 92 87 -0.05 -0.35 0.24 0.72
Ho et al. 2016 - BMS 24 48 0.38 -0.11 0.87 0.12
Ho et al. 2016 - support 24 47 0.15 -0.33 0.64 0.54
Sandgren et al. 2003 EE 24 92 0.31 -0.14 0.75 0.18
Sandgren et al. 2003 PsyEd 24 77 0.04 -0.42 0.49 0.88
602 790 0.02 -0.09 0.13 0.67
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Appendix 9: 
Treatment effects at post-treatment for anxiety, depression and general distress 
in the distressed sub-sample based on effect sizes (study 3) 
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy 
Figure 9A: Forest plot of effect sizes for anxiety at post treatment in the distressed sub-sample 
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy 
Figure 9B: Forest plot of effect sizes for depression at post treatment in the distressed sub-sample 
Study name Sample size Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Antoni et al. 2001 22 18 0.53 -0.10 1.15 0.10
Beutel et al. 2014 58 59 0.60 0.23 0.97 0.00
Bredal et al. 2014 52 47 0.10 -0.29 0.49 0.61
Classen et al. 2008 18 26 0.18 -0.41 0.77 0.56
Desautels et al. 2018 - BLT 15 9 0.65 -0.17 1.47 0.12
Desautels et al. 2018 - WLC 8 9 0.85 -0.10 1.80 0.08
Dirksen et al. 2008 5 13 1.35 0.27 2.42 0.01
Groarke et al. 2013 12 12 0.18 -0.59 0.96 0.64
Ho et al. 2016 - BMS 4 5 2.02 0.53 3.52 0.01
Ho et al. 2016 - support 4 9 0.15 -0.94 1.25 0.78
Lechner et al. 2014 57 53 0.10 -0.27 0.47 0.59
Merckeart et al. 2016 15 21 0.15 -0.50 0.80 0.66
Savard et al. 2005 3 2 0.41 -0.91 1.74 0.54
Savard et al. 2006 9 10 0.33 -0.53 1.20 0.45
Stanton et al. 2005 24 40 -0.20 -0.70 0.30 0.44
306 333 0.33 0.13 0.53 0.00
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy; EE = emotional expression; PsyEd = psychoeducation 
Figure 9C: Forest plot of effect sizes for general distress at post treatment in the distressed sub-sample 
Study name Sample size Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Andersen et al. 2004 30 48 0.04 -0.41 0.49 0.86
Beutel et al. 2014 57 59 0.48 0.12 0.85 0.01
Bredal et al. 2014 80 81 0.14 -0.17 0.45 0.36
Carlson et al.  2013 - MBT 7 27 0.44 -0.38 1.26 0.29
Carlson et al. 2013 - support 7 29 -0.28 -1.08 0.53 0.50
Classen et al. 2008 44 49 -0.12 -0.52 0.29 0.57
Desautels et al. 2018 - BLT 21 11 0.14 -0.57 0.85 0.71
Desautels et al. 2018 - WLC 9 11 1.50 0.53 2.46 0.00
Groarke et al. 2013 25 28 0.76 0.21 1.31 0.01
Ho et al. 2016 - BMS 10 14 0.70 -0.11 1.51 0.09
Ho et al. 2016 - support 10 24 0.04 -0.68 0.76 0.92
Merckeart et al. 2016 32 39 0.20 -0.26 0.66 0.40
Sandgren et al. 2003 - EE 11 30 -0.07 -0.75 0.61 0.84
Sandgren et al. 2003 - PsyEd 11 22 0.01 -0.70 0.72 0.98
Savard et al. 2005 7 8 0.39 -0.57 1.36 0.43
Savard et al. 2006 11 13 0.83 0.02 1.64 0.05
372 493 0.26 0.08 0.44 0.00
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note. BMS = body mind spirit; support = supportive therapy 
Figure 9D: Forest plot of effect sizes for anxiety at follow-up in the distressed sub-
sample 
 
 
Note. BMS = body mind spirit; support = supportive therapy 
Figure 9E: Forest plot of effect sizes for depression at follow-up in the distressed 
sub-sample 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Bredal et al. 2014 101 90 -0.02 -0.30 0.27 0.90
Classen et al. 2008 55 49 -0.21 -0.59 0.17 0.28
Desautels et al. 2018 20 20 0.01 -0.59 0.62 0.96
Groarke et al. 2012 28 35 -0.08 -0.57 0.41 0.74
Ho et al. 2016 - BMS 11 15 0.05 -0.70 0.80 0.90
Ho et al. 2016 - support 11 22 -0.05 -0.75 0.66 0.90
226 231 -0.07 -0.25 0.12 0.48
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Antoni et al. 2001 18 17 0.66 -0.01 1.33 0.05
Bredal et al. 2014 47 45 -0.15 -0.55 0.26 0.48
Classen et al. 2008 19 28 0.12 -0.45 0.69 0.68
Desautels et al. 2018 16 19 0.25 -0.40 0.90 0.45
Groarke et al. 2013 12 12 -0.27 -1.05 0.50 0.49
Ho et al. 2016 - BMS 3 5 1.17 -0.20 2.54 0.10
Ho et al. 2016 - support 3 9 0.32 -0.89 1.54 0.60
Lechner et al. 2014 56 52 0.07 -0.31 0.44 0.72
Stanton et al. 2005 24 38 -0.63 -1.15 -0.11 0.02
198 225 0.04 -0.23 0.32 0.76
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist 
control; BMS = body mind spirit; support = supportive therapy; EE = emotional 
expression; PsyEd = psychoeducation 
Figure 9F: Forest plot of effect sizes for general distress at follow-up in the 
distressed sub-sample 
 
 
 
 
 
 
 
 
Study name Sample size Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
control Tx g limit limit p-Value
Andersen et al. 2004 29 44 0.18 -0.28 0.65 0.44
Bredal et al. 2014 78 81 -0.10 -0.41 0.21 0.54
Classen et al. 2008 42 45 0.20 -0.22 0.62 0.35
Desautels et al. 2018 24 24 0.41 -0.15 0.97 0.15
Groarke et al. 2013 25 28 0.21 -0.32 0.74 0.44
Ho et al. 2016 - BMS 10 13 0.48 -0.33 1.28 0.25
Ho et al. 2016 - support 10 24 0.33 -0.39 1.06 0.37
Sandgren et al. 2003 - EE 10 30 0.15 -0.55 0.85 0.68
Sandgren et al. 2003 - PsyEd 10 21 -0.17 -0.91 0.56 0.65
238 310 0.13 -0.04 0.29 0.15
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Appendix 10: 
Classification of patients at post-treatment and follow-up according to 
Jacobson’s second criterion (RCI) for anxiety, depression and general distress 
in the total sample (study 3) 
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Table 10A: Classification of patients at post-treatment and follow-up according to Jacobson’s second criterion (RCI) for anxiety in the 
total sample  
    Post-treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type 
 
Total Deteriorated 
No 
change 
Improved   Total Deteriorated No change Improved 
Beutel et al. 2014 Treatment Other - Psychodynamic therapy  59 10 41 49   Follow-up data not reported 
  95% CI      (4-21) (28-54) (36-63)   
  Control 
Treatment as usual - Offered 
referral to GP for psychological or 
pharmacological treatment 
 
58 9 60 31   
  95% CI      (3-19) (47-73) (20-45)   
Bredal et al. 2014 Treatment Psychoeducation  170 18 45 37   176 9 36 55 
  95% CI      (12-24) (38-53) (30-45)     (5-14) (29-44) (47-62) 
  Control 
Treatment as usual - Nurse-led 
support group 
 
173 17 49 34   171 10 41 49 
  95% CI      (12-24) (41-56) (27-42)     (6-15) (33-49) (41-57) 
Classen et al. 
2008 
Treatment 
Supportive therapy + education 
material 
 
151 16 66 19   141 16 60 24 
  95% CI      (10-23) (57-73) (13-26)     (11-23) (51-68) (17-32) 
  Control Education material  148 15 67 18   145 12 65 23 
  95% CI      (10-22) (59-74) (12-25)     (7-18) (56-73) (27-31) 
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    Post-treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type 
 
Total Deteriorated 
No 
change 
Improved   Total Deteriorated No change Improved 
Desautels et al. 
2018 
Treatment Cognitive behavioural therapy 
 
25 0 76 24   27 4 30 67 
  95% CI      (0-14) (55-91) (9-45)     (0-19) (14-50) (46-83) 
  Control Bright light therapy  22 9 14 77   25 4 32 64 
  95% CI      (1-29) (3-35) (55-92)     (0-20) (15-54) (43-82) 
  Control Wait-list control  10 10 60 30   Not applicable 
  95% CI      (0-45) (26-88) (7-65)           
Groarke et al. 
2013 
Treatment Cognitive behavioural therapy 
 
87 8 59 33   87 17 53 30 
  95% CI      (3-16) (48-69) (24-44)     (10-27) (42-64) (21-41) 
  Control 
Treatment as usual - Support from 
oncology nurses 
 
92 23 65 12   92 18 61 21 
  95% CI      (15-33) (55-75) (6-20)     (11-28) (50-71) (13-30) 
Ho et al. 2016 Treatment  Other - Body-mind-spirit   45 11 67 22   46 17 63 20 
  95% CI      (4-24) (51-80) (11-37)     (8-31) (48-77) (9-34) 
  Treatment Supportive therapy   47 19 66 15   47 15 70 15 
  95% CI      (9-33) (51-79) (6-28)     (6-28) (55-83) (6-28) 
  Control Self-help support group  51 14 67 20   48 19 54 27 
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    Post-treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type 
 
Total Deteriorated 
No 
change 
Improved   Total Deteriorated No change Improved 
  95% CI      (6-26) (52-79) (10-33)     (9-33) (39-69) (15-42) 
Merckaert et al. 
2016 
Treatment Cognitive behavioural therapy 
 
82 11 62 27   Follow-up data not reported 
  95% CI      (5-20) (51-73) (18-38)           
  Control 
Treatment as usual - Peer support 
group 
 
77 5 71 23           
  95% CI      (1-13) (60-81) (14-34)           
Savard et al. 2005 Treatment Cognitive behavioural therapy 
 
19 0 74 26   Not applicable 
  95% CI      (0-18) (49-91) (9-51)           
  Control Wait-list control  29 24 66 10           
  95% CI      (10-44) (46-82) (2-27)           
Savard et al. 2006 Treatment Cognitive behavioural therapy  15 0 27 73   Not applicable 
  95% CI      (0-22) (8-55) (45-92)           
  Control Wait-list control  12 17 50 33           
  95% CI      (2-48) (21-79) (10-65)           
Note. n = number of patients; RCI = reliable change index at P<0.05; CI = confidence interval 
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Table 10B: Classification of patients at post-treatment and follow-up according to Jacobson’s second criterion (RCI) for depression in 
the total sample  
       Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type  Total Deteriorated 
No 
change 
Improved  Total Deteriorated 
No 
change 
Improved 
Antoni et al. 2001 Treatment 
Cognitive behavioural 
therapy 
 54 13 70 17  48 6 65 29 
  95% CI     (5-25) (56-82) (8-29)   (1-17) (49-78) (17-44) 
  Control 
Condensed version of active 
treatment 
 72 8 78 14  59 7 78 15 
  95% CI     (3-17) (66-87) (7-24)   (2-16) (65-88) (7-27) 
Beutel et al. 2014 Treatment 
Other - Psychodynamic 
therapy 
 59 3 24 73  Follow-up data not reported 
  95% CI     (0-12) (14-37) (60-84)      
  Control 
Treatment as usual - Offered 
referral to GP for 
psychological or 
pharmacological treatment 
 58 17 41 41      
  95% CI     (9-29) (29-55) (29-55)      
Bredal et al. 2014 Treatment Psychoeducation  177 19 67 15  177 12 56 32 
  95% CI     (13-25) (59-74) (10-21)   (7-18) (48-63) (25-40) 
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       Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type  Total Deteriorated 
No 
change 
Improved  Total Deteriorated 
No 
change 
Improved 
  Control 
Treatment as usual - Nurse-
led support group 
 156 17 65 18  152 12 45 43 
  95% CI 
 
    (12-24) (57-72) (12-25)   (7-18) (37-53) (35-52) 
Classen et al. 2008 Treatment 
Supportive therapy+ 
education material 
 151 15 67 18  141 9 70 22 
  95% CI     (10-22) (59-74) (12-25)   (4-14) (61-77) (15-30) 
  Control Education material  148 11 71 18  145 12 69 19 
  95% CI     (7-18) (63-78) (12-25)   (8-19) (61-76) (13-26) 
Desautels et al. 
2018 
Treatment 
Cognitive behavioural 
therapy 
 25 0 48 52  27 4 22 74 
  95% CI     (0-14) (28-69) (31-72)   (0-19) (9-42) (54-89) 
  Control Bright light therapy  22 9 36 55  25 8 32 60 
  95% CI     (1-29) (17-59) (32-76)   (0-26) (15-54) (39-79) 
  Control Wait-list control  10 0 70 30  Not applicable 
  95% CI     (0-31) (35-93) (7-65)      
Dirksen et al. 2008 Treatment 
Cognitive behavioural 
therapy 
 34 3 76 21  Follow-up data not reported 
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       Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type  Total Deteriorated 
No 
change 
Improved  Total Deteriorated 
No 
change 
Improved 
  95% CI     (0-15) (59-89) (9-38)      
  Control 
Educational components of 
active treatment 
 38 3 87 11      
  95% CI     (0-14) (72-96) (3-25)      
Groarke et al. 2013 Treatment 
Cognitive behavioural 
therapy 
 87 13 68 20  87 11 70 18 
 95% CI    (6-21) (57-77) (12-29)   (6-20) (59-79) (11-28) 
  Control 
Treatment as usual - 
Support from oncology 
nurses 
 92 12 78 10  92 13 73 14 
  95% CI     (6-20) (68-86) (5-18)   (7-22) (63-82) (8-23) 
Ho et al. 2016  Treatment  
Other - Body-mind-spirit 
intervention 
 45 11 76 13  46 7 80 13 
  95% CI     (4-24) (60-87) (5-27)   (1-18) (66-91) (5-26) 
  Treatment Supportive therapy    47 15 72 13  47 9 79 13 
  95% CI     (6-28) (57-84) (5-26)   (2-20) (64-89) (5-26) 
  Control Self-help support group  51 16 71 14  48 19 67 15 
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       Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type  Total Deteriorated 
No 
change 
Improved  Total Deteriorated 
No 
change 
Improved 
  95% CI     (7-29) (56-83) (6-26)   (9-33) (52-80) (6-28) 
Lechner et al. 2014 Treatment 
Cognitive behavioural 
therapy 
 53 8 75 17  52 4 75 21 
  95% CI     (2-18) (62-86) (8-30)   (0-13) (61-86) (11-35) 
  Control 
Educational information 
delivered by therapist 
 57 12 67 21  56 9 66 25 
  95% CI     (5-24) (53-79) (11-34)   (3-20) (52-78) (14-38) 
Merckaert et al. 
2016 
Treatment 
Cognitive behavioural 
therapy 
 82 6 65 29  Follow-up data not reported 
  95% CI     (2-14) (53-75) (20-40)      
  Control 
Treatment as usual - Peer 
support group 
 77 14 70 16      
  95% CI     (7-24) (59-80) (8-26)      
Savard et al. 2005 Treatment 
Cognitive behavioural 
therapy 
 19 0 74 26  Not applicable 
  95% CI     (0-18) (49-91) (9-51)      
  Control Wait-list control  29 7 83 10      
 245 
 
       Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type  Total Deteriorated 
No 
change 
Improved  Total Deteriorated 
No 
change 
Improved 
  95% CI     (0-23) (64-94) (2-27)      
Savard et al. 2006 Treatment 
Cognitive behavioural 
therapy 
 15 0 27 73   Not applicable 
  95% CI     (0-22) (8-55) (45-92)           
  Control Wait-list control  12 0 58 42           
  95% CI     (0-26) (28-85) (15-72)           
Stanton et al. 2005 Treatment 
Psychoeducation + 
educational material 
 144 9 79 12   132 6 83 11 
  95% CI     (5-15) (72-85) (7-18)     (3-12) (76-89) (6-17) 
  Control Education material  142 8 83 8   136 8 82 10 
  95% CI     (4-14) (76-89) (4-14)     (4-14) (75-88) (5-16) 
Note. n = number of patients; RCI = reliable change index at P<0.05; CI = confidence interval 
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Table 10C: Classification of patients at post-treatment and follow-up according to Jacobson’s second criterion (RCI) for general distress 
in the total sample 
    Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type   Total Deteriorated 
No 
change 
Improved   Total Deteriorated 
No 
change 
Improved 
Andersen et al. 2004 Treatment Other - Biobehavioral intervention    106 12 51 37   97 10 54 36 
  95% CI       (7-20) (41-61) (28-47)     (5-18) (43-64) (27-46) 
  Control Assessment only   90 9 64 27   86 6 60 34 
  95% CI       (4-17) (54-74) (18-37)     (2-13) (49-71) (24-45) 
Beutel et al. 2014 Treatment Other - Psychodynamic therapy   59 7 22 71   Follow-up data not reported 
  95% CI       (2-16) (12-35) (58-82)           
  Control 
Treatment as usual - Offered 
referral to GP for psychological or 
pharmacological treatment 
  58 14 47 40           
  95% CI       (6-25) (33-60) (27-53)           
Bredal et al. 2014 Treatment Psychoeducation   169 15 54 30   174 9 47 44 
  95% CI       (10-22) (47-62) (23-38)     (5-15) (39-54) (37-52) 
  Control 
Treatment as usual - Nurse-led 
support group 
  160 22 52 26   158 9 41 50 
  95% CI       (16-29) (44-60) (20-34)     (5-15) (33-49) (42-58) 
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    Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type   Total Deteriorated 
No 
change 
Improved   Total Deteriorated 
No 
change 
Improved 
Carlson et al. 2013 Treatment Mindfulness-based therapy   69 4 59 36   Follow-up data not reported 
  95% CI       (0-12) (47-71) (25-49)           
  Treatment Supportive therapy   72 14 56 31           
  95% CI       (7-24) (43-67) (20-43)           
  Control Stress management seminar   36 8 61 31           
  95% CI       (2-22) (43-77) (16-48)           
Classen et al. 2008 Treatment 
Supportive therapy + education 
material 
  151 11 68 22   141 9 62 29 
  95% CI       (6-17) (59-75) (16-29)     (4-14) (54-70) (22-37) 
  Control Education material   148 10 70 20   145 12 61 26 
  95% CI       (6-16) (62-77) (14-27)     (8-19) (53-69) (19-34) 
Desautels et al. 2018 Treatment Cognitive behavioural therapy   25 0 24 76   27 4 19 78 
  95% CI       (0-14) (9-45) (55-91)     (0-19) (6-38) (58-91) 
  Control Bright light therapy   22 0 32 68   25 0 40 60 
  95% CI       (0-15) (14-55) (45-86)     (0-14) (21-61) (39-79) 
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    Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type   Total Deteriorated 
No 
change 
Improved   Total Deteriorated 
No 
change 
Improved 
 Control Wait-list control   10 10 50 40   Not applicable 
  95% CI       (0-45) (19-81) (12-74)           
Graves et al. 2003 Treatment Cognitive behavioural therapy   7 29 29 43   Follow-up data not reported 
 95% CI      (4-71) (4-71) (10-82)       
 Control 
Treatment as usual from medical 
community + educational material 
  6 17 83 0           
  95% CI       (0-64) (36-100) (0-46)           
Groarke et al. 2013 Treatment Cognitive behavioural therapy   87 13 64 23   87 11 70 18 
  95% CI       (6-21) (53-74) (15-33)     6-20% 59-79% 11-28% 
  Control 
Treatment as usual - Support from 
oncology nurses 
  92 17 73 10   92 22 62 16 
  95% CI       (10-27) (63-82) (5-18)     14-32% 52-72% 9-25% 
Ho et al. 2016 Treatment 
Other - Body-mind-spirit 
intervention 
  45 11 73 16   47 11 74 15 
  95% CI       (4-24) (58-85) (6-29)     4-23% 60-86% 6-28% 
  Treatment Supportive therapy    47 19 66 15   47 13 70 17 
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    Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type   Total Deteriorated 
No 
change 
Improved   Total Deteriorated 
No 
change 
Improved 
  95% CI       (9-33) (51-79) (6-28)     5-26% 55-83% 8-31% 
  Control Self-help support group   51 8 78 14   48 23 56 21 
  95% CI       (2-19) (65-89) (6-26)     12-37% 41-71% 10-35% 
Merckaert et al. 2016 Treatment Cognitive behavioural therapy   82 7 63 29   Follow-up data not reported 
  95% CI       (3-15) (52-74) (20-40)           
  Control 
Treatment as usual - Peer support 
group 
  77 9 71 19           
  95% CI       (4-18) (60-81) (11-30)           
Sandgren et al 2003; 
2007 
Treatment Psychoeducation   81 15 60 25   77 65 27 8 
  95% CI       (8-24) (49-71) (16-36)     53-75% 18-39% 3-16% 
  Treatment Other - Emotional expression   90 12 64 23   92 61 34 5 
  95% CI      (6-21) (54-74) (15-33)     50-71% 24-44% 2-12% 
  Control 
Treatment as usual - Nurse help 
line was available 
  53 13 55 32   49 61 33 6 
  95% CI       (5-25) (40-68) (20-46)     46-75% 20-48% 1-17% 
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    Post treatment (%)  Follow-up (%) 
Study name 
Treatment 
or control 
Type   Total Deteriorated 
No 
change 
Improved   Total Deteriorated 
No 
change 
Improved 
Savard et al. 2005 Treatment Cognitive behavioural therapy   19 0 79 21   Not applicable 
  95% CI       (0-18) (54-94) (6-46)           
  Control Wait-list control   29 17 72 10           
  95% CI       (6-36) (53-87) (2-27)           
Savard et al. 2006 Treatment Cognitive behavioural therapy   15 0 20 80   Not applicable 
  95% CI       (0-22) (4-48) (52-96)           
  Control Wait-list control   12 0 58 42           
  95% CI       (0-26) (28-85) (15-72)           
Note. n = number of patients; RCI = reliable change index at P<0.05; CI = confidence interval 
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Appendix 11: 
Treatment effects at post-treatment and follow-up for anxiety, depression and 
general distress in the total sample based on risk differences for improvement 
(study 3) 
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy 
Figure 11A: Forest plot of risk differences for improvement for anxiety at post treatment in the total sample 
Study name Improved / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Beutel et al. 2014 18 / 58 29 / 59 0.18 0.01 0.36 0.04
Bredal et al. 2014 59 / 173 63 / 170 0.03 -0.07 0.13 0.57
Classen et al. 2008 27 / 148 28 / 151 0.00 -0.08 0.09 0.95
Desautels et al. 2018 - BLT 17 / 22 3 / 12 -0.52 -0.82 -0.22 0.00
Desautels et al. 2018 - WLC 3 / 10 3 / 12 -0.05 -0.43 0.33 0.79
Groarke et al. 2013 11 / 92 29 / 87 0.21 0.09 0.33 0.00
Ho et al. 2016 - BMS 5 / 25 10 / 45 0.02 -0.18 0.22 0.83
Ho et al. 2016 - support 5 / 25 7 / 47 -0.05 -0.24 0.14 0.59
Merckeart et al. 2016 18 / 77 22 / 82 0.03 -0.10 0.17 0.62
Savard et al. 2005 3 / 29 5 / 19 0.16 -0.07 0.39 0.17
Savard et al. 2006 4 / 12 11 / 15 0.40 0.05 0.75 0.02
170 / 671 210 / 699 0.05 -0.04 0.14 0.29
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy 
Figure 11B: Forest plot of risk differences for improvement for depression at post treatment in the total sample 
Study name Improved / Total Statistics for each study quality MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Antoni et al. 2001 10 / 72 9 / 54 0.03 -0.10 0.16 0.67 14
Beutel et al. 2014 24 / 58 43 / 59 0.32 0.14 0.49 0.00 20
Bredal et al. 2014 28 / 156 26 / 177 -0.03 -0.11 0.05 0.42 12
Classen et al. 2008 26 / 148 27 / 151 0.00 -0.08 0.09 0.94 16
Desautels et al. 2018 - BLT 12 / 22 6 / 12 -0.05 -0.40 0.31 0.80 29
Desautels et al. 2018 - WLC 3 / 10 6 / 12 0.20 -0.20 0.60 0.33 29
Dirksen et al. 2008 4 / 38 7 / 34 0.10 -0.07 0.27 0.24 16
Groarke et al. 2013 9 / 92 17 / 87 0.10 -0.01 0.20 0.06 15
Ho et al. 2016 - BMS 3 / 25 6 / 45 0.01 -0.15 0.17 0.87 18
Ho et al. 2016 - support 3 / 25 6 / 47 0.01 -0.15 0.17 0.92 18
Lechner et al. 2014 12 / 57 9 / 53 -0.04 -0.19 0.11 0.59 19
Merckeart et al. 2016 12 / 77 24 / 82 0.14 0.01 0.26 0.04 15
Savard et al. 2005 3 / 29 5 / 19 0.16 -0.07 0.39 0.17 19
Savard et al. 2006 5 / 12 11 / 15 0.32 -0.04 0.67 0.08 20
Stanton et al. 2005 12 / 142 17 / 144 0.03 -0.04 0.10 0.35 15
166 / 963219 / 991 0.06 0.01 0.10 0.02
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
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Note. 
BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive therapy; 
EE = emotional expression; PsyEd = psychoeducation 
Figure 11C: Forest plot of risk differences for improvement for general distress at post treatment in the total sample 
Study name Improved / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Andersen et al. 2004 24 / 90 39 / 106 0.10 -0.03 0.23 0.13
Beutel et al. 2014 23 / 58 42 / 59 0.32 0.14 0.49 0.00
Bredal et al. 2014 42 / 153 51 / 167 0.03 -0.07 0.13 0.54
Carlson et al. 2013 - MBT 6 / 18 25 / 69 0.03 -0.22 0.27 0.82
Carlson et al. 2013 - support 6 / 18 22 / 72 -0.03 -0.27 0.21 0.82
Classen et al. 2008 29 / 148 33 / 151 0.02 -0.07 0.11 0.63
Desautels et al. 2018 - BLT 15 / 22 9 / 12 0.07 -0.24 0.38 0.67
Desautels et al. 2018 - WLC 4 / 10 9 / 12 0.35 -0.04 0.74 0.08
Graves et al. 2003 0 / 6 3 / 7 0.43 0.04 0.82 0.03
Groarke et al. 2013 9 / 92 20 / 87 0.13 0.02 0.24 0.02
Ho et al. 2016 - BMS 3 / 25 7 / 45 0.04 -0.13 0.20 0.67
Ho et al. 2016 - support 3 / 25 7 / 47 0.03 -0.13 0.19 0.73
Merckeart et al. 2016 15 / 77 24 / 82 0.10 -0.03 0.23 0.15
Sandgren et al. 2003 - EE 8 / 26 21 / 90 -0.07 -0.27 0.12 0.46
Sandgren et al. 2003 - PsyEd 8 / 26 20 / 81 -0.06 -0.26 0.14 0.55
Savard et al. 2005 3 / 29 4 / 19 0.11 -0.11 0.32 0.33
Savard et al. 2006 5 / 12 12 / 15 0.38 0.04 0.73 0.03
203 / 835 348 / 1121 0.08 0.03 0.13 0.00
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
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Study name Improved / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Antoni et al. 2001 9 / 59 14 / 48 0.14 -0.02 0.30 0.08
Bredal et al. 2014 66 / 152 57 / 177 -0.11 -0.22 -0.01 0.04
Classen et al. 2008 27 / 145 31 / 141 0.03 -0.06 0.13 0.48
Desautels et al. 2018 15 / 25 20 / 27 0.14 -0.11 0.39 0.28
Groarke et al. 2013 13 / 92 16 / 87 0.04 -0.07 0.15 0.44
Ho et al. 2016 - BMS 4 / 24 6 / 46 -0.04 -0.21 0.14 0.69
Ho et al. 2016 - support 4 / 24 6 / 47 -0.04 -0.22 0.14 0.67
Lechner et al. 2014 14 / 56 11 / 52 -0.04 -0.20 0.12 0.63
Stanton et al. 2005 13 / 136 14 / 132 0.01 -0.06 0.08 0.78
165 / 713 175 / 757 0.01 -0.04 0.05 0.82
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
Note. BMS = body mind spirit; support = supportive therapy 
Figure 11D. Forest plot of risk differences for improvement for anxiety at 
follow-up in the total sample 
 
 
 
 
 
 
 
 
 
 
Note. BMS = body mind spirit; support = supportive therapy 
Figure 11E: Forest plot of risk differences for improvement for depression at 
follow-up in the total sample 
 
Study name Improved / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Bredal et al. 2014 84 / 171 96 / 176 0.05 -0.05 0.16 0.31
Classen et al. 2008 34 / 145 34 / 141 0.01 -0.09 0.11 0.89
Desautels et al. 2018 16 / 25 18 / 27 0.03 -0.23 0.29 0.84
Groarke et al. 2013 19 / 92 26 / 87 0.09 -0.03 0.22 0.15
Ho et al. 2016 - BMS 7 / 24 9 / 46 -0.10 -0.31 0.12 0.38
Ho et al. 2016 - support 7 / 24 7 / 47 -0.14 -0.35 0.07 0.18
167 / 481 190 / 524 0.02 -0.04 0.08 0.51
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
 256 
 
Note. BMS = body mind spirit; support = supportive therapy; EE = emotional 
expression; PsyEd = psychoeducation 
Figure 11F: Forest plot of risk differences for improvement for general distress 
at follow-up in the total sample 
 
 
 
 
 
 
 
 
 
 
Study name Improved / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Andersen et al. 2004 29 / 86 35 / 97 0.02 -0.11 0.16 0.74
Bredal et al. 2014 79 / 151 77 / 172 -0.08 -0.18 0.03 0.17
Classen et al. 2008 38 / 145 41 / 141 0.03 -0.07 0.13 0.59
Desautels et al. 2018 15 / 25 21 / 27 0.18 -0.07 0.43 0.16
Groarke et al. 2013 15 / 92 16 / 87 0.02 -0.09 0.13 0.71
Ho et al. 2016 - BMS 5 / 24 6 / 46 -0.08 -0.27 0.11 0.42
Ho et al. 2016 - support 5 / 24 8 / 47 -0.04 -0.23 0.16 0.70
Sandgren et al. 2003 - EE 2 / 24 5 / 92 -0.03 -0.15 0.09 0.64
Sandgren et al. 2003 - PsyEd 2 / 24 6 / 77 -0.01 -0.13 0.12 0.93
190 / 595 215 / 786 -0.01 -0.05 0.04 0.77
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
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Appendix 12: 
Classification of patients at post-treatment and follow-up according to 
Jacobson’s first and second (RCI) criteria for anxiety, depression and general 
distress in the distressed sub-sample (study 3) 
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Table 12A: Classification of patients at post-treatment and follow-up according to Jacobson’s first and second (RCI) criteria for anxiety 
in the distressed sub-sample 
    Post-treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved 
Recovere
d 
Beutel et 
al. 2014 
Tx 
Other - Psychodynamic 
therapy 
 54 9 39 28 24   Follow-up data not reported 
  95% CI      (3-20) (26-53) (16-42) (13-38)             
  Control 
Treatment as usual - 
Offered referral to GP 
for psychological or 
pharmacological 
treatment 
 50 8 58 26 8             
  95% CI      (2-19) (43-72) (15-40) (2-19)             
Bredal et 
al. 2014 
Tx Psychoeducation  90 12 40 16 32   90 4 22 21 52 
  95% CI      (6-21) (30-51) (9-25) (23-43)     (1-11) (14-32) (13-31) (41-63) 
  Control 
Treatment as usual - 
Nurse-led support 
group 
 106 13 47 11 28   101 5 28 14 53 
  95% CI      (7-21) (37-57) (6-19) (20-38)     (2-11) (19-38) (8-22) (43-63) 
Classen et 
al. 2008 
Tx 
Supportive therapy + 
education material 
 56 13 43 18 27   49 12 43 27 18 
  95% CI      (5-24) (30-57) (9-30) (16-40)     (5-25) (29-58) (15-41) (9-32) 
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    Post-treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved 
Recovere
d 
  Control Education material  57 9 60 14 18   55 7 51 16 25 
  95% CI      (3-19) (46-72) (6-26) (19-30)     (2-18) (37-65) (8-29) (15-39) 
Desautels 
et al. 
2018 
Tx 
Cognitive behavioural 
therapy 
 19 0 68 16 16   7 0 57 0 43 
  95% CI      (0-18) (43-87) (3-40) (3-40)     (0-41) (18-90) (0-41) (10-82) 
  Control Bright light therapy  17 6 0 41 53   5 0 80 0 20 
  95% CI      (0-29) (0-20) (18-67) (28-77)     (0-52) (28-99) (0-52) (0-72) 
  Control Wait-list therapy  6 0 50 50 0     Not applicable 
  95% CI      (0-46) (12-88) (12-88) (0-46)             
Groarke 
et al. 
2013 
Tx 
Cognitive behavioural 
therapy 
 35 0 34 11 54   35 17 23 20 40 
  95% CI      (0-10) (19-52) (3-27) (37-71)     (7-34) (10-40) (8-37) (24-58) 
  Control 
Treatment as usual - 
Support from oncology 
nurses 
 28 7 75 7 11   28 7 46 11 36 
  95% CI      (0-24) (55-89) (0-24) (2-28)     (0-24) (28-66) (2-28) (19-56) 
Ho et al. 
2016 
Tx  
Other - Body-mind-
spirit intervention 
 16 6 56 6 31   15 20 53 7 20 
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    Post-treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved 
Recovere
d 
  95% CI      (0-30) (30-80) (0-30) (11-59)     (4-48) (27-79) (0-32) (4-48) 
  Tx Supportive therapy   22 23 55 5 18   22 9 68 9 14 
  95% CI      (8-45) (32-76) (0-23) (5-40)     (1-29) (45-86) (1-29) (3-35) 
  Control 
Self-help support 
group 
 23 13 52 13 22   22 23 36 18 23 
  95% CI      (3-34) (31-73) (3-34) (7-44)     (8-45) (17-59) (5-40) (8-45) 
Merckaert 
et al. 
2016 
Tx 
Cognitive behavioural 
therapy 
 40 5 50 15 30   Follow-up data not reported 
  95% CI      (0-17) (34-66) (6-30) (17-47)             
  Control 
Treatment as usual - 
peer support group 
 43 5 63 14 19             
  95% CI      (0-16) (47-77) (5-28) (8-33)             
Savard et 
al. 2005 
Tx 
Cognitive behavioural 
therapy 
 9 0 44 11 44   Not applicable 
  95% CI      (0-34) (14-79) (0-48) (14-79)             
  Control Wait-list control  12 33 50 0 17             
  95% CI      (10-65) (21-79) (0-26) (2-48)             
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    Post-treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved 
Recovere
d 
Savard et 
al. 2006 
Tx 
Cognitive behavioural 
therapy 
 12 0 8 42 50   Not applicable 
  95% CI      (0-26) (0-38) (15-72) (21-79)             
  Control Wait-list control  11 18 45 27 9             
  95% CI      (2-52) (17-77) (6-61) (0-41)             
Note. Tx = treatment; n = number of patients; RCI = reliable change index at P<0.05; CI = confidence interval 
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Table 12B: Classification of patients at post-treatment and follow-up according to Jacobson’s first and second (RCI) criteria for 
depression in the distressed sub-sample 
        Post treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated No change Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
Antoni et 
al. 2001 
Tx 
Cognitive 
behavioural therapy 
  18 11 44 17 28   17 0 35 29 35 
  95% CI       (1-35) (22-69) (4-41) (10-53)     (0-20) (14-62) (10-56) (14-62) 
  Control 
Condensed version 
of active treatment 
  22 0  59  23  18   18 6 50 33 11 
  95% CI       (0-15)   (36-79)  (8-45)  (5-40)     (0-27) (26-74) (13-59) (1-35) 
Beutel et 
al. 2014 
Tx 
Other - 
Psychodynamic 
therapy 
  59 3 24 37 36   Follow-up data not reported 
  95% CI       (0-12) (14-37) (25-51) (24-49)             
  Control 
Treatment as usual - 
Offered referral to 
GP for 
psychological or 
pharmacological 
treatment 
  58  17  41 21   21             
  95% CI        (9-29)  (29-55)  (11-33)  (11-33)             
Bredal et 
al. 2014 
Tx Psychoeducation   47 4 62 6 28   45 2 27 0 71 
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        Post treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated No change Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
  95% CI       (0-15) (46-75) (1-18) (16-43)     (0-12) (15-42) (0-8) (56-84) 
  Control 
Treatment as usual - 
Nurse-led support 
group 
  52  4  63 8  25    47 2 13 9 77 
  95% CI        (0-13)  (49-76)  (2-19)  (14-39)     (0-11) (5-26) (2-20) (62-88) 
Classen et 
al. 2008 
Tx 
Supportive therapy + 
education material 
  26 4 42 19 35   28 0 46 21 32 
  95% CI       (0-20) (23-63) (7-39) (17-56)     (0-12) (28-66) (8-41) (16-52) 
  Control Education material   18  11 28  17  44    19 11 47 5 37 
  95% CI        (1-35)  (10-53)  (4-41)  (22-69)     (1-33) (24-71) (0-26) (16-62) 
Desautels 
et al. 2018 
Tx 
Cognitive 
behavioural therapy 
  19 0 42 16 42   19 0 21 11 68 
  95% CI       (0-18) (20-67) (3-40) (20-67)     (0-18) (6-46) (1-33) (43-87) 
  Control Bright light therapy   15  0 27  33  40    16 0 19 25 56 
  95% CI        (0-22)  (8-55)  (12-62)  (16-68)     (0-21) (4-46) (7-52) (30-80) 
  Control Wait-list control   8  0 63  13  25    Not applicable 
  95% CI        (0-37)  (24-91)  (0-53)  (3-65)             
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        Post treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated No change Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
Dirksen et 
al. 2008 
Tx Cognitive 
behavioural therapy 
13 0 54 15 31 Follow-up data not reported 
  95% CI       (0-25) (25-81) (2-45) (9-61)             
  Control 
Educational 
components of 
active treatment 
  5  20 40  0  40              
  95% CI        (0-72)  (5-85)  (0-52)  (5-85)             
Groarke et 
al. 2013 
Tx 
Cognitive 
behavioural therapy 
  12 0 67 0 33   12 17 42 8 33 
  95% CI       (0-26) (35-90) (0-26) (10-65)     (2-48) (15-72) (0-38) (10-65) 
  Control 
Treatment as usual - 
Support from 
oncology nurses 
  12  0 58  0  42    12 8 25 33 33 
  95% CI        (0-26)  (28-85)  (0-26)  (15-72)     (0-38) (5-57) (10-65) (10-65) 
Ho et al. 
2016  
Tx 
Other - Body-mind-
spirit intervention 
  5 0 40 20 40   5 0 20 20 60 
  95% CI       (0-52) (5-85) (0-72) (5-85)     (0-52) (0-72) (0-72) (15-95) 
  Tx Supportive therapy    9 33 44 0 22   9 0 78 0 22 
  95% CI       (7-70) (14-79) (0-34) (3-60)     (0-34) (40-97) (0-34) (3-60) 
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        Post treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated No change Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
  Control 
Self-help support 
group 
   7  14 71  14  0    7 29 43 14 14 
  95% CI        (0-58)  (29-96)  (0-58)  (0-41)     (4-71) (10-82) (0-58) (0-58) 
Lechner et 
al. 2016 
Tx 
Cognitive 
behavioural therapy 
  53 8 75 17 0   52 4 75 21 0 
  95% CI       (2-18) (62-86) (8-30) (0-7)     (0-13) (61-86) (11-35) (0-7) 
  Control 
Educational 
information 
delivered by 
therapist 
  57  12 67  21  0    56 9 66 25 0 
  95% CI        (5-24)  (53-79)  (11-34)  (0-6)     (3-20) (52-78) (14-38) (0-6) 
Merckaert 
et al. 2016 
Tx 
Cognitive 
behavioural therapy 
  21 0 33 19 48   Follow-up data not reported 
  95% CI       0-16% 15-57% 5-42% 26-70%             
  Control 
Treatment as usual - 
Peer support group 
   15 0  53  7  40              
  95% CI        (0-22)  (27-79)  (0-32)  (16-68)             
Savard et 
al. 2005 
Tx 
Cognitive 
behavioural therapy 
  2 0 0 0 100   Not applicable 
  95% CI       (0-84) (0-84) (0-84) (16-100)             
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        Post treatment (%)  Follow-up (%) 
Study 
name 
Tx or 
control 
Type  Total Deteriorated No change Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
  Control Wait-list control    3 0  33  0  67              
  95% CI        (0-71)  (0-91)  (0-71)  (9-99)             
Savard et 
al. 2006 
Tx 
Cognitive 
behavioural therapy 
  10 0 10 30 60   Not applicable 
  95% CI       (0-31) (0-45) (7-65) (26-88)             
  Control Wait-list control   9  0 56  0  44              
  95% CI        (0-34)  (21-86)  (0-34)  (14-79)             
Stanton et 
al. 2005 
Tx 
Psychoeducation + 
educational material 
  40 8 53 25 15   38 5 63 26 5 
  95% CI       (2-20) (36-68) (13-41) (6-30)     (0-18) (46-78) (13-43) (0-18) 
  Control Education material   24  4 67  21  0    24 4 50 8 38 
  95% CI        (0-21)  (53-79)  (11-34)  (0-6)     (0-21) (29-71) (1-27) (19-59) 
Note. Tx = treatment; n = number of patients; RCI = reliable change index at P<0.05; CI = confidence interval 
 
 
 
 267 
 
Table 12C: Classification of patients at post-treatment and follow-up according to Jacobson’s first and second (RCI) criteria for general 
distress in the distressed sub-sample 
        Post treatment (%)  Follow-up (%) 
Study name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
Andersen et 
al. 04 
Tx 
Other - Biobehavioral 
intervention  
  48 13 27 40 21  44 2 41 25 32 
  95% CI      (5-25) (15-42) (26-55) (10-35)   (0-12) (26-57) (13-40) (19-48) 
  Control Assessment only   30 7 37 47 10  29 3 34 38 24 
  95% CI      (0-22) (20-56) (28-66) (2-27)   (0-18) (18-54) (21-58) (10-44) 
Beutel et al. 
2014 
Tx 
Other - 
Psychodynamic 
therapy 
  59 7 22 51 20  Follow-up data not reported 
  95% CI      (2-16) (12-35) (37-64) (11-33)       
  Control 
Treatment as usual - 
Offered referral to GP 
for psychological or 
pharmacological 
treatment 
  57 14 47 32 7       
  95% CI      (6-26) (34-61) (20-45) (2-17)       
Bredal et al. 
2014 
Tx Psychoeducation   81 7 51 15 27  81 4 22 21 53 
  95% CI      (3-15) (39-62) (8-24) (18-38)   (0-10) (14-33) (13-31) (42-64) 
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        Post treatment (%)  Follow-up (%) 
Study name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
  Control 
Treatment as usual - 
Nurse-led support 
group 
  80 15 50 8 28  78 4 15 26 55 
  95% CI      (8-25) (39-61) (3-16) (18-39)   (0-11) (8-25) (16-37) (43-66) 
Carlson et al. 
2013 
Tx 
Mindfulness-based 
therapy 
  27 7 26 19 48  Follow-up data not reported 
  95% CI      (0-24) (11-46) (6-38) (29-68)       
  Tx Supportive therapy   29 17 34 28 21       
  95% CI      (6-36) (18-54) (13-47) (8-40)       
  Control 
Stress management 
seminar 
  14 14 29 21 36       
  95% CI      (2-43) (8-58) (5-51) (13-65)       
Classen et al. 
2008 
Tx 
Supportive therapy + 
education material 
  49 12 37 20 31  45 4 33 33 29 
  95% CI      (5-25) (23-52) (10-34) (18-45)   (0-15) (20-49) (20-49) (16-44) 
  Control Education material   44 5 45 23 27  42 17 26 26 31 
  95% CI      (0-15) (30-61) (11-38) (15-43)   (7-31) (14-42) (14-42) (18-47) 
Desautels et 
al. 2018 
Tx 
Cognitive behavioural 
therapy 
  23 0 17 43 39  24 0 17 33 50 
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        Post treatment (%)  Follow-up (%) 
Study name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
  95% CI      (0-15) (5-39) (23-66) (20-61)   (0-14) (5-37) (16-55) (29-71) 
  Control Bright light therapy   21 0 29 33 38  24 0 38 25 38 
  95% CI      (0-16) (11-52) (15-57) (18-62)   (0-14) (19-59) (10-47) (19-59) 
  Control Wait-list control   9 11 56 33 0  Not applicable 
  95% CI      (0-48) (21-86) (7-70) (0-34)       
Graves et al. 
2003 
Tx 
Cognitive behavioural 
therapy 
  3 33 33 33 0  Follow-up data not reported 
  95% CI      (0-91) (0-91) (0-91) (0-71)       
  Control 
Treatment as usual 
from medical 
community + 
educational material 
  0 0 0 0 0       
  95% CI     0 0 0 0 0       
Groarke et 
al. 2013 
Tx 
Cognitive behavioural 
therapy 
  28 0 0.5 0.14 0.36  28 4 50 11 36 
  95% CI      (0-12) (31-69) (4-33) (19-56)   (0-18) (31-69) (2-28) (19-56) 
  Control 
Treatment as usual - 
Support from 
oncology nurses 
  25 8 80 4 8  25 12 48 24 16 
  95% CI      (0-26) (59-93) (0-20) (0-26)   (3-31) (28-69) (9-45) (5-36) 
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        Post treatment (%)  Follow-up (%) 
Study name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
Ho et al. 
2016 
Tx 
Other - body-mind-
spirit intervention 
  14 0 71 14 14  13 0 69 23 8 
  95% CI      (0-23) (42-92) (2-43) (2-43)   (0-25) (39-91) (5-54) (0-36) 
  Tx Supportive therapy     24 21 54 4 21  24 13 54 8 25 
  95% CI      (7-42) (33-74) (0-21) (7-42)   (3-32) (33-74) (1-27) (10-47) 
  Control 
Self-help support 
group 
  20 5 75 15 5  19 26 37 32 5 
  95% CI      (0-25) (51-91) (3-38) (0-25)   (9-51) (16-62) (13-57) (0-26) 
Merckaert et 
al. 2016 
Tx 
Cognitive behavioural 
therapy 
  39 8 38 28 26  Follow-up data not reported 
  95% CI      (2-21) (23-55) (15-45) (13-42)       
  Control 
Treatment as usual - 
peer support group 
  32 13 53 22 13       
  95% CI      (4-29) (35-71) (9-40) (4-29)       
Sandgren et 
al 2003; 
2007 
Tx Psychoeducation   22 9 32 14 45  21 19 52 29 0 
  95% CI      (1-29) (14-55) (3-35) (24-68)   (5-42) (30-74) (11-52) (0-16) 
  Tx 
Other - Emotional 
expression 
  30 7 43 23 27  30 20 63 17 0 
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        Post treatment (%)  Follow-up (%) 
Study name 
Tx or 
control 
Type  Total Deteriorated 
No 
change 
Improved Recovered   Total Deteriorated 
No 
change 
Improved Recovered 
  95% CI      (0-22) (25-63) (10-42) (12-46)   (8-39) (44-80) (6-35) (0-12) 
  Control 
Treatment as usual - 
Nurse help line was 
available 
  21 5 29 43 24  20 25 60 15 0 
  95% CI      (0-24) (11-52) (22-66) (8-47)   (9-49) (36-81) (3-38) (0-17) 
Savard et al. 
2005 
Tx 
Cognitive behavioural 
therapy 
  8 0 63 13 25  Not applicable 
  95% CI      (0-37) (24-91) (0-53) (3-65)       
  Control Wait-list control   7 14 71 14 0       
  95% CI      (0-58) (29-96) (0-58) (0-41)       
Savard et al. 
2006 
Tx 
Cognitive behavioural 
therapy 
  13 0 8 54 38  Not applicable 
  95% CI      (0-25) (0-36) (25-81) (14-68)       
  Control Wait-list control   11 0 64 27 9       
  95% CI      (0-28) (31-89) (6-61) (0-41)       
Note. Tx = treatment; n = number of patients; RCI = reliable change index at P<0.05; CI = confidence interval 
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Appendix 13: 
Treatment effects at post-treatment and follow-up for anxiety, depression and general 
distress in the distressed sub-sample based on risk differences for recovery (study 3) 
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy 
Figure 13A: Forest plot of risk differences for recovery for anxiety at post treatment in the distressed sub-sample 
Study name Recovered / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Beutel et al. 2014 4 / 50 13 / 54 0.16 0.02 0.30 0.02
Bredal et al. 2014 30 / 106 29 / 90 0.04 -0.09 0.17 0.55
Classen et al. 2008 10 / 57 15 / 56 0.09 -0.06 0.24 0.23
Desautels et al. 2018 - WLC 0 / 6 2 / 9 0.22 -0.11 0.55 0.19
Desautels et al. 2018 - BLT 9 / 17 2 / 9 -0.31 -0.67 0.05 0.10
Groarke et al. 2012 3 / 28 19 / 35 0.44 0.23 0.64 0.00
Ho et al. 2016 - BMS 3 / 11 5 / 16 0.04 -0.31 0.39 0.82
Ho et al. 2016 - support 3 / 11 4 / 22 -0.09 -0.40 0.22 0.56
Merckeart et al. 2016 8 / 43 12 / 40 0.11 -0.07 0.30 0.22
Savard et al. 2005 2 / 12 4 / 9 0.28 -0.11 0.66 0.16
Savard et al. 2006 1 / 11 6 / 12 0.41 0.08 0.74 0.02
73 / 352 111 / 352 0.13 0.03 0.24 0.01
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
 274 
 
 
 
 
 
 
 
 
 
 
 
Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy 
Figure 13B: Forest plot of risk differences for recovery for depression at post treatment in the distressed sub-sample 
Study name Recovered / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Antoni et al. 2001 4 / 22 5 / 18 0.10 -0.17 0.36 0.47
Beutel et al. 2014 12 / 58 21 / 59 0.15 -0.01 0.31 0.07
Bredal et al. 2014 13 / 52 13 / 47 0.03 -0.15 0.20 0.76
Classen et al. 2008 8 / 18 9 / 26 -0.10 -0.39 0.20 0.51
Desautels et al. 2018 - BLT 6 / 15 4 / 9 0.04 -0.36 0.45 0.83
Desautels et al. 2018 - WLC 2 / 8 4 / 9 0.19 -0.25 0.64 0.39
Dirksen et al. 2008 2 / 5 4 / 13 -0.09 -0.59 0.41 0.72
Groarke et al. 2013 5 / 12 4 / 12 -0.08 -0.47 0.30 0.67
Ho et al. 2016 - BMS 1 / 4 2 / 5 0.15 -0.45 0.75 0.63
Ho et al. 2016 - support 1 / 4 2 / 9 -0.03 -0.53 0.48 0.91
Lechner et al. 2014 12 / 57 9 / 53 -0.04 -0.19 0.11 0.59
Merckeart et al. 2016 6 / 15 10 / 21 0.08 -0.25 0.40 0.65
Savard et al. 2005 2 / 3 2 / 2 0.33 -0.30 0.97 0.30
Savard et al. 2006 4 / 9 6 / 10 0.16 -0.29 0.60 0.49
Stanton et al. 2005 5 / 24 6 / 40 -0.06 -0.25 0.14 0.56
83 / 306 101 / 333 0.03 -0.04 0.10 0.39
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
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Note. BLT = bright light therapy; MBT = mindfulness-based therapy; WLC = waitlist control; BMS = body mind spirit; support = supportive 
therapy; EE = emotional expression; PsyEd = psychoeducation 
Figure 13C: Forest plot of risk differences for recovery for general distress at post treatment in the distressed sub-sample 
Study name Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Andersen et al. 2004 3 / 30 10 / 48 0.11 -0.05 0.27 0.18
Beutel et al. 2014 4 / 57 12 / 59 0.13 0.01 0.26 0.03
Bredal et al. 2014 22 / 78 22 / 81 -0.01 -0.15 0.13 0.88
Carlson et al. 2013 - MBT 3 / 7 13 / 27 0.05 -0.36 0.47 0.80
Carlson et al. 2013 - support 3 / 7 6 / 29 -0.22 -0.62 0.17 0.27
Classen et al. 2008 12 / 44 15 / 49 0.03 -0.15 0.22 0.72
Desautels et al. 2018 - WLC 0 / 9 4 / 11 0.36 0.06 0.67 0.02
Desautels et al. 2018 - BLT 8 / 21 4 / 11 -0.02 -0.37 0.33 0.92
Groarke et al. 2013 2 / 25 10 / 28 0.28 0.07 0.48 0.01
Ho et al. 2016 - BMS 1 / 10 2 / 14 0.09 -0.13 0.32 0.42
Ho et al. 2016 - support 1 / 10 5 / 24 0.16 -0.05 0.37 0.14
Merckeart et al. 2016 4 / 32 10 / 39 0.13 -0.05 0.31 0.15
Sandgren et al. 2003 - EE 3 / 11 8 / 30 -0.01 -0.31 0.30 0.97
Sandgren et al. 2003 - PsyEd 3 / 11 10 / 22 0.18 -0.15 0.52 0.29
Savard et al. 2005 0 / 7 2 / 8 0.25 -0.09 0.59 0.15
Savard et al. 2006 1 / 11 5 / 13 0.29 -0.02 0.61 0.07
69 / 370 138 / 493 0.11 0.06 0.17 0.00
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
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Note. BLT = BMS = body mind spirit; support = supportive therapy 
Figure 13D:  Forest plot of risk differences for recovery for anxiety at follow-up 
in the distressed sub sample 
 
Note. BLT = BMS = body mind spirit; support = supportive therapy 
Figure 13E: Forest plot of risk differences for recovery for depression at follow-
up in the distressed sub-sample 
 
 
 
Study name Recovered / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Bredal et al. 2014 54 / 101 47 / 90 -0.01 -0.15 0.13 0.86
Classen et al. 2008 14 / 55 9 / 49 -0.07 -0.23 0.09 0.38
Desautels et al. 2018 9 / 20 9 / 20 0.00 -0.31 0.31 1.00
Groarke et al. 2012 10 / 28 14 / 35 0.04 -0.20 0.28 0.73
Ho et al. 2016 - BMS 3 / 11 3 / 15 -0.07 -0.40 0.26 0.67
Ho et al. 2016 - support 3 / 11 3 / 22 -0.14 -0.44 0.16 0.37
93 / 226 85 / 231 -0.04 -0.12 0.05 0.41
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
Meta Analysis
Study name Recovered / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Antoni et al. 2001 2 / 18 6 / 17 0.24 -0.03 0.51 0.08
Bredal et al. 2014 36 / 47 32 / 45 -0.05 -0.23 0.12 0.55
Classen et al. 2008 7 / 19 9 / 28 -0.05 -0.32 0.23 0.74
Desautels et al. 2018 9 / 16 13 / 19 0.12 -0.20 0.44 0.46
Groarke et al. 2013 4 / 12 4 / 12 0.00 -0.38 0.38 1.00
Ho et al. 2016 - BMS 1 / 3 3 / 5 0.27 -0.42 0.95 0.45
Ho et al. 2016 - support 1 / 3 2 / 9 -0.11 -0.71 0.49 0.72
Lechner et al. 2014 0 / 56 0 / 52 0.00 -0.04 0.04 1.00
Stanton et al. 2005 9 / 24 2 / 38 -0.32 -0.53 -0.12 0.00
69 / 198 71 / 225 -0.02 -0.13 0.09 0.71
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
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Note. BLT = BMS = body mind spirit; support = supportive therapy; EE = emotional 
expression; PsyEd = psychoeducation 
Figure 13F: Forest plot of risk differences for recovery for general distress at 
follow-up in the distressed sub-sample 
 
 
 
 
 
 
 
 
Study name Recovered / Total Statistics for each study MH risk difference and 95% CI
MH risk Lower Upper 
control Tx difference limit limit p-Value
Andersen et al. 2004 7 / 29 14 / 44 0.08 -0.13 0.28 0.47
Bredal et al. 2014 43 / 78 43 / 81 -0.02 -0.18 0.13 0.80
Classen et al. 2008 13 / 42 13 / 45 -0.02 -0.21 0.17 0.83
Desautels et al. 2018 9 / 24 12 / 24 0.13 -0.15 0.40 0.38
Groarke et al. 2013 4 / 25 10 / 28 0.20 -0.03 0.43 0.09
Ho et al. 2016 - BMS 1 / 10 1 / 13 -0.02 -0.26 0.21 0.85
Ho et al. 2016 - support 1 / 10 6 / 24 0.15 -0.10 0.40 0.25
Sandgren et al. 2003 - EE 0 / 10 0 / 30 0.00 -0.13 0.13 1.00
Sandgren et al. 2003 - PsyEd 0 / 10 0 / 21 0.00 -0.14 0.14 1.00
78 / 238 99 / 310 0.03 -0.03 0.09 0.36
-2.00 -1.00 0.00 1.00 2.00
Favours control Favours Tx
